PureTech Health (PRTC) 20-F 25 Apr 24 2023 FY Annual report (foreign) Financial data

Cover

Cover	12 Months Ended
	Dec. 31, 2023 shares
Document and Entity Information [Line Items]
Document Type	20-F
Document Registration Statement	false
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-39670
Entity Registrant Name	PURETECH HEALTH PLC
Entity Incorporation, State or Country Code	X0
Entity Address, Address Line One	6 Tide Street
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02210
Entity Address, Country	US
Entity Common Stock, Shares Outstanding	271,853,731
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction	false
Document Accounting Standard	International Financial Reporting Standards
Entity Shell Company	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Central Index Key	0001782999
Amendment Flag	false
Business Contact
Document and Entity Information [Line Items]
Entity Address, Address Line One	6 Tide Street
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02210
Entity Address, Country	US
Contact Personnel Name	Bharatt Chowrira
City Area Code	617
Local Phone Number	482-2333
American Depositary Shares
Document and Entity Information [Line Items]
Title of 12(b) Security	American Depositary Shares, each representing 10 ordinary shares, par value £0.01 per share
Trading Symbol	PRTC
Security Exchange Name	NASDAQ
Common
Document and Entity Information [Line Items]
Title of 12(b) Security	Ordinary shares, par value £0.01 per share*
Security Exchange Name	NASDAQ
No Trading Symbol Flag	true

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Auditor Information [Abstract]
Auditor Name	PricewaterhouseCoopers LLP	KPMG LLP
Auditor Location	Boston, Massachusetts	London, United Kingdom27 April 2023 except for Note 4 and Note 20, as to which the date is 25 April 2024
Auditor Firm ID	238	1118

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Income/(Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Profit or loss [abstract]
Contract revenue	$ 750	$ 2,090	$ 9,979
Grant revenue	2,580	13,528	7,409
Total revenue	3,330	15,618	17,388
Operating expenses:
General and administrative expenses	(53,295)	(60,991)	(57,199)
Research and development expenses	(96,235)	(152,433)	(110,471)
Operating income/(loss)	(146,199)	(197,807)	(150,282)
Other income/(expense):
Gain/(loss) on deconsolidation of subsidiary	61,787	27,251	0
Gain/(loss) on investments held at fair value	77,945	(32,060)	179,316
Realized gain/(loss) on sale of investments	(122)	(29,303)	(20,925)
Gain/(loss) on investments in notes from associates	(27,630)	0	0
Other income/(expense)	(908)	8,131	1,592
Other income/(expense)	111,072	(25,981)	159,983
Finance income/(costs):
Finance income	16,012	5,799	214
Finance costs – contractual	(3,424)	(3,939)	(4,771)
Finance income/(costs) – fair value accounting	2,650	137,063	9,606
Total finance costs - non cash interest expense related to sale of future royalties	(10,159)	0	0
Net finance income/(costs)	5,078	138,924	5,050
Share of net income/(loss) of associates accounted for using the equity method	(6,055)	(27,749)	(73,703)
Gain/(loss) on dilution of ownership interest in associates	0	28,220	0
Impairment of investment in associates	0	(8,390)	0
Income/(loss) before taxes	(36,103)	(92,783)	(58,953)
Taxation	(30,525)	55,719	(3,756)
Income/(loss) for the year	(66,628)	(37,065)	(62,709)
Other comprehensive income/(loss):
Equity-accounted associate – share of other comprehensive income (loss)	92	(166)	0
Reclassification of foreign currency differences on dilution of interest	0	(213)	0
Total other comprehensive income/(loss)	92	(379)	0
Total comprehensive income/(loss) for the year	(66,535)	(37,444)	(62,709)
Income/(loss) attributable to:
Owners of the Group	(65,697)	(50,354)	(60,558)
Non-controlling interests	(931)	13,290	(2,151)
Comprehensive income/(loss) attributable to:
Owners of the Group	(65,604)	(50,733)	(60,558)
Non-controlling interests	$ (931)	$ 13,290	$ (2,151)
Earnings/(loss) per share:
Basic earnings/(loss) per share (in dollars per share)	$ (0.24)	$ (0.18)	$ (0.21)
Diluted earnings/(loss) per share (in dollars per share)	$ (0.24)	$ (0.18)	$ (0.21)

Consolidated Statement of Finan

Consolidated Statement of Financial Position - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Non-current assets
Property and equipment, net	$ 9,536	$ 22,957
Right of use asset, net	9,825	14,281
Intangible assets, net	906	831
Investments held at fair value	317,841	251,892
Investment in associates – equity method	3,185	9,147
Investments in notes from associates	4,600	16,501
Lease receivable – long-term	0	835
Other non-current assets	878	10
Total non-current assets	346,771	316,454
Current assets
Trade and other receivables	2,376	11,867
Income tax receivable	11,746	10,040
Prepaid expenses	4,309	11,617
Lease receivable – short-term	0	450
Other financial assets	1,628	2,124
Short-term investments	136,062	200,229
Cash and cash equivalents	191,081	149,866
Total current assets	347,201	386,192
Total assets	693,973	702,647
Equity
Share capital	5,461	5,455
Share premium	290,262	289,624
Treasury stock	(44,626)	(26,492)
Merger reserve	138,506	138,506
Translation reserve	182	89
Other reserve	(9,538)	(14,478)
Retained earnings	83,820	149,516
Equity attributable to the owners of the Group	464,066	542,220
Non-controlling interests	(5,835)	5,369
Total equity	458,232	547,589
Non-current liabilities
Sale of future royalties liability	110,159	0
Deferred tax liability	52,462	19,645
Lease liability, non-current	18,250	24,155
Long-term loan	0	10,244
Liability for share-based awards	3,501	4,128
Total non-current liabilities	184,371	58,172
Current liabilities
Deferred revenue	0	2,185
Lease liability, current	3,394	4,972
Trade and other payables	44,107	54,840
Notes payable	3,699	2,345
Warrant liability	0	47
Preferred shares	169	27,339
Current portion of long-term loan	0	5,156
Total current liabilities	51,370	96,885
Total liabilities	235,741	155,057
Total equity and liabilities	$ 693,973	$ 702,647

Consolidated Statement of Chang

Consolidated Statement of Changes in Equity - USD ($) $ in Thousands	Total	Share Capital	Share premium	Treasury Shares	Merger reserve	Translation reserve	Other reserve	Retained earnings/ (accumulated deficit)	Total parent equity	Non-controlling interests
Beginning balance number of shares outstanding (in shares) at Dec. 31, 2020		285,885,025		0
Equity at beginning of period at Dec. 31, 2020	$ 653,539	$ 5,417	$ 288,978	$ 0	$ 138,506	$ 469	$ (24,050)	$ 260,429	$ 669,748	$ (16,209)
Net income/(loss)	(62,709)							(60,558)	(60,558)	(2,151)
Other comprehensive income/(loss), net	0
Total comprehensive income/(loss) for the year	(62,709)							(60,558)	(60,558)	(2,151)
Exercise of stock options (in shares)		1,911,560
Exercise of stock options	352	$ 27	326						352
Revaluation of deferred tax assets related to share-based awards	615						615		615
Equity-settled share-based awards	13,361						7,109		7,109	6,252
Reclassification of equity settled awards to liability awards	(6,773)						(6,773)		(6,773)
Vesting of share-based awards and net share exercise	(2,582)						(2,582)		(2,582)
Acquisition of subsidiary non-controlling interest	(968)						(9,636)		(9,636)	8,668
Settlement of restricted stock units	(10,749)						(10,749)		(10,749)
NCI exercise of share options in subsidiaries	66						5,988		5,988	(5,922)
Other	(6)									(6)
Ending balance number of shares outstanding (in shares) at Dec. 31, 2021		287,796,585		0
Equity at end of period at Dec. 31, 2021	584,147	$ 5,444	289,303	$ 0	138,506	469	(40,077)	199,871	593,515	(9,368)
Net income/(loss)	(37,065)							(50,354)	(50,354)	13,290
Other comprehensive income/(loss), net	(379)					(379)			(379)
Total comprehensive income/(loss) for the year	(37,444)					(379)		(50,354)	(50,733)	13,290
Deconsolidation of Subsidiary	11,904									11,904
Exercise of stock options (in shares)		577,022
Exercise of stock options	332	$ 11	321						332
Revaluation of deferred tax assets related to share-based awards	45						45		45
Purchase of Treasury stock (in shares)				(10,595,347)
Purchase of Treasury stock	(26,492)			$ (26,492)					(26,492)
Equity-settled share-based awards	13,567						8,856		8,856	4,711
Settlement of restricted stock units (in shares)		788,046
Settlement of restricted stock units	1,528						1,528		1,528
NCI exercise of share options in subsidiaries	7						15,171		15,171	(15,164)
Other	(4)									(4)
Ending balance number of shares outstanding (in shares) at Dec. 31, 2022		289,161,653		(10,595,347)
Equity at end of period at Dec. 31, 2022	547,589	$ 5,455	289,624	$ (26,492)	138,506	89	(14,478)	149,516	542,220	5,369
Net income/(loss)	(66,628)							(65,697)	(65,697)	(931)
Other comprehensive income/(loss), net	92					92			92
Total comprehensive income/(loss) for the year	(66,535)					92		(65,697)	(65,604)	(931)
Deconsolidation of Subsidiary	(9,085)									(9,085)
Exercise of stock options (in shares)		306,506		239,226
Exercise of stock options	1,153	$ 6	638	$ 530			(22)		1,153
Purchase of Treasury stock (in shares)				(7,683,526)
Purchase of Treasury stock	(19,650)			$ (19,650)					(19,650)
Equity-settled share-based awards	3,625						3,348		3,348	277
Settlement of restricted stock units (in shares)				425,219
Settlement of restricted stock units	1,142			$ 986			156		1,142
Expiration of share options in subsidiary	0						1,458		1,458	(1,458)
Other	$ (6)									(6)
Ending balance number of shares outstanding (in shares) at Dec. 31, 2023	289,468,159	289,468,159		(17,614,428)
Equity at end of period at Dec. 31, 2023	$ 458,232	$ 5,461	$ 290,262	$ (44,626)	$ 138,506	$ 182	$ (9,538)	$ 83,820	$ 464,066	$ (5,835)

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Income/(loss) for the year	$ (66,628)	$ (37,065)	$ (62,709)
Non-cash items:
Depreciation and amortization	4,933	8,893	7,287
Share-based compensation expense	4,415	14,698	13,950
(Gain)/loss on investment held at fair value	(77,945)	32,060	(179,316)
Realized loss on sale of investments	265	29,303	20,925
Gain on dilution of ownership interest in associate	0	(28,220)	0
Impairment of investment in associates	0	8,390	0
Gain on deconsolidation of subsidiary	(61,787)	(27,251)	0
Share of net loss of associates accounted for using the equity method	6,055	27,749	73,703
Loss on investments in notes from associates	27,630	0	0
Fair value gain on other financial instruments	0	(8,163)	(800)
Loss on disposal of assets	318	138	53
Impairment of fixed assets	1,260	0
Income taxes, net	30,525	(55,719)	3,756
Finance (income)/costs, net	(5,078)	(138,924)	(5,050)
Changes in operating assets and liabilities:
Trade and other receivables	9,750	(7,734)	(617)
Prepaid expenses	2,834	(862)	(5,350)
Deferred revenue	(283)	2,123	(1,407)
Trade and other payables	3,844	22,033	8,338
Other	1,374	359	(103)
Income taxes paid	(150)	(20,696)	(27,766)
Interest received	14,454	3,460	214
Interest paid	(1,701)	(3,366)	(3,382)
Net cash used in operating activities	(105,917)	(178,792)	(158,274)
Cash flows from investing activities:
Purchase of property and equipment	(70)	(2,176)	(5,571)
Proceeds from sale of property and equipment	865	0	30
Purchases of intangible assets	(175)	0	(90)
Investment in associates	0	(19,961)	0
Purchase of investments held at fair value	0	(5,000)	(500)
Sale of investments held at fair value	33,309	118,710	218,125
Purchase of short-term note from associate	0	0	(15,000)
Repayment of short-term note from associate	0	15,000	0
Purchase of Convertible Note from associate	(16,850)	(15,000)	0
Cash derecognized upon loss of control over subsidiary (see table below)	(13,784)	(479)	0
Purchases of short-term investments	(178,860)	(248,733)	0
Proceeds from maturity of short-term investments	244,556	50,000	0
Receipt of payment of sublease	0	415	381
Net cash provided by (used in) investing activities	68,991	(107,223)	197,375
Cash flows from financing activities:
Receipt of cash from sale of future royalties	100,000	0	0
Issuance of subsidiary preferred Shares	0	0	37,610
Issuance of Subsidiary Convertible Note	0	393	2,215
Payment of lease liability	(3,338)	(4,025)	(3,375)
Exercise of stock options	1,153	332	352
Settlement of restricted stock unit equity awards	0	0	(10,749)
Vesting of restricted stock units and net share exercise	0	0	(2,582)
NCI exercise of stock options in subsidiary	0	7	66
Purchase of treasury stock	(19,650)	(26,492)	0
Acquisition of a non-controlling Interest of a subsidiary	0	0	(806)
Other	(23)	(41)	(5)
Net cash provided by (used in) financing activities	78,141	(29,827)	22,727
Net increase (decrease) in cash and cash equivalents	41,215	(315,842)	61,827
Cash and cash equivalents at beginning of year	149,866	465,708	403,881
Cash and cash equivalents at end of year	191,081	149,866	465,708
Supplemental disclosure of non-cash investment and financing activities:
Purchase of intangible assets not yet paid in cash	25	0
Settlement of restricted stock units through issuance of equity	1,142	1,528	0
Purchase of property, plant and equipment against trade and other payables	0	0	1,841
Leasehold improvements purchased through lease incentives (deducted from Right of Use Asset)	0	0	1,010
Conversion of subsidiary convertible note into preferred share liabilities	$ 0	$ 0	$ 25,797

Consolidated Statement of Cas_2

Consolidated Statement of Cash Flows - Parenthetical - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Statement Of Cash Flows [Line Items]
Trade and other receivables	$ (2,376)	$ (11,867)
Prepaid assets	(4,309)	(11,617)
Property, plant and equipment, net	(9,536)	(22,957)
Right of use asset, net	(9,825)	(14,281)
Trade and other payables	44,107	54,840
Deferred revenue	0	2,185
Lease liabilities (including current potion)	21,644	29,128
Long-term loan (including current portion)	0	5,156
Subsidiary notes payable	3,699	2,345
Non-controlling interests	(5,835)	5,369
Total equity	458,232	547,589
Investment retained in deconsolidated subsidiary	77,945	(32,060)
Gain on deconsolidation	61,787	27,251
Deconsolidated former subsidiary operating companies
Statement Of Cash Flows [Line Items]
Trade and other receivables	(702)	0
Prepaid assets	(3,516)	0
Property, plant and equipment, net	(8,092)	0
Right of use asset, net	(2,477)	0
Trade and other payables	15,078	1,407
Deferred revenue	1,902	0
Lease liabilities (including current potion)	4,146	0
Long-term loan (including current portion)	15,446	0
Subsidiary notes payable	0	3,403
Subsidiary preferred shares and warrants	24,568	15,853
Other assets and liabilities, net	(323)	123
Non-controlling interests	9,085	(11,904)
Total equity	55,115	8,882
Investment retained in deconsolidated subsidiary	20,456	18,848
Gain on deconsolidation	(61,787)	(27,251)
Cash in deconsolidated subsidiary	$ 13,784	$ 479

Material Accounting Policies

Material Accounting Policies	12 Months Ended
	Dec. 31, 2023
Accounting Policies 1 [Abstract]
Material Accounting Policies	Material Accounting Policies Description of Business PureTech Health plc (the “Parent”) is a public company incorporated, domiciled and registered in the United Kingdom (“UK”). The registered number is 09582467 and the registered address is 13th Floor, One Angel Court, London, EC2R 7HJ, United Kingdom. The Parent and its subsidiaries are together referred to as the “Group”. The accounting policies set out below have, unless otherwise stated, been applied consistently to all periods presented in these group financial statements. For presentation of the Consolidated Statement of Comprehensive Income/(Loss), the Group uses a classification based on the function of expenses, rather than based on their nature, as it is more representative of the format used for internal reporting and management purposes and is consistent with international practice. Certain amounts in the Consolidated Financial Statements and accompanying notes may not add due to rounding. All percentages have been calculated using unrounded amounts. Basis of Measurement The Consolidated Financial Statements are prepared on the historical cost basis except that the following assets and liabilities are stated at their fair value: investments held at fair value, investments in notes from associates and liabilities classified as fair value through the profit or loss. Use of Judgments and Estimates In preparing the Consolidated Financial Statements, management has made judgements, estimates and assumptions that affect the application of the Group’s accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an on-going basis. Significant estimation is applied in determining the following: • Financial instruments valuations (see Note 18. Financial Instruments): In accordance with IFRS 9, the Group carries certain financial assets and financial liabilities at fair value, with changes in fair value through profit and loss ("FVTPL"). Valuation of the aforementioned financial instruments (assets and liabilities) includes making significant estimates, specifically determining the appropriate valuation methodology and making certain estimates such as the future expected returns on the financial instrument in different scenarios, appropriate discount rate, volatility, and term to exit. Significant judgement is also applied in determining the following: • Whether financial instruments should be classified as liability or equity (see Note 16. Subsidiary Preferred Shares.). The judgement includes an assessment of whether the financial instruments include contractual obligations of the Group to deliver cash or other financial assets or to exchange financial assets or financial liabilities with another party, and whether those obligations could be settled by the Group exchanging a fixed amount of cash or other financial assets for a fixed number of its own equity instruments. Further information about these critical judgements and estimates is included below under Financial Instruments. • Whether the power to control investees exists (see Note 5. Investments Held at Fair Value and Note 6. Investments in Associates and accounting policy with regard to Subsidiaries below). The judgement includes an assessment of whether the Group has (i) power over the investee; (ii) exposure, or rights, to variable returns from its involvement with the investee; and (iii) the ability to use its power over the investee to affect the amount of its own returns. The Group considers among others its voting shares, shareholder agreements, ability to appoint board members, representation on the board, rights to appoint management, de facto control, investee dependence on the Group, etc. If the power to control the investee exists, it consolidates the financial statements of such investee in the Consolidated Financial Statements of the Group. Upon issuance of new shares in an investee and/or a change in any shareholders or governance agreements, the Group reassesses its ability to control the investee based on the revised voting interest, revised board composition and revised subsidiary governance and management structure. When such new circumstances result in the Group losing its power to control the investee, the investee is deconsolidated. On March 1 2023 Vedanta was deconsolidated. Although the Group holds 47% of the voting rights and the other shareholders are widely dispersed, the Group does not have de facto control because the investor rights agreement stipulates that the relevant activities of Vedanta are directed by Vedanta's Board and the Group does not control Vedanta's Board decision making. Voting rights are not the dominant factor for directing Vedanta's relevant activities. • Whether the Group has significant influence over financial and operating policies of investees in order to determine if the Group should account for its investment as an associate based on IAS 28 or a financial instrument based on IFRS 9. (refer to Note 5. Investments Held at Fair Value and Note 6. Investments in Associates ). This judgement includes, among others, an assessment whether the Group has representation on the board of directors of the investee, whether the Group participates in the policy making processes of the investee, whether there is any interchange of managerial personnel, whether there is any essential technical information provided to the investee and if there are any transactions between the Group and the investee. • Upon determining that the Group does have significant influence over the financial and operating policies of an investee, if the Group holds more than a single instrument issued by its equity-accounted investee, judgement is required to determine whether the additional instrument forms part of the investment in the associate, which is accounted for under IAS 28 and scoped out of IFRS 9, or it is a separate financial instrument that falls in the scope of IFRS 9. This judgement includes an assessment of the characteristics of the financial instrument of the investee held by the Group and whether such financial instrument provides access to returns underlying an ownership interest. • When the Group has other investments in an equity accounted investee that are not accounted for under IAS 28, judgement is required in determining if such investments constitute long-term interests ("LTI") for the purposes of IAS 28. This determination is based on the individual facts and circumstances and characteristics of each investment, but is driven, among other factors, by the intention and likelihood to settle the instrument through redemption or repayment in the foreseeable future, and whether or not the investment is likely to be converted to common stock or other equity instruments. After considering the individual facts and circumstances of the Group’s investment in its associate's preferred stock in the manner described above, including the long-term nature of such investment, the ability of the Group to convert its preferred stock investment to an investment in common shares and the likelihood of such conversion, the Group concluded that such investment was considered a long term interest. • In determining the appropriate accounting treatment for the Royalty Purchase Agreement, management applied significant judgement (refer to Note 17. Sale of Future Royalties Liability). As of December 31, 2023, the Group had cash and cash equivalents of $191,081 and short-term investments of $136,062. Considering the Group’s financial position as of December 31, 2023, and its principal risks and opportunities, the Group prepared a going concern analysis covering a period of at least the twelve-month period from the date of signing the Consolidated Financial Statements ("the going concern period") utilizing realistic scenarios and applying a severe but plausible downside scenario. Even under the downside scenario, the analysis demonstrates the Group continues to maintain sufficient liquidity headroom and continues to comply with all financial obligations. The Board of Directors believe the Group and the Parent is adequately resourced to continue in operational existence for at least the twelve-month period from the date of signing the Consolidated Financial Statements. Accordingly, the Board of Directors considered it appropriate to adopt the going concern basis of accounting in preparing the Consolidated Financial Statements and the PureTech Health plc Financial Statements. Basis of consolidation The Consolidated Financial Statements as of December 31, 2023 and 2022, and for each of the years ended December 31, 2023, 2022 and 2021, comprises PureTech Health plc and its consolidated subsidiaries. Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated. Subsidiaries As used in these financial statements, the term subsidiaries refers to entities that are controlled by the Group. Under applicable accounting rules, the Group controls an entity when it is exposed to, or has the rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. In assessing control, the Group takes into consideration potential voting rights, board representation, shareholders' agreements, ability to appoint board of directors and management, de facto control and other related factors. The financial statements of subsidiaries are included in the Consolidated Financial Statements from the date that control commences until the date that control ceases. Losses applicable to the non-controlling interests in a subsidiary are allocated to the non-controlling interests even if doing so causes the non-controlling interests to have a deficit balance. A list of all current and former subsidiaries organized with respect to classification as of December 31, 2023, and the Group’s total voting percentage, based on outstanding voting common and preferred shares as of December 31, 2023, 2022 and 2021, is outlined below. All current subsidiaries are domiciled within the United States and conduct business activities solely within the United States. Voting percentage at December 31, through the holdings in 2023 2022 2021 Subsidiary Common Preferred Common Preferred Common Preferred Subsidiary operating companies Alivio Therapeutics, Inc. 2 — 100.0 — 100.0 — 100.0 Entrega, Inc. (indirectly held through Enlight) 2 — 77.3 — 77.3 — 77.3 PureTech LYT, Inc. (formerly Ariya Therapeutics, Inc.) 2 — 100.0 — 100.0 — 100.0 PureTech LYT 100, Inc. 2 — 100.0 — 100.0 — 100.0 PureTech Management, Inc. 3 100.0 — 100.0 — 100.0 — PureTech Health LLC 3 100.0 — 100.0 — 100.0 — Deconsolidated former subsidiary operating companies Sonde Health, Inc. 2,5 — 40.2 — 40.2 — 51.8 Akili Interactive Labs, Inc. 2,6 14.6 — 14.7 — — 26.7 Gelesis, Inc. 1,2 — — 22.8 — 4.8 19.7 Karuna Therapeutics, Inc. 2,6 2.3 — 3.1 — 5.6 — Vedanta Biosciences, Inc. 2, 4 — 47.0 — 47.0 — 48.6 Vedanta Biosciences Securities Corp. (indirectly held through Vedanta) 2, 4 — 47.0 — 47.0 — 48.6 Vor Biopharma Inc .2,6 3.9 — 4.1 — 8.6 — Nontrading holding companies Endra Holdings, LLC (held indirectly through Enlight) 2 86.0 — 86.0 — 86.0 — Ensof Holdings, LLC (held indirectly through Enlight) 2 86.0 — 86.0 — 86.0 — PureTech Securities Corp. 2 100.0 — 100.0 — 100.0 — PureTech Securities II Corp. 2 100.0 — 100.0 — 100.0 — Inactive subsidiaries Appeering, Inc. 2 — 100.0 — 100.0 — 100.0 Commense Inc. 2 — 99.1 — 99.1 — 99.1 Enlight Biosciences, LLC 2 86.0 — 86.0 — 86.0 — Ensof Biosystems, Inc. (held indirectly through Enlight) 2 57.7 28.3 57.7 28.3 57.7 28.3 Follica, LLC 2 28.7 56.7 28.7 56.7 28.7 56.7 Knode Inc. (indirectly held through Enlight) 2 — 86.0 — 86.0 — 86.0 Libra Biosciences, Inc. 2 — 100.0 — 100.0 — 100.0 Mandara Sciences, LLC 2 98.3 — 98.3 — 98.3 — Tal Medical, Inc. 2 — 100.0 — 100.0 — 100.0 1 On October 30, 2023, Gelesis ceased operations and filed a voluntary petition for relief under the United States bankruptcy code. See Note 6. Investments in Associates for details. 2 Registered address is Corporation Trust Center, 1209 Orange St., Wilmington, DE 19801, USA. 3 Registered address is 2711 Centerville Rd., Suite 400, Wilmington, DE 19808, USA. 4 On March 1, 2023, the Group lost control over Vedanta and Vedanta was deconsolidated from the Group’s financial statements, resulting in only the profits and losses generated by Vedanta through the deconsolidation date being included in the Group’s Consolidated Statement of Comprehensive Income/(Loss). See Notes 5. Investments Held at Fair Value for further details about the accounting for the investments in Vedanta subsequent to deconsolidation. 5 On May 25, 2022, the Group lost control over Sonde and Sonde was deconsolidated from the Group’s financial statements, resulting in only the profits and losses generated by Sonde through the deconsolidation date being included in the Group’s Consolidated Statement of Comprehensive Income/(Loss). See Notes 5. Investments Held at Fair Value and 6. Investments in Associates for further details about the accounting for the investments in Sonde subsequent to deconsolidation. 6 See Notes 5. Investments Held at Fair Value and 6. Investments in Associates for additional discussion on the Group's investment held in Akili, Karuna and Vor. 7 Follica became inactive during 2023. Change in Subsidiary Ownership and Loss of Control Changes in the Group’s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. Where the Group loses control of a subsidiary, the assets and liabilities are derecognized along with any related non-controlling interest (“NCI”). Any interest retained in the former subsidiary is measured at fair value when control is lost. Any resulting gain or loss is recognized as profit or loss in the Consolidated Statement of Comprehensive Income/(Loss). Associates As used in these financial statements, the term associates are those entities in which the Group has no control but maintains significant influence over the financial and operating policies. Significant influence is presumed to exist when the Group holds between 20 and 50 percent of the voting power of an entity, unless it can be clearly demonstrated that this is not the case. The Group evaluates if it maintains significant influence over associates by assessing if the Group has the power to participate in the financial and operating policy decisions of the associate. Application of the Equity Method to Associates Associates are accounted for using the equity method (equity accounted investees) and are initially recognized at cost, or if recognized upon deconsolidation, they are initially recorded at fair value at the date of deconsolidation. The Consolidated Financial Statements include the Group’s share of the total comprehensive income or loss of equity accounted investees, from the date that significant influence commences until the date that significant influence ceases. To the extent the Group holds interests in associates that are not providing access to returns underlying ownership interests, the instrument is accounted for in accordance with IFRS 9 as investments held at fair value. When the Group’s share of losses exceeds its equity method investment in the investee, losses are applied against long-term interests, which are investments accounted for under IFRS 9. Investments are determined to be long-term interests when they are long-term in nature and in substance they form part of the Group's net investment in that associate. This determination is impacted by many factors, among others, whether settlement by the investee through redemption or repayment is planned or likely in the foreseeable future, whether the investment can be converted and/or is likely to be converted to common stock or other equity instrument and other factors regarding the nature of the investment. Whilst this assessment is dependent on many specific facts and circumstances of each investment, typically conversion features whereby the investment is likely to convert to common stock or other equity instruments would point to the investment being a long-term interest. Similarly, where the investment is not planned or likely to be settled through redemption or repayment in the foreseeable future, this would indicate that the investment is a long-term interest. When the net investment in the associate, which includes the Group’s investments in other long-term interests, is reduced to nil, recognition of further losses is discontinued except to the extent that the Group has incurred legal or constructive obligations or made payments on behalf of an investee. The Group has adopted the amendments to IAS 28 Investments in Associates that addresses the dual application of IAS 28 and IFRS 9 when equity method losses are applied against long-term interests. The amendments provide the annual sequence in which both standards are to be applied in such a case. The Group has applied the equity method losses to the long-term interests presented as part of Investments held at fair value subsequent to remeasuring such investments to their fair value at balance sheet date. Sale of Future Royalties Liability The Group accounts for the sale of future royalties liability as a financial liability, as it continues to hold the rights under the royalty bearing licensing agreement and has a contractual obligation to deliver cash to an investor for a portion of the royalty it receives. Interest on the sale of future royalties liability is recognized using the effective interest rate over the life of the related royalty stream. The sale of future royalties liability and the related interest expense are based on the Group’s current estimates of future royalties expected to be paid over the life of the arrangement. Forecasts are updated periodically as new data is obtained. Any increases, decreases or a shift in timing of estimated cash flows require the Group to re-calculate the amortized cost of the sale of future royalties liability as the present value of the estimated future contractual cash flows that are discounted at the liability’s original effective interest rate. The adjustment is recognized immediately in profit or loss as income or expense. Financial Instruments Classification The Group classifies its financial assets in the following measurement categories: • Those to be measured subsequently at fair value either through other comprehensive income "FVOCI", or through profit or loss "FVTPL", and • Those to be measured at amortized cost. The classification depends on the Group’s business model for managing the financial assets and the contractual terms of the cash flows. For assets measured at fair value, gains and losses are recorded in profit or loss. Measurement At initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset not at FVTPL, transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets that are carried at FVTPL are expensed. Impairment The Group assesses on a forward-looking basis the expected credit losses associated with its debt instruments carried at amortized cost. For trade receivables, the Group applies the simplified approach permitted by IFRS 9, which requires expected lifetime losses to be recognized from initial recognition of the receivables. Financial Assets The Group’s financial assets consist of cash and cash equivalents, investments in debt securities, trade and other receivables, notes, restricted cash deposits and investments in equity securities. The Group’s financial assets are virtually all classified into the following categories: investments held at fair value, notes, trade and other receivables, short-term investments and cash and cash equivalents. The Group determines the classification of financial assets at initial recognition depending on the purpose for which the financial assets were acquired. Investments held at fair value are investments in equity instruments. Such investments consist of the Group's minority interest holdings where the Group has no significant influence or preferred share investments that are not providing access to returns underlying ownership interests and are categorized as debt instruments that are presented at fair value through profit and loss because the amounts receivable do not represent solely payments of principal and interest. These financial assets are initially measured at fair value and subsequently re-measured at fair value at each reporting date. The Group has elected to record the changes in fair values for the financial assets falling under this category through profit and loss. Please refer to Note 5. Investments Held at Fair Value. Changes in the fair value of financial assets at FVTPL are recognized in other income/(expense) in the Consolidated Statement of Comprehensive Income/(Loss) as applicable. The notes from an associate, since their contractual terms do not consist solely of cash flow payments of principal and interest on the principal amount outstanding, are initially and subsequently measured at fair value, with changes in fair value recognized through profit and loss. Cash and cash equivalents consist of demand deposits with banks and other financial institutions and highly liquid instruments with original maturities of three months or less at the date of purchase. Cash and cash equivalents are carried at cost, which approximates their fair value. Short-term investments consist of short-term US treasury bills that are held to maturity. The contractual terms consist solely of payment of the principal and interest and the Group's business model is to hold the treasury bills to maturity. As such, such short-term investments are recorded at amortized cost. As of balance sheet date, amortized cost approximated the fair value of such short-term investments. Trade and other receivables are non-derivative financial assets with fixed and determinable payments that are not quoted on active markets. These financial assets are carried at the amounts expected to be received less any expected lifetime losses. Such losses are determined taking into account previous experience, credit rating and economic stability of counterparty and economic conditions. When a trade receivable is determined to be uncollectible, it is written off against the available provision. As of balance sheet date, the Group did not record any such expected lifetime losses related to the outstanding trade and other receivable balances. Trade and other receivables are included in current assets, unless maturities are greater than 12 months after the end of the reporting period. Financial Liabilities The Group’s financial liabilities primarily consist of trade and other payables, and preferred shares. The majority of the Group’s subsidiaries have preferred shares and certain notes payable with embedded derivatives, which are classified as current liabilities. When the Group has preferred shares and notes with embedded derivatives that qualify for bifurcation, the Group has elected to account for the entire instrument as FVTPL after determining under IFRS 9 that the instrument qualifies to be accounted for under such FVTPL method. The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled or expire. Equity Instruments Issued by the Group Financial instruments issued by the Group are treated as equity only to the extent that they meet the following two conditions, in accordance with IAS 32: 1. They include no contractual obligations upon the Group to deliver cash or other financial assets or to exchange financial assets or financial liabilities with another party under conditions that are potentially unfavorable to the Group; and 2. Where the instrument will or may be settled in the Group’s own equity instruments, it is either a non-derivative that includes no obligation to deliver a variable number of the Group’s own equity instruments or is a derivative that will be settled by the Group exchanging a fixed amount of cash or other financial assets for a fixed number of its own equity instruments. To the extent that this definition is not met, the financial instrument is classified as a financial liability. Where the instrument so classified takes the legal form of the Group’s own shares, the amounts presented in the Group's shareholders' equity exclude amounts in relation to those shares. Changes in the fair value of liabilities at FVTPL are recognized in net finance income /(costs) in the Consolidated Statement of Comprehensive Income/(Loss) as applicable. IFRS 15, Revenue from Contracts with Customers The standard establishes a five-step principle-based approach for revenue recognition and is based on the concept of recognizing an amount that reflects the consideration for performance obligations only when they are satisfied and the control of goods or services is transferred. The majority of the Group’s contract revenue is generated from licenses and services, some of which are part of collaboration arrangements. Management reviewed contracts where the Group received consideration in order to determine whether or not they should be accounted for in accordance with IFRS 15. To date, the Group has entered into transactions that generate revenue and meet the scope of either IFRS 15 or IAS 20 Accounting for Government Grants. Contract revenue is recognized at either a point-in-time or over time, depending on the nature of the performance obligations. The Group accounts for agreements that meet the definition of IFRS 15 by applying the following five step model: • Identify the contract(s) with a customer – A contract with a customer exists when (i) the Group enters into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to those goods or services, (ii) the contract has commercial substance and, (iii) the Group determines that collection of substantially all consideration for goods or services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration. • Identify the performance obligations in the contract – Performance obligations promised in a contract are identified based on the goods or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the good or service either on its own or together with other resources that are readily available from third parties or from the Group, and are distinct in the context of the contract, whereby the transfer of the goods or services is separately identifiable from other promises in the contract. • Determine the transaction price – The transaction price is determined based on the consideration to which the Group will be entitled in exchange for transferring goods or services to the customer. To the extent the transaction price includes variable consideration, the Group estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in the Group’s judgement, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. • Allocate the transaction price to the performance obligations in the contract – If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price basis. • Recognize revenue when (or as) the Group satisfies a performance obligation – The Group satisfies performance obligations either over time or at a point in time as discussed in further detail below. Revenue is recognized at the time the related performance obligation is satisfied by transferring a promised good or service to a customer. Revenue generated from services agreements (typically where licenses and related services were combined into one performance obligation) is determined to be recognized over time when it can be determined that the services meet one of the following: (a) the customer simultaneously receives and consumes the benefits provided by the entity’s performance as the entity performs; (b) the entity’s performance creates or enhances an asset that the customer controls as the asset is created or enhanced; or (c) the entity’s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. It was determined that the Group has contracts that meet criteria (a), since the customer simultaneously receives and consumes the benefits provided by the Group’s performance as the Group performs. Therefore revenue is recognized over time using the input method based on costs incurred to date as compared to total contract costs. The Group believes that in research and development service type agreements using costs incurred to date represents the most faithful depiction of the entity’s performance towards complete satisfaction of a performance obligation. Revenue from licenses that are not part of a combined performance obligation are recognized at a point in time due to the licenses relating to intellectual property that has significant stand-alone functionality and as such represent a right to use the entity's intellectual property as it exists at the point in time at which the license is granted. Royalty income received in respect of licensing agreements when the license of intellectual property is the predominant item in the arrangement is recognized as the related third-party sales in the licensee occur. Amounts that are receivable or have been received per contractual terms but have not been recognized as revenue since performance has not yet occurred or has not yet been completed are recorded as deferred revenue. The Group classifies as non-current deferred revenue amounts received for which performance is expected to occur beyond one year or one operating cycle. Grant Revenue The Group recognizes grants from governmental agencies as grant revenue in the Consolidated Statement of Comprehensive Income/(Loss), gross of the expenditures that were related to obtaining the grant, when there is reasonable assurance that the Group will comply with the conditions within the grant agreement and there is reasonable assurance that payments under the grants will be received. The Group evaluates the conditions of each grant as of each reporting date to ensure that the Group has reasonable assurance of meeting the conditions of each grant arrangement and that it is expected that the grant payment will be received as a result of meeting the necessary conditions. The Group submits qualifying expenses for reimbursement after the Group has incurred the research and development expense. The Group records an unbilled receivable upon incurring such expenses. In cases in which the grant revenue is received prior to the expenses being incurred or recognized, the amounts received are deferred until the related expense is incurred and/or recognized. Grant revenue is recognized in the Consolidated Statement of Comprehensive Income/(Loss) at the time in which the Group recognizes the related reimbursable expense for which the grant is intended to compensate. Functional and Presentation Currency The Consolidated Financial Statements are presented in United States dollars (“US dollars”). The functional currency of all members of the Group is the U.S. dollar. The Group's share in foreign exchange differences in associates were reported in other comprehensive income/(loss). Foreign Currency Transactions in foreign currencies are translated to the respective functional currencies of Group entities at the foreign exchange rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are retranslated to the functional currency at the foreign exchange rate ruling at that date. Foreign exchange differences arising on remeasurement are recognized in the Consolidate

New Standards and Interpretatio

New Standards and Interpretations	12 Months Ended
	Dec. 31, 2023
New Standards and Interpretations Not Yet Adopted [Abstract]
New Standards and Interpretations	New Standards and Interpretations The Group has applied the following amendments for the first time for its annual reporting period commencing January 1, 2023: • IFRS 17 Insurance Contracts • Definition of Accounting Estimates (Amendments to IAS 8) • Deferred Tax related to Assets and Liabilities Arising from a Single Transaction (Amendments to IAS 12) The amendments listed above did not have any impact on the amounts recognized in prior and current periods and are not expected to significantly affect the future periods. Certain new accounting standards, amendments to accounting standards and interpretations have been published that are not mandatory for December 31, 2023 reporting periods and have not been early adopted by the Group. These standards, amendments or interpretations are not expected to have a material impact on the Group in the current or future reporting periods and on foreseeable future transactions.

Revenue

Revenue	12 Months Ended
	Dec. 31, 2023
Revenue [abstract]
Revenue	Revenue Revenue recorded in the Consolidated Statement of Comprehensive Income/(Loss) consists of the following: For the years ended December 31, 2023 $ 2022 $ 2021 $ Contract revenue 750 2,090 9,979 Grant revenue 2,580 13,528 7,409 Total revenue 3,330 15,618 17,388 All amounts recorded in contract revenue were generated in the United States. For the years ended December 31, 2023, 2022 and 2021, contract revenue includes royalties received from an associate in the amounts of zero, $509 and $231, respectively. Substantially all of the Group’s contracts related to contract revenue for the years ended December 31, 2023, 2022 and 2021 were determined to have a single performance obligation which consists of a combined deliverable of license of intellectual property and research and development services. Therefore, for such contracts, revenue is recognized over time based on the input method which the Group believes is a faithful depiction of the transfer of goods and services. Progress is measured based on costs incurred to date as compared to total projected costs. Payments for such contracts are primarily made up-front on a periodic basis. During the year ended December 31, 2021, the Group received a $6,500 payment from Imbrium Therapeutics, Inc. following the exercise of the option to acquire an exclusive license for the Initial Product Candidate, as defined in the agreement. Since the license transferred was a right to use license, revenue from the option exercise was recognized at a point in time upon transfer of the license, which occurred during the year ended December 31, 2021. Disaggregated Revenue The Group disaggregates contract revenue in a manner that depicts how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. The Group disaggregates revenue based on contract revenue or grant revenue, and further disaggregates contract revenue based on the transfer of control of the underlying performance obligations. Timing of contract revenue recognition For the years ended December 31, 2023 $ 2022 $ 2021 $ Transferred at a point in time – Licensing Income — 527 6,809 Transferred over time 750 1,563 3,171 750 2,090 9,979 Customers over 10% of revenue 2023 $ 2022 $ 2021 $ Customer A 750 1,500 1,500 Customer B — — 7,250 Customer C — 509 — 750 2,009 8,750

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2023
Segment Information [Abstract]
Segment Information	Segment Information Basis for Segmentation The Directors are the Group’s chief operating decision-makers. The Group’s operating segments are determined based on the financial information provided to the Board of Directors periodically for the purposes of allocating resources and assessing performance. During the second half of 2023, the Group changed the financial information that was regularly reviewed by the Board of Directors to allocate resources and assess performance. The Group has determined each of its Wholly-Owned Programs represents an operating segment and the Group has aggregated each of these operating segments into one reportable segment, the Wholly-Owned Programs segment, given the high level of operational and financial similarities across its Wholly-Owned Programs. Each of the Group’s Controlled Founded Entities represents an operating segment. The Group aggregates each Controlled Founded Entity operating segment into one reportable segment, the Controlled Founded Entities segment. For the Group’s entities that do not meet the definition of an operating segment, the Group presents this information in the Parent & Other column in its segment footnote to reconcile the information in this footnote to the Consolidated Financial Statements. Substantially all of the Group’s revenue and profit generating activities are generated within the United States and, accordingly, no geographical disclosures are provided. The Group has retroactively recast its fiscal year 2022 and 2021 results on the new basis for comparability. Following is the description of the Group's reportable segments: Wholly-Owned Programs The Wholly-Owned Programs segment is advancing Wholly-Owned Programs which are focused on treatments for patients with devastating diseases. The Wholly-Owned Programs segment is comprised of the technologies that are wholly-owned and will be advanced through with either the Group's funding or non-dilutive sources of financing. The operational management of the Wholly-Owned Programs segment is conducted by the PureTech Health team, which is responsible for the strategy, business development, and research and development. Controlled Founded Entities The Controlled Founded Entities segment is comprised of the Group’s consolidated operational subsidiaries as of December 31, 2023 that either have, or have plans to hire, independent management teams and currently have already raised third-party dilutive capital. These subsidiaries have active research and development programs and either have entered into or plan to seek an equity or debt investment partner, who will provide additional industry knowledge and access to networks, as well as additional funding to continue the pursued growth of the entity. The Group’s entities that were determined not to meet the definition of an operating segment are included in the Parent Company and Other column to reconcile the information in this footnote to the financial statements. This column captures activities not directly attributable to the Group's operating segments and includes the activities of the Parent, corporate support functions and certain research and development support functions that are not directly attributable to a strategic business segment as well as the elimination of intercompany transactions. This column also captures the operating results for the deconsolidated entities through the date of deconsolidation (e.g. Vedanta in 2023 and Sonde in 2022) and accounting for the Group's holdings in Founded Entities for which control has been lost, which primarily represents: the activity associated with deconsolidating an entity when the Group no longer controls the entity (e.g. Vedanta in 2023 and Sonde in 2022), the gain or loss on the Group's investments accounted for at fair value (e.g. the Group's ownership stakes in Karuna, Vor and Akili) and the Group's net income or loss of associates accounted for using the equity method. (The term "Founded Entities" refers to entities which the Company incorporated and announced the incorporation as a Founded Entity externally. It includes certain of the Company’s wholly-owned subsidiaries which have been announced by the Company as Founded Entities, Controlled Founded Entities and deconsolidated Founded Entities.) In January 2024, the Group launched two new Founded Entities to advance certain programs from the Wholly-Owned Programs segment. Refer to Note 28. Subsequent Events for detail. The financial results of these programs were included in the Wholly-Owned Programs segment as of December 31, 2023 and 2022 and for the three years ended December 31, 2023, 2022 and 2021, respectively. Upon raising dilutive third-party financing, the financial results of these two entities will be included in the Controlled Founded Entities segment to the extent that the Group maintains control over these entities. The Group’s Board of Directors reviews segment performance and allocates resources based upon revenue and operating loss as well as the funds available for each segment. The Board of Directors do not review any other information for purposes of assessing segment performance or allocating resources. For the year ended December 31, 2023 Wholly-Owned Programs $ Controlled Founded Entities $ Parent Company & Other $ Consolidated $ Contract revenue — 750 — 750 Grant revenue 853 — 1,727 2,580 Total revenue 853 750 1,727 3,330 General and administrative expenses (14,020) (562) (38,713) (53,295) Research and development expenses (89,495) (672) (6,068) (96,235) Total operating expense (103,516) (1,233) (44,781) (149,530) Operating income/(loss) (102,662) (483) (43,054) (146,199) Income/expenses not allocated to segments Other income/(expense): Gain on deconsolidation of subsidiary 61,787 Gain/(loss) on investment held at fair value 77,945 Realized loss on sale of investments (122) Gain/(loss) on investment in notes from associates (27,630) Other income/(expense) (908) Total other income/(expense) 111,072 Net finance income/(costs) 5,078 Share of net income/(loss) of associates accounted for using the equity method (6,055) Income/(loss) before taxes (36,103) As of December 31, 2023 Available Funds Cash and cash equivalents 2,140 675 188,266 191,081 Short-term Investments — — 136,062 136,062 Consolidated cash, cash equivalents and short-term investments 2,140 675 324,328 327,143 For the year ended December 31, 2022 Wholly-Owned Programs Controlled Founded Entities $ Parent Company & Other $ Consolidated $ Contract revenue — 1,500 590 2,090 Grant revenue 2,826 — 10,702 13,528 Total revenue 2,826 1,500 11,292 15,618 General and administrative expenses (8,301) (419) (52,272) (60,991) Research and development expenses (116,054) (1,051) (35,328) (152,433) Total Operating expenses (124,355) (1,470) (87,600) (213,425) Operating income/(loss) (121,529) 30 (76,308) (197,807) Income/expenses not allocated to segments Other income/(expense): Gain on deconsolidation 27,251 Gain/(loss) on investment held at fair value (32,060) Realized loss on sale of investments (29,303) Other income/(expense) 8,131 Total other income/(expense) (25,981) Net finance income/(costs) 138,924 Share of net income/(loss) of associate accounted for using the equity method (27,749) Gain on dilution of ownership interest in associate 28,220 Impairment of investment in associates (8,390) Income/(loss) before taxes (92,783) As of December 31, 2022 Available Funds Cash and cash equivalents 7,306 823 141,737 149,866 Short-term Investments — — 200,229 200,229 Consolidated cash, cash equivalents and short-term investments 7,306 823 341,966 350,095 For the year ended December 31, 2021 Wholly-Owned Programs Controlled Founded Entities $ Parent Company & Other $ Consolidated $ Contract revenue 8,129 1,500 350 9,979 Grant revenue 1,253 — 6,156 7,409 Total revenue 9,382 1,500 6,506 17,388 General and administrative expenses (8,673) (365) (48,161) (57,199) Research and development expenses (65,444) (918) (44,108) (110,471) Total operating expense (74,118) (1,284) (92,269) (167,671) Operating income/(loss) (64,736) 216 (85,763) (150,282) Income/expenses not allocated to segments Other income/(expense): Gain/(loss) on investment held at fair value 179,316 Realized loss on sale of investments (20,925) Other income/(expense) 1,592 Other income/(expense) 159,983 Net finance income/(costs) 5,050 Share of net income/(loss) of associate accounted for using the equity method (73,703) Income/(loss) before taxes (58,953)

Investments held at fair value

Investments held at fair value	12 Months Ended
	Dec. 31, 2023
Investments held at fair value [Abstract]
Investments held at fair value	Investments Held at Fair Value Investments held at fair value include both unlisted and listed securities held by the Group. These investments, which include interests in Akili, Vor, Karuna, Sonde, Vedanta, Gelesis and other insignificant investments, are initially measured at fair value and are subsequently re-measured at fair value at each reporting date with changes in the fair value recorded through profit and loss. Activities related to such investments during the periods are shown below: Investments held at fair value $ Balance as of January 1, 2022 493,888 Investment in Sonde preferred shares - Sonde deconsolidation 11,168 Sale of Karuna and Vor shares (118,710) Loss realised on sale of investments as a result of written call option (29,303) Investment in Akili common shares 5,000 Gelesis Earn-out Shares received in the SPAC exchange 14,214 Exchange of Gelesis preferred shares to Gelesis common shares (92,303) Loss – change in fair value through profit and loss (32,060) Balance as of December 31, 2022 and January 1, 2023 251,892 Investment in Vedanta preferred shares – Vedanta deconsolidation 20,456 Investment in Gelesis 2023 Warrants 1,121 Sale of Karuna shares (33,309) Loss realised on sale of investments (265) Gain – change in fair value through profit and loss 77,945 Balance as of December 31, 2023 317,841 Vedanta On March 1, 2023, Vedanta issued convertible debt to a syndicate of investors. The Group did not participate in this round of financing. As part of the issuance of the debt, the convertible debt holders were granted representation on Vedanta's Board of Directors and the Group lost control over the Vedanta Board of Directors and the power to direct the relevant Vedanta activities. Consequently, Vedanta was deconsolidated on March 1, 2023 and its results of operations are included in the Consolidated Financial Statements through the date of deconsolidation. Following deconsolidation, the Group has significant influence over Vedanta through its voting interest in Vedanta and its remaining representation on Vedanta's Board of Directors. However, the Group only holds convertible preferred shares in Vedanta that do not provide their holders with access to returns associated with a residual equity interest, and as such are accounted for under IFRS 9, as investments held at fair value with changes in fair value recorded in profit and loss. Under IFRS 9, the preferred share investments are categorized as debt instruments that are presented at fair value through profit and loss because the amounts receivable do not represent solely payments of principal and interest. Upon deconsolidation, the Group derecognized its assets, liabilities and non-controlling interest in respect of Vedanta and recorded its aforementioned investment in Vedanta at fair value. The deconsolidation resulted in a gain of $61,787. As of the date of deconsolidation, the investment in Vedanta convertible preferred shares held at fair value amounted to $20,456. During the year ended December 31, 2023, the Group recognized a loss of $6,303 for the changes in the fair value of the investment in Vedanta that was included in gain/(loss) on investments held at fair value within the Consolidated Statement of Comprehensive Income/(Loss). The fair value of the Group’s investment in Vedanta is $14,153 as of December 31, 2023. Karuna Karuna was deconsolidated in March 2019. During 2019, Karuna completed its IPO and the Group lost its significant influence in Karuna. The shares held in Karuna are accounted for as an investment held at fair value under IFRS 9. 2021 On February 9, 2021, the Group sold 1,000,000 common shares of Karuna for $118,000. On November 9, 2021, the Group sold an additional 750,000 common shares of Karuna for $100,125. As a result of the aforementioned sales, the Group recorded a loss of $20,925, attributable to blockage discount included in the sales price, in realized gain/(loss) on sale of investments within the Consolidated Statement of Comprehensive Income/(Loss). 2022 On August 8, 2022, the Group sold 125,000 shares of Karuna common stock. In addition, the Group wrote a series of call options entitling the holders thereof to purchase up to 477,100 Karuna common stock at a set price, which were exercised in full in August and September 2022. Aggregate proceeds to the Group from all aforementioned transactions amounted to $115,457, net of transaction fees. As a result of the aforementioned sales, the Group recorded a loss of $29,303, attributable to the exercise of the aforementioned call options, in realized gain/(loss) on sale of investment within the Consolidated Statement of Comprehensive Income/(Loss). 2023 During the three months ended December 31, 2023, the Group sold 167,579 shares of Karuna common stock with aggregate proceeds of $33,309, net of transaction fees. During the years ended December 31, 2023, 2022, and 2021 the Group recorded gains of $107,079, $134,952, $109,987, respectively for the changes in the fair value of the Karuna investment that were included in gain/(loss) on investments held at fair value within the Consolidated Statement of Comprehensive Income/(Loss). As of December 31, 2023, the Group held 886,885 shares or 2.3 percent of total outstanding Karuna common stock. In December 2023, Karuna entered into a definitive merger agreement with Bristol Myers Squibb ("BMS") under which Karuna common shares were acquired by Bristol Myers Squibb for $330 per share in March 2024. See Note 28. Subsequent Events. The fair value of the Group’s investment in Karuna is $280,708 as of December 31, 2023. Vor Vor was deconsolidated in February 2019. As the Group did not hold common shares in Vor upon deconsolidation and the preferred shares it held did not have equity-like features. Therefore, the preferred shares held by the Group fell under the guidance of IFRS 9 and were treated as a financial asset held at fair value with changes in fair value recorded in the Consolidated Statement of Comprehensive Income/(Loss). 2021 On January 8, 2021, the Group participated in the second closing of Vor’s Series B preferred share financing. For consideration of $500, the Group received an additional 961,538 Series B preferred shares. On February 9, 2021, Vor closed its initial public offering (the "IPO") of 9,828,017 shares of its common stock at a price of $18.00 per share. Subsequent to the closing, the Group held 3,207,200 shares of Vor common stock, representing 8.6 percent of Vor common stock. 2022 In August and December 2022, the Group sold an aggregate of 535,400 shares of Vor common stock for aggregate proceeds of $3,253. During the years ended December 31, 2023, 2022 and 2021, the Group recognized a loss of $11,756, a loss of $16,247, and a gain of $3,903, respectively, for the changes in the fair value of the investment that were included in gain/(loss) on investments held at fair value within the Consolidated Statement of Comprehensive Income/(Loss). The fair value of the Group’s investment in Vor is $6,012 as of December 31, 2023. Gelesis Gelesis was deconsolidated in July 2019. The common stock held in Gelesis was accounted for under the equity method, while the preferred shares and warrants held by the Group fell under the guidance of IFRS 9 and were treated as financial assets held at fair value, with changes to the fair value of the instruments recorded through the Consolidated Statement of Comprehensive Income/(Loss). Please refer to Note 6. Investments in Associates for information regarding the Group's investment in Gelesis as an associate. 2021 During the year ended December 31, 2021, as the equity method based investment in Gelesis was reduced to zero previously, the Group allocated a portion of its share in the net loss in Gelesis of $73,703, to its preferred share and warrant investments in Gelesis, which were considered to be long-term interests in Gelesis. 2022 On January 13, 2022, Gelesis completed its business combination with Capstar Special Purpose Acquisition Corp ("Capstar"). As part of the business combination, all shares in Gelesis, common and preferred, including the shares held by the Group, were exchanged for common shares of the merged entity and unvested common shares that will vest upon the stock price of the new combined entity reaching certain target prices (hereinafter "Gelesis Earn-out Shares"). In addition, the Group invested $15,000 in the class A common shares of Capstar as part of the Private Investment in Public Equity ("PIPE") transaction that took place immediately prior to the closing of the business combination and an additional approximately $4,961, as part of the Backstop agreement signed with Capstar on December 30, 2021 (See Note 6. Investments in Associates). Pursuant to the business combination, Gelesis became a wholly-owned subsidiary of Capstar and Capstar changed its name to Gelesis Holdings, Inc., which began trading on the New York Stock Exchange under the ticker symbol "GLS" on January 14, 2022. The exchange of the preferred stock (including warrants) for common stock (including common stock warrants) represents an additional investment in Gelesis equity investment. The Group recorded the changes in fair value of the preferred stock and warrants through the date of the exchange upon which the preferred shares and warrants were derecognized and recorded as an additional investment in Gelesis equity interest. All equity method losses allocated in prior periods against the investment in Gelesis held at fair value were reclassified to include within the equity method investment in Gelesis and were offset against the gain on dilution of interest. As part of the aforementioned exchange, the Group received 4,526,622 Gelesis Earn-out Shares, which were valued on the date of the exchange at $14,214. The Group accounted for such Gelesis Earn-out Shares under IFRS 9 as investments held at fair value with changes in fair value recorded through profit and loss. 2023 In February and May 2023, as part of Gelesis' issuance of senior secured promissory notes to the Group, Gelesis also issued to the Group (i) warrants to purchase 23,688,047 shares of Gelesis common stock with an exercise price of $0.2744 per share (ii) warrants to purchase 192,307,692 shares of Gelesis common stock at an exercise price of $0.0182 per share and (iii) warrants to purchase 43,133,803 shares of Gelesis common stock at an exercise price of $0.0142 per share. These warrants expire five years after issuance and are collectively referred to as the Gelesis 2023 Warrants. The Gelesis 2023 Warrants were recorded at their initial fair value of $1,121 and then subsequently re-measured to fair value through the profit and loss. As of December 31, 2023, the fair value of the Gelesis 2023 Warrants was $0 as Gelesis ceased operations in October 2023 . During the years ended December 31, 2023, 2022 and 2021, the Group recognized a loss of $1,264, a loss of $18,476 and a gain of $34,566, respectively, related to the change in the fair value of these instruments that was included in gain/(loss) on investments held at fair value within the Consolidated Statement of Comprehensive Income/(Loss). Sonde On May 25, 2022, Sonde completed a Series B preferred share financing, which resulted in the Group losing control over Sonde and the deconsolidation of Sonde. Therefore, the results of operations of Sonde are included in the Consolidated Financial Statements through the date of deconsolidation. Upon deconsolidation, the Group derecognized its assets and liabilities and non-controlling interest in respect of Sonde and recorded its aforementioned investments in Sonde at fair value. The deconsolidation resulted in a gain of $27,251. As of the date of deconsolidation, the investment in Sonde preferred shares held at fair value amounted to $11,168. Following deconsolidation, the Group had significant influence in Sonde through its 48.2% voting interest in Sonde and its remaining representation on Sonde's Board of Directors. The Group holds Preferred A-1, A-2 and B shares. The Preferred A-1 shares have the same terms as common stock and provide their shareholders with access to returns associated with a residual equity ownership in Sonde. Consequently, the investment in Preferred A-1 shares is accounted for under the equity method. The convertible Preferred A-2 and B shares do not provide their shareholders with access to returns associated with a residual equity interest and as such are accounted for under IFRS 9, as investments held at fair value with changes in fair value recorded in profit and loss. Under IFRS 9, the A-2 and B preferred share investments are categorized as debt instruments that are presented at fair value through profit and loss because the amounts receivable do not represent solely payments of principal and interest. During the years ended December 31, 2023 and 2022, the Group recognized a loss of $994, and a gain of $235, respectively, for the changes in the fair value of the investment in Sonde that were included in gain/(loss) on investments held at fair value within the Consolidated Statement of Comprehensive Income/(Loss). The fair value of the Group’s investment in Sonde is $10,408 as of December 31, 2023. Akili Akili was deconsolidated in 2018. At time of deconsolidation, as the Group did not hold common shares in Akili and the preferred shares it held did not have equity-like features. Therefore, the preferred shares held by the Group fell under the guidance of IFRS 9 and were treated as a financial asset held at fair value and changes to the fair value of the preferred shares were recorded through the Consolidated Statement of Comprehensive Income/(Loss), in accordance with IFRS 9. On May 25, 2021, Akili completed its Series D financing for gross proceeds of $110,000 in which Akili issued 13,053,508 Series D preferred shares. The Group did not participate in this round of financing and as a result, the Group's interest in Akili was reduced from 41.9 percent to 27.5 percent. On August 19, 2022, Akili Interactive merged with Social Capital Suvretta Holdings Corp. I, a special purpose acquisition company. The combined company's securities began trading on August 22, 2022 on the Nasdaq Stock Market under the ticker symbol "AKLI". As part of this transaction, the Akili Interactive shares held by the Group were exchanged for the common stock of the combined company's securities as well as unvested common stock ("Akili Earnout Shares") that will vest when the share price exceeds certain thresholds. In addition, as part of a PIPE transaction that took place concurrently with the closing of the transaction, the Group purchased 500,000 shares for a total consideration of $5,000. Following the closing of the aforementioned transactions, the Group holds 12,527,477 shares of the combined entity and 1,433,914 Akili Earn-out Shares, with fair value amounted to $6,422 as of December 31, 2023. During the years ended December 31, 2023, 2022 and 2021, the Group recognized a loss of $8,681, a loss of $131,419, and a gain of $32,151, respectively, for the changes in the fair value of the investment in Akili that were included in gain/(loss) on investments held at fair value within the Consolidated Statement of Comprehensive Income/(Loss).

Investments in Associates

Investments in Associates	12 Months Ended
	Dec. 31, 2023
Investment in Associates [Abstract]
Investments in Associates	Investments in Associates Gelesis Gelesis was founded by the Group and raised funding through preferred shares financings as well as issuances of warrants and loans. As of July 1, 2019, Gelesis was deconsolidated from the Group’s financial statements. Upon deconsolidation, the preferred shares and warrants held by the Group fell under the guidance of IFRS 9 Financial Instruments and were treated as financial assets held at fair value and the investment in common shares of Gelesis was subject to IAS 28 Investment in Associates as the Group had significant influence over Gelesis. 2021 Due to the Group's share in the losses of Gelesis, in 2020, the Group's investment in Gelesis accounted for under the equity method was reduced to zero. Since the Group had investments in Gelesis warrants and preferred shares that were deemed to be long-term interests, the Group continued recognizing its share in Gelesis losses while applying such losses to its preferred share and warrant investment in Gelesis accounted for as an investment held at fair value. In 2021, total investment in Gelesis, including the long-term interests, was reduced to zero. Since the Group did not incur legal or constructive obligations or made payments on behalf of Gelesis, the Group discontinued recognizing equity method losses in 2021. As of December 31, 2021, unrecognized equity method losses amounted to $38,101, which included $709 of unrecognized other comprehensive loss. During 2021, due to exercise of stock options into common shares in Gelesis, the Group's equity interest in Gelesis was reduced from 47.9 percent at December 31, 2020 to 42.0 percent as of December 31, 2021. The gain resulting from the issuance of shares to third parties and the resulting reduction in the Group's share in the accumulated deficit of Gelesis under the equity method was fully offset by the unrecognized equity method losses. Backstop agreement – 2022 and 2021 On December 30, 2021, the Group signed a Backstop agreement with Capstar and had committed to acquire Capstar class A common shares at $10 per share immediately prior to the closing of the business combination between Gelesis and Capstar, in case, the Available Funds, as defined in the agreement, were less than $15,000. According to the Backstop agreement, if the Group had to acquire any shares under the agreement, the Group would receive an additional 1,322,500 class A common shares of Capstar at no additional consideration. The Group determined that such agreement meets the definition of a derivative under IFRS 9 and as such should be recorded at fair value with changes in fair value recorded through profit and loss. The derivative was initially recorded at fair value adjusted to defer the day 1 gain equal to the difference between the fair value of $11,200 and transaction price of zero on the effective date of the Backstop agreement and as such was initially recorded at zero. The deferred gain was amortized over the period from the effective date until settlement date, January 13, 2022. During the years ended December 31, 2022 and 2021, the Group recognized income of $10,400 and $800, respectively, for the amortization of the deferred gain. During the year ended December 31, 2022, the Group recognized a loss of $2,776 in respect of the decrease in the fair value of the derivative until the settlement date, resulting in a net gain of $7,624 recorded during the year ended December 31, 2022 in respect of the Backstop agreement. The gain was included in other Income/(expense) in the Consolidated Statement of Comprehensive Income/(Loss). The fair value of the derivative on the settlement date in the amount of $8,424 represents an additional investment in Gelesis as part of the SPAC transaction described below. On January 13, 2022, as part of the conclusion of the aforementioned Backstop agreement, the Group acquired 496,145 class A common shares of Capstar for $4,961 and received an additional 1,322,500 class A common shares of Capstar for no additional consideration. 2022 Share exchange – Capstar On January 13, 2022, Gelesis completed its business combination with Capstar. As part of the business combination, all shares in Gelesis, common and preferred, including the shares held by the Group, were exchanged for common shares of the merged entity and unvested common shares that will vest upon the stock price of the new combined entity reaching certain target prices (the "Gelesis Earn-out Shares"). In addition, the Group invested $15,000 in the class A common shares of Capstar as part of the PIPE transaction that took place immediately prior to the closing of the business combination and an additional $4,961, as part of the Backstop agreement described above. Pursuant to the business combination, Gelesis became a wholly-owned subsidiary of Capstar and Capstar changed its name to Gelesis Holdings, Inc., which began trading on the New York Stock Exchange under the ticker symbol "GLS" on January 14, 2022. Following the closing of the business combination, the PIPE transaction, the settlement of the aforementioned Backstop agreement with Capstar, and the exchange of all preferred shares in Gelesis to common shares in the new combined entity, the Group holds 16,727,582 common shares of Gelesis Holdings Inc., which was equal to approximately 23.2% of Gelesis Holdings Inc's outstanding common shares at the time of the exchange. Due to the Group's significant equity holding and voting interest in Gelesis, the Group continued to maintain significant influence in Gelesis and as such continued to account for its Gelesis equity investment under the equity method. Gelesis was deemed to be the acquirer in Gelesis Holdings Inc. and the financial assets and financial liabilities in Capstar were deemed to be acquired by Gelesis in consideration for the shares held by Capstar legacy shareholders. As such, the Group did not revalue the retained investment in Gelesis but rather treated the exchange as a dilution of its equity interest in Gelesis from 42.0 percent as of December 31, 2021 to 22.8 percent as of January 13, 2022 (including warrants that provide its holders access to returns associated with equity holders). After considering the aforementioned additional investments, the exchange of the preferred stock, previously accounted for as an investment held at fair value, to common stock (and representing an additional equity investment in Gelesis), the earn-out shares received in Gelesis (see Note 5. Investments Held at Fair Value) and the offset of previously unrecognized equity method losses, the net gain recorded on the dilution of interest amounted to $28,255. Impairment Following Gelesis’ decline in its market price in 2022 and its lack of liquidity, the Group recorded an impairment loss of $8,390 as of December 31, 2022 in respect of its investment in Gelesis. The recoverable amount of the investment in Gelesis was $4,910 as of December 31, 2022, which was determined based on fair value less costs to sell (which were estimated to be insignificant). Fair value was determined based on level 1 of the fair value hierarchy as Gelesis shares were traded on an active market as of December 31, 2022. The impairment loss was presented separately in the Consolidated Statement of Comprehensive Income/(loss) for the year ended December 31, 2022 in the line item impairment of investment in associates. 2023 During the year ended December 31, 2023, the Group entered into agreements with Gelesis to purchase senior secured convertible promissory notes and warrants for shares of Gelesis common stock (see Note 7. Investment in Notes from Associates). The warrants to purchase shares of Gelesis common stock represented potential voting rights to the Group and it is therefore necessary to consider whether they were substantive. If these potential voting rights were substantive and the Group had the practical ability to exercise the rights and take control of greater than 50% of Gelesis common stock, the Group would be required to consolidate Gelesis under the accounting standards. In February 2023, the Group obtained warrants to purchase 23,688,047 shares of Gelesis common stock (the “February Warrants”) at an exercise price of $0.2744 per share. The exercise of the February Warrants was subject to the approval of the Gelesis stockholders until May 1, 2023. On May 1, 2023, stockholder approval was no longer required for the Group to exercise the February Warrants. The potential voting rights associated with the February Warrants were not substantive as the exercise price of the February Warrants was at a significant premium to the fair value of the Gelesis common stock. In May 2023, the Group obtained warrants to purchase 235,441,495 shares of Gelesis common stock (the “May Warrants”). The May Warrants were exercisable at the option of the Group and had an exercise price of either $0.0182 or $0.0142. The May Warrants were substantive as the Group would have benefited from exercising such warrants since their exercise price was at the money or at an insignificant premium over the fair value of the Gelesis common stock. However, that benefit from exercising the May Warrants only existed for a short period of time because in June 2023, the potential voting rights associated with the May Warrants were impacted by the terms and conditions of the Merger Agreement as described below and were no longer substantive. In October 2023, the Group terminated the Merger Agreement with Gelesis and the potential voting rights associated with the May Warrants were not substantive. Also, in October 2023, Gelesis ceased operations and filed a voluntary petition for relief under the provisions of Chapter 7 of Title 11 of the United States Bankruptcy Code. A Chapter 7 trustee has been appointed by the Bankruptcy Court who has control over the assets and liabilities of Gelesis, effectively eliminating the authority and powers of the Board of Directors of Gelesis and its executive officers to act on behalf of Gelesis. The assets of Gelesis will be liquidated and Gelesis no longer has any officers or employees. The Group ceased accounting for Gelesis as an equity method investment as it no longer had significant influence in Gelesis. During the year ended December 31, 2023, the Group recorded $4,910 as its share in the losses of Gelesis and the Group’s balance in this equity method investment was zero as of December 31, 2023. Merger Agreement On June 12, 2023, PureTech Health LLC and Caviar Merger Sub LLC, a Delaware limited liability company and a wholly-owned subsidiary of PureTech (“Merger Sub”), entered into an agreement (the "Merger Agreement"), pursuant to which Gelesis would merge with and into Merger Sub, with Merger Sub continuing as the surviving company ( the “Merger”). If the Merger had been completed, PureTech would have acquired all issued and outstanding shares of common stock of Gelesis not otherwise held by PureTech, and Gelesis would have become an indirect wholly-owned subsidiary of PureTech. On October 12, 2023, the Group terminated the Merger Agreement. Sonde On May 25, 2022, Sonde completed a Series B preferred share financing. As a result of the aforementioned financing, the Group's voting interest was reduced below 50% and the Group lost its control over Sonde and as such ceased to consolidate Sonde on the date the round of financing was completed. Following deconsolidation, the Group has significant influence in Sonde through its voting interest in Sonde and its remaining representation on Sonde's Board of Directors. The Group's voting interest at date of deconsolidation and as of December 31, 2022 was 48.2% and 40.17%, respectively. The Group holds Preferred A-1, A-2 and B shares. The Preferred A-1 shares, in substance, have the same terms as common stock and as such provide their shareholders with access to returns associated with a residual equity ownership in Sonde. Consequently, the investment in Preferred A-1 shares is accounted for under the equity method. The Preferred A-2 and B shares, however, do not provide their shareholders with access to returns associated with a residual equity interest and as such are accounted for under IFRS 9, as investments held at fair value. The fair value of the Preferred A-1 shares on the date of deconsolidation amounted to $7,716, which is the initial value of the equity method investment in Sonde. During the years ended December 31, 2023 and 2022, the Group recorded losses of $1,052 and $3,443, respectively, related to Sonde's equity method of accounting. As of December 31, 2023, the Sonde equity method investment has a balance of $3,185. The following table summarizes the activity related to the investment in associates balance for the years ended December 31, 2023 and 2022. Investment in Associates $ As of January 1, 2022 — Cash investment in associates 19,961 Additional investment as a result of settling the Backstop agreement (see above) 8,424 Gain on dilution of interest in associate (*) 13,793 Investment in Sonde - deconsolidation 7,680 Share in net loss of associates (27,749) Reversal of equity method losses recorded against LTI (due to decrease in the fair value of such LTI): (4,406) Share in other comprehensive loss of associates (166) Impairment (8,390) As of December 31, 2022 and January 1, 2023 9,147 Share in net loss of associates (6,055) Share in other comprehensive income of associates 92 As of December 31, 2023 3,185 * Gain on dilution of interest was further increased due to the receipt of Gelesis Earn-out Shares accounted for as investments held at fair value (see above). Summarized financial information The following table summarizes the financial information of Gelesis as of December 31, 2022 and for the years ended December 31, 2022 and 2021, as included in its own financial statements, adjusted for fair value adjustments at deconsolidation and differences in accounting policies. The table also reconciles the summarized financial information to the carrying amount of the Group’s interest in Gelesis. As of December 31, 2023, the Group’s investment in Gelesis is $0 and Gelesis does not represent a significant equity method investment. As a result, such a disclosure for Gelesis is not presented for the year ended December 31, 2023. 2022 $ As of and for the year ended December 31, Percentage ownership interest 22.5 % Non-current assets 333,040 Current assets 23,495 Non-current liabilities (99,053) Current liabilities (80,010) Non-controlling interests and options issued to third parties (46,204) Net assets (deficit) attributable to shareholders of Gelesis Inc. 131,268 Group's share of net assets (net deficit) 29,504 Goodwill 3,858 Impairment (28,452) Investment in associates 4,910 2022 $ 2021 $ Revenue 25,767 11,185 Loss from continuing operations (100%) (111,567) (271,430) Total comprehensive loss (100%) (112,285) (273,005) Group's share in net losses - limited to net investment amount (*) (24,306) (73,703) Group's share of total comprehensive loss - limited to net investment amount (24,472) (73,703) * For the year ended December 31, 2022, the amount includes $4,406 reversal of equity method losses recorded against long-term Interests ("LTI") due to the decrease in fair value of such LTI. Gelesis Unsecured Promissory Note On July 27, 2022, the Group, as a lender, entered into an unsecured promissory note (the "Junior Note") with Gelesis, as a borrower, in the amount of $15,000. The Junior Note bears an annual interest rate of 15% per annum. The maturity date of the Junior Note is the earlier of December 31, 2023 or five business days following the consummation of a qualified financing by Gelesis. Based on the terms of the Junior Note, due to the option to convert to a variable amount of shares at the time of default, the Junior Note is required to be measured at fair value with changes in fair value recorded through profit and loss. As of December 31, 2023 and December 31, 2022 the fair value of the Junior Note was $0 and $16,501, respectively. In the year ended December 31, 2023, the Group recorded a loss of $16,501 for the change in the fair value of the Junior Note which was included in gain/(loss) on investments in notes from associates within the Consolidated Statement of Comprehensive Income/(Loss). The fair value of the Junior Note was determined to be $0 as of December 31, 2023 as Gelesis has ceased operations and filed for bankruptcy. In the year ended December 31, 2022, the Group recorded interest income of $963 and a gain of $539 for the change in the fair value of the Junior Note which was included in other income/(expense) in the Consolidated Statement of Comprehensive Income/(Loss). Senior Secured Convertible Promissory Notes During the year ended December 31, 2023, the Group entered into multiple agreements with Gelesis to purchase for $11,850 senior secured convertible promissory notes (the "Senior Notes") and warrants for share of Gelesis common stock. The initial fair value of the Senior Notes was determined to be $10,729 while $1,121 was determined to be the initial fair value of the warrants. The Senior Notes represent debt instruments that are presented at fair value through profit and loss as the amounts receivable do not solely represent payments of principal and interest as the Senior Notes are convertible into Gelesis common stock. The Senior Notes are secured by a first-priority lien on substantially all assets of Gelesis and the guarantors (other than the equity interests in, and assets held by Gelesis s.r.l., a subsidiary of Gelesis, and certain other exceptions). In October 2023, Gelesis ceased operations and filed a voluntary petition for relief under the provisions of Chapter 7 of Title 11 of the United States Bankruptcy Code. Therefore, the Group determined that the fair value of the Senior Notes was $0 as of December 31, 2023 and the Group recorded a loss of $10,729 for the changes in the fair value of the Senior Notes. The loss was included in gain/(loss) on investments in notes from associates in the Consolidated Statement of Comprehensive Income/(Loss). Vedanta On April 24, 2023, Vedanta closed the second tranche of its convertible debt for additional proceeds of $18,000, of which $5,000 were invested by the Group. The convertible debt carries an interest rate of 9 percent per annum. The debt has various conversion triggers and the conversion price is established at the lower of 80% of the equity price of the last financing round, or a certain pre-money valuation cap established in the agreement. If the convertible debt is not earlier converted or repaid, the entire outstanding amount of the convertible debt shall be due and payable upon the earliest to occur of (a) the later of (x) November 1, 2025 and (y) the date which is sixty (60) days after all amounts owed under, or in connection with, the loan Vedanta received from a certain investor have been paid in full, or (b) the consummation of a Deemed Liquidation Event (as defined in Vedanta’s Amended and Restated Certificate of Incorporation). Due to the terms of the convertible debt, the investment in such convertible debt is measured at fair value with changes in the fair value recorded through profit and loss. During the years ended December 31, 2023, the Group recorded a loss of $400 for the changes in the fair value of the Vedanta convertible debt which was included in gain/(loss) on investments in notes from associates in the Consolidated Statement of Comprehensive Income/(Loss). Following is the activity in respect of investments in notes from associates during the periods . The fair value of the $4,600 note from associate as of December 31, 2023 is determined using unobservable Level 3 inputs. See Note 18. Financial Instruments for additional information. Investment in notes from associates $ Balance as of January 1, 2022 — Investment In Gelesis notes 15,000 Changes in the fair value of the notes 1,501 Balance as of December 31, 2022 and January 1, 2023 16,501 Investment In Gelesis notes 10,729 Investment in Vedanta convertible debt 5,000 Changes in the fair value of the notes and convertible debt (27,630) Balance as of December 31, 2023 4,600

Investment in Notes from Associ

Investment in Notes from Associates	12 Months Ended
	Dec. 31, 2023
Investment in Notes from Associates [Abstract]
Investment in Notes from Associates	Investments in Associates Gelesis Gelesis was founded by the Group and raised funding through preferred shares financings as well as issuances of warrants and loans. As of July 1, 2019, Gelesis was deconsolidated from the Group’s financial statements. Upon deconsolidation, the preferred shares and warrants held by the Group fell under the guidance of IFRS 9 Financial Instruments and were treated as financial assets held at fair value and the investment in common shares of Gelesis was subject to IAS 28 Investment in Associates as the Group had significant influence over Gelesis. 2021 Due to the Group's share in the losses of Gelesis, in 2020, the Group's investment in Gelesis accounted for under the equity method was reduced to zero. Since the Group had investments in Gelesis warrants and preferred shares that were deemed to be long-term interests, the Group continued recognizing its share in Gelesis losses while applying such losses to its preferred share and warrant investment in Gelesis accounted for as an investment held at fair value. In 2021, total investment in Gelesis, including the long-term interests, was reduced to zero. Since the Group did not incur legal or constructive obligations or made payments on behalf of Gelesis, the Group discontinued recognizing equity method losses in 2021. As of December 31, 2021, unrecognized equity method losses amounted to $38,101, which included $709 of unrecognized other comprehensive loss. During 2021, due to exercise of stock options into common shares in Gelesis, the Group's equity interest in Gelesis was reduced from 47.9 percent at December 31, 2020 to 42.0 percent as of December 31, 2021. The gain resulting from the issuance of shares to third parties and the resulting reduction in the Group's share in the accumulated deficit of Gelesis under the equity method was fully offset by the unrecognized equity method losses. Backstop agreement – 2022 and 2021 On December 30, 2021, the Group signed a Backstop agreement with Capstar and had committed to acquire Capstar class A common shares at $10 per share immediately prior to the closing of the business combination between Gelesis and Capstar, in case, the Available Funds, as defined in the agreement, were less than $15,000. According to the Backstop agreement, if the Group had to acquire any shares under the agreement, the Group would receive an additional 1,322,500 class A common shares of Capstar at no additional consideration. The Group determined that such agreement meets the definition of a derivative under IFRS 9 and as such should be recorded at fair value with changes in fair value recorded through profit and loss. The derivative was initially recorded at fair value adjusted to defer the day 1 gain equal to the difference between the fair value of $11,200 and transaction price of zero on the effective date of the Backstop agreement and as such was initially recorded at zero. The deferred gain was amortized over the period from the effective date until settlement date, January 13, 2022. During the years ended December 31, 2022 and 2021, the Group recognized income of $10,400 and $800, respectively, for the amortization of the deferred gain. During the year ended December 31, 2022, the Group recognized a loss of $2,776 in respect of the decrease in the fair value of the derivative until the settlement date, resulting in a net gain of $7,624 recorded during the year ended December 31, 2022 in respect of the Backstop agreement. The gain was included in other Income/(expense) in the Consolidated Statement of Comprehensive Income/(Loss). The fair value of the derivative on the settlement date in the amount of $8,424 represents an additional investment in Gelesis as part of the SPAC transaction described below. On January 13, 2022, as part of the conclusion of the aforementioned Backstop agreement, the Group acquired 496,145 class A common shares of Capstar for $4,961 and received an additional 1,322,500 class A common shares of Capstar for no additional consideration. 2022 Share exchange – Capstar On January 13, 2022, Gelesis completed its business combination with Capstar. As part of the business combination, all shares in Gelesis, common and preferred, including the shares held by the Group, were exchanged for common shares of the merged entity and unvested common shares that will vest upon the stock price of the new combined entity reaching certain target prices (the "Gelesis Earn-out Shares"). In addition, the Group invested $15,000 in the class A common shares of Capstar as part of the PIPE transaction that took place immediately prior to the closing of the business combination and an additional $4,961, as part of the Backstop agreement described above. Pursuant to the business combination, Gelesis became a wholly-owned subsidiary of Capstar and Capstar changed its name to Gelesis Holdings, Inc., which began trading on the New York Stock Exchange under the ticker symbol "GLS" on January 14, 2022. Following the closing of the business combination, the PIPE transaction, the settlement of the aforementioned Backstop agreement with Capstar, and the exchange of all preferred shares in Gelesis to common shares in the new combined entity, the Group holds 16,727,582 common shares of Gelesis Holdings Inc., which was equal to approximately 23.2% of Gelesis Holdings Inc's outstanding common shares at the time of the exchange. Due to the Group's significant equity holding and voting interest in Gelesis, the Group continued to maintain significant influence in Gelesis and as such continued to account for its Gelesis equity investment under the equity method. Gelesis was deemed to be the acquirer in Gelesis Holdings Inc. and the financial assets and financial liabilities in Capstar were deemed to be acquired by Gelesis in consideration for the shares held by Capstar legacy shareholders. As such, the Group did not revalue the retained investment in Gelesis but rather treated the exchange as a dilution of its equity interest in Gelesis from 42.0 percent as of December 31, 2021 to 22.8 percent as of January 13, 2022 (including warrants that provide its holders access to returns associated with equity holders). After considering the aforementioned additional investments, the exchange of the preferred stock, previously accounted for as an investment held at fair value, to common stock (and representing an additional equity investment in Gelesis), the earn-out shares received in Gelesis (see Note 5. Investments Held at Fair Value) and the offset of previously unrecognized equity method losses, the net gain recorded on the dilution of interest amounted to $28,255. Impairment Following Gelesis’ decline in its market price in 2022 and its lack of liquidity, the Group recorded an impairment loss of $8,390 as of December 31, 2022 in respect of its investment in Gelesis. The recoverable amount of the investment in Gelesis was $4,910 as of December 31, 2022, which was determined based on fair value less costs to sell (which were estimated to be insignificant). Fair value was determined based on level 1 of the fair value hierarchy as Gelesis shares were traded on an active market as of December 31, 2022. The impairment loss was presented separately in the Consolidated Statement of Comprehensive Income/(loss) for the year ended December 31, 2022 in the line item impairment of investment in associates. 2023 During the year ended December 31, 2023, the Group entered into agreements with Gelesis to purchase senior secured convertible promissory notes and warrants for shares of Gelesis common stock (see Note 7. Investment in Notes from Associates). The warrants to purchase shares of Gelesis common stock represented potential voting rights to the Group and it is therefore necessary to consider whether they were substantive. If these potential voting rights were substantive and the Group had the practical ability to exercise the rights and take control of greater than 50% of Gelesis common stock, the Group would be required to consolidate Gelesis under the accounting standards. In February 2023, the Group obtained warrants to purchase 23,688,047 shares of Gelesis common stock (the “February Warrants”) at an exercise price of $0.2744 per share. The exercise of the February Warrants was subject to the approval of the Gelesis stockholders until May 1, 2023. On May 1, 2023, stockholder approval was no longer required for the Group to exercise the February Warrants. The potential voting rights associated with the February Warrants were not substantive as the exercise price of the February Warrants was at a significant premium to the fair value of the Gelesis common stock. In May 2023, the Group obtained warrants to purchase 235,441,495 shares of Gelesis common stock (the “May Warrants”). The May Warrants were exercisable at the option of the Group and had an exercise price of either $0.0182 or $0.0142. The May Warrants were substantive as the Group would have benefited from exercising such warrants since their exercise price was at the money or at an insignificant premium over the fair value of the Gelesis common stock. However, that benefit from exercising the May Warrants only existed for a short period of time because in June 2023, the potential voting rights associated with the May Warrants were impacted by the terms and conditions of the Merger Agreement as described below and were no longer substantive. In October 2023, the Group terminated the Merger Agreement with Gelesis and the potential voting rights associated with the May Warrants were not substantive. Also, in October 2023, Gelesis ceased operations and filed a voluntary petition for relief under the provisions of Chapter 7 of Title 11 of the United States Bankruptcy Code. A Chapter 7 trustee has been appointed by the Bankruptcy Court who has control over the assets and liabilities of Gelesis, effectively eliminating the authority and powers of the Board of Directors of Gelesis and its executive officers to act on behalf of Gelesis. The assets of Gelesis will be liquidated and Gelesis no longer has any officers or employees. The Group ceased accounting for Gelesis as an equity method investment as it no longer had significant influence in Gelesis. During the year ended December 31, 2023, the Group recorded $4,910 as its share in the losses of Gelesis and the Group’s balance in this equity method investment was zero as of December 31, 2023. Merger Agreement On June 12, 2023, PureTech Health LLC and Caviar Merger Sub LLC, a Delaware limited liability company and a wholly-owned subsidiary of PureTech (“Merger Sub”), entered into an agreement (the "Merger Agreement"), pursuant to which Gelesis would merge with and into Merger Sub, with Merger Sub continuing as the surviving company ( the “Merger”). If the Merger had been completed, PureTech would have acquired all issued and outstanding shares of common stock of Gelesis not otherwise held by PureTech, and Gelesis would have become an indirect wholly-owned subsidiary of PureTech. On October 12, 2023, the Group terminated the Merger Agreement. Sonde On May 25, 2022, Sonde completed a Series B preferred share financing. As a result of the aforementioned financing, the Group's voting interest was reduced below 50% and the Group lost its control over Sonde and as such ceased to consolidate Sonde on the date the round of financing was completed. Following deconsolidation, the Group has significant influence in Sonde through its voting interest in Sonde and its remaining representation on Sonde's Board of Directors. The Group's voting interest at date of deconsolidation and as of December 31, 2022 was 48.2% and 40.17%, respectively. The Group holds Preferred A-1, A-2 and B shares. The Preferred A-1 shares, in substance, have the same terms as common stock and as such provide their shareholders with access to returns associated with a residual equity ownership in Sonde. Consequently, the investment in Preferred A-1 shares is accounted for under the equity method. The Preferred A-2 and B shares, however, do not provide their shareholders with access to returns associated with a residual equity interest and as such are accounted for under IFRS 9, as investments held at fair value. The fair value of the Preferred A-1 shares on the date of deconsolidation amounted to $7,716, which is the initial value of the equity method investment in Sonde. During the years ended December 31, 2023 and 2022, the Group recorded losses of $1,052 and $3,443, respectively, related to Sonde's equity method of accounting. As of December 31, 2023, the Sonde equity method investment has a balance of $3,185. The following table summarizes the activity related to the investment in associates balance for the years ended December 31, 2023 and 2022. Investment in Associates $ As of January 1, 2022 — Cash investment in associates 19,961 Additional investment as a result of settling the Backstop agreement (see above) 8,424 Gain on dilution of interest in associate (*) 13,793 Investment in Sonde - deconsolidation 7,680 Share in net loss of associates (27,749) Reversal of equity method losses recorded against LTI (due to decrease in the fair value of such LTI): (4,406) Share in other comprehensive loss of associates (166) Impairment (8,390) As of December 31, 2022 and January 1, 2023 9,147 Share in net loss of associates (6,055) Share in other comprehensive income of associates 92 As of December 31, 2023 3,185 * Gain on dilution of interest was further increased due to the receipt of Gelesis Earn-out Shares accounted for as investments held at fair value (see above). Summarized financial information The following table summarizes the financial information of Gelesis as of December 31, 2022 and for the years ended December 31, 2022 and 2021, as included in its own financial statements, adjusted for fair value adjustments at deconsolidation and differences in accounting policies. The table also reconciles the summarized financial information to the carrying amount of the Group’s interest in Gelesis. As of December 31, 2023, the Group’s investment in Gelesis is $0 and Gelesis does not represent a significant equity method investment. As a result, such a disclosure for Gelesis is not presented for the year ended December 31, 2023. 2022 $ As of and for the year ended December 31, Percentage ownership interest 22.5 % Non-current assets 333,040 Current assets 23,495 Non-current liabilities (99,053) Current liabilities (80,010) Non-controlling interests and options issued to third parties (46,204) Net assets (deficit) attributable to shareholders of Gelesis Inc. 131,268 Group's share of net assets (net deficit) 29,504 Goodwill 3,858 Impairment (28,452) Investment in associates 4,910 2022 $ 2021 $ Revenue 25,767 11,185 Loss from continuing operations (100%) (111,567) (271,430) Total comprehensive loss (100%) (112,285) (273,005) Group's share in net losses - limited to net investment amount (*) (24,306) (73,703) Group's share of total comprehensive loss - limited to net investment amount (24,472) (73,703) * For the year ended December 31, 2022, the amount includes $4,406 reversal of equity method losses recorded against long-term Interests ("LTI") due to the decrease in fair value of such LTI. Gelesis Unsecured Promissory Note On July 27, 2022, the Group, as a lender, entered into an unsecured promissory note (the "Junior Note") with Gelesis, as a borrower, in the amount of $15,000. The Junior Note bears an annual interest rate of 15% per annum. The maturity date of the Junior Note is the earlier of December 31, 2023 or five business days following the consummation of a qualified financing by Gelesis. Based on the terms of the Junior Note, due to the option to convert to a variable amount of shares at the time of default, the Junior Note is required to be measured at fair value with changes in fair value recorded through profit and loss. As of December 31, 2023 and December 31, 2022 the fair value of the Junior Note was $0 and $16,501, respectively. In the year ended December 31, 2023, the Group recorded a loss of $16,501 for the change in the fair value of the Junior Note which was included in gain/(loss) on investments in notes from associates within the Consolidated Statement of Comprehensive Income/(Loss). The fair value of the Junior Note was determined to be $0 as of December 31, 2023 as Gelesis has ceased operations and filed for bankruptcy. In the year ended December 31, 2022, the Group recorded interest income of $963 and a gain of $539 for the change in the fair value of the Junior Note which was included in other income/(expense) in the Consolidated Statement of Comprehensive Income/(Loss). Senior Secured Convertible Promissory Notes During the year ended December 31, 2023, the Group entered into multiple agreements with Gelesis to purchase for $11,850 senior secured convertible promissory notes (the "Senior Notes") and warrants for share of Gelesis common stock. The initial fair value of the Senior Notes was determined to be $10,729 while $1,121 was determined to be the initial fair value of the warrants. The Senior Notes represent debt instruments that are presented at fair value through profit and loss as the amounts receivable do not solely represent payments of principal and interest as the Senior Notes are convertible into Gelesis common stock. The Senior Notes are secured by a first-priority lien on substantially all assets of Gelesis and the guarantors (other than the equity interests in, and assets held by Gelesis s.r.l., a subsidiary of Gelesis, and certain other exceptions). In October 2023, Gelesis ceased operations and filed a voluntary petition for relief under the provisions of Chapter 7 of Title 11 of the United States Bankruptcy Code. Therefore, the Group determined that the fair value of the Senior Notes was $0 as of December 31, 2023 and the Group recorded a loss of $10,729 for the changes in the fair value of the Senior Notes. The loss was included in gain/(loss) on investments in notes from associates in the Consolidated Statement of Comprehensive Income/(Loss). Vedanta On April 24, 2023, Vedanta closed the second tranche of its convertible debt for additional proceeds of $18,000, of which $5,000 were invested by the Group. The convertible debt carries an interest rate of 9 percent per annum. The debt has various conversion triggers and the conversion price is established at the lower of 80% of the equity price of the last financing round, or a certain pre-money valuation cap established in the agreement. If the convertible debt is not earlier converted or repaid, the entire outstanding amount of the convertible debt shall be due and payable upon the earliest to occur of (a) the later of (x) November 1, 2025 and (y) the date which is sixty (60) days after all amounts owed under, or in connection with, the loan Vedanta received from a certain investor have been paid in full, or (b) the consummation of a Deemed Liquidation Event (as defined in Vedanta’s Amended and Restated Certificate of Incorporation). Due to the terms of the convertible debt, the investment in such convertible debt is measured at fair value with changes in the fair value recorded through profit and loss. During the years ended December 31, 2023, the Group recorded a loss of $400 for the changes in the fair value of the Vedanta convertible debt which was included in gain/(loss) on investments in notes from associates in the Consolidated Statement of Comprehensive Income/(Loss). Following is the activity in respect of investments in notes from associates during the periods . The fair value of the $4,600 note from associate as of December 31, 2023 is determined using unobservable Level 3 inputs. See Note 18. Financial Instruments for additional information. Investment in notes from associates $ Balance as of January 1, 2022 — Investment In Gelesis notes 15,000 Changes in the fair value of the notes 1,501 Balance as of December 31, 2022 and January 1, 2023 16,501 Investment In Gelesis notes 10,729 Investment in Vedanta convertible debt 5,000 Changes in the fair value of the notes and convertible debt (27,630) Balance as of December 31, 2023 4,600

Operating Expenses

Operating Expenses	12 Months Ended
	Dec. 31, 2023
Operating Expense [Abstract]
Operating Expenses	Operating Expenses Total operating expenses were as follows: For the years ending December 31, 2023 $ 2022 $ 2021 $ General and administrative 53,295 60,991 57,199 Research and development 96,235 152,433 110,471 Total operating expenses 149,530 213,425 167,671 The average number of persons employed by the Group during the year, analyzed by category, was as follows: For the years ending December 31, 2023 2022 2021 General and administrative 40 57 52 Research and development 56 144 119 Total 96 201 171 The aggregate payroll costs of these persons were as follows: 2023 $ 2022 $ 2021 $ For the years ending December 31, General and administrative 24,586 25,322 26,438 Research and development 21,102 36,321 28,950 Total 45,688 61,643 55,388 Detailed operating expenses were as follows: 2023 $ 2022 $ 2021 $ For the years ending December 31, Salaries and wages 37,084 41,750 36,792 Healthcare and other benefits 2,599 2,908 2,563 Payroll taxes 1,590 2,286 2,084 Share-based payments 4,415 14,699 13,950 Total payroll costs 45,688 61,643 55,388 Amortization 1,979 3,048 2,940 Depreciation 2,955 5,845 4,347 Total amortization and depreciation expenses 4,933 8,893 7,287 Other general and administrative expenses 25,180 31,600 26,714 Other research and development expenses 73,729 111,288 78,282 Total other operating expenses 98,909 142,888 104,996 Total operating expenses 149,530 213,425 167,671 Please refer to Note 9. Share-based Payments for further disclosures related to share-based payments and Note 26. Related Parties Transactions for management’s remuneration disclosures.

Share-based Payments

Share-based Payments	12 Months Ended
	Dec. 31, 2023
Share-based Payments [Abstract]
Share-based Payments	Share-based Payments Share-based payments includes stock options, time-based restricted stock units (“RSUs”) and performance-based RSUs in which the expense is recognized based on the grant date fair value of these awards, except for performance-based RSUs to executives that are treated as liability awards where expense is recognized based on reporting date fair value up until settlement date. Share-based Payment Expense The Group's share-based payment expense for the years ended December 31, 2023, 2022 and 2021, was $4,415, $14,699, and $13,950 respectively. The following table provides the classification of the Group’s consolidated share-based payment expense as reflected in the Consolidated Statement of Income/(Loss): Year ended December 31, 2023 $ 2022 $ 2021 $ General and administrative 3,185 8,862 9,310 Research and development 1,230 5,837 4,640 Total 4,415 14,699 13,950 The Performance Share Plan In June 2015, the Group adopted the Performance Stock Plan (the “2015 PSP”). Under the 2015 PSP and subsequent amendments, awards of ordinary shares may be made to the Directors, senior managers and employees, and other individuals providing services to the Group up to a maximum authorized amount of 10.0 percent of the total ordinary shares outstanding. The shares have various vesting terms over a period of service between one In June 2023 the Group adopted a new Performance Stock Plan (the "2023 PSP") that has the same terms as the 2015 PSP but instituted for all new awards a limit of 10.0 percent of the total ordinary shares outstanding over a five-year period. The share-based awards granted under the PSPs are generally equity-settled (see cash settlements below). As of December 31, 2023, the Group had issued 27,384,777 units of share-based awards under these plans. RSUs RSU activity for the years ended December 31, 2023, 2022 and 2021 is detailed as follows: Number of Shares/Units Weighted Average Grant Date Fair Value (GBP) (*) Outstanding (Non-vested) at January 1, 2021 3,422,582 2.46 RSUs Granted in Period 2,195,133 2.15 Vested (1,176,695) 2.93 Forfeited (808,305) 2.25 Outstanding (Non-vested) at December 31, 2021 and January 1, 2022 3,632,715 1.91 RSUs Granted in Period 4,309,883 1.76 Vested (696,398) 2.80 Forfeited (1,155,420) 2.67 Outstanding (Non-vested) at December 31, 2022 and January 1, 2023 6,090,780 1.74 RSUs Granted in Period 3,679,669 1.28 Vested (716,029) 2.00 Forfeited (1,880,274) 1.94 Outstanding (Non-vested) at December 31, 2023 7,174,146 1.10 * For liability awards - based on fair value at reporting date. Each RSU entitles the holder to one ordinary share on vesting and the RSU awards are generally based on a vesting schedule over a one RSUs granted to the non-executive directors are time-based and equity-settled. The grant date fair value on such RSUs is recognized over the vesting term. RSUs granted to executives are performance-based and vesting of such RSUs is subject to the satisfaction of both performance and market conditions. The performance condition is based on the achievement of the Group's strategic targets. The market conditions are based on the achievement of the absolute total shareholder return (“TSR”), TSR as compared to the FTSE 250 Index, and TSR as compared to the MSCI Europe Health Care Index. The RSU award performance criteria have changed over time as the criteria are continually evaluated by the Group’s Remuneration Committee. The Group recognizes the estimated fair value of performance-based awards with non-market conditions as share-based compensation expense over the performance period based upon its determination of whether it is probable that the performance targets will be achieved. The Group assesses the probability of achieving the performance targets at each reporting period. Cumulative adjustments, if any, are recorded to reflect subsequent changes in the estimated outcome of performance-related conditions. The fair value of the performance-based awards with market conditions is based on the Monte Carlo simulation analysis utilizing a Geometric Brownian Motion process with 100,000 simulations to value those shares. The model considers share price volatility, risk-free rate and other covariance of comparable public companies and other market data to predict distribution of relative share performance. Liability settled RSUs classification The RSUs to executives are treated as liability awards as the Group has a historical practice of settling these awards in cash, and as such adjusted to fair value at every reporting date until settlement with changes in fair value recorded in earnings as stock based compensation expense. The Group incurred share-based payment expenses for RSUs of $827 (including $402 expense in respect of RSU liability awards), $1,637 (including $1,131 expense in respect of RSU liability awards), and $1,540 (including $589 expense in respect of RSU liability awards) for the years ended December 31, 2023, 2022 and 2021, respectively. The decrease in the share-based compensation expense in respect of the RSUs for the year ended December 31, 2023, as compared to the year ended December 31, 2022 is due to reduction in the fair value of the liability awards. As of December 31, 2023, the carrying amount of the RSU liability awards was $4,782, $1,281 current; $3,501 non current, out of which $1,283 related to awards that have met all their performance and market conditions. Stock Options Stock option activity for the years ended December 31, 2023, 2022 and 2021, is detailed as follows: Number of Options Wtd Average Exercise Price (GBP) Wtd Average of Wtd Average Stock Price at Exercise (GBP) Outstanding at January 1, 2021 10,916,086 1.81 8.38 Granted 5,424,000 3.34 Exercised (2,238,187) 0.70 3.63 Forfeited and expired (687,781) 2.53 Options Exercisable at December 31, 2021 and January 1, 2022 4,773,873 1.42 6.50 Outstanding at December 31, 2021 and January 1, 2022 13,414,118 2.58 8.29 Granted 8,881,000 2.04 Exercised (577,022) 0.50 2.43 Forfeited and expired (3,924,215) 2.89 Options Exercisable at December 31, 2022 and January 1, 2023 6,185,216 2.03 6.21 Outstanding at December 31, 2022 and January 1, 2023 17,793,881 2.31 8.03 Granted 3,120,975 2.22 Exercised (534,034) 1.71 2.46 Forfeited and expired (3,424,232) 2.40 Options Exercisable at December 31, 2023 9,065,830 2.19 6.01 Outstanding at December 31, 2023 16,956,590 2.29 7.20 The fair value of the stock options awarded by the Group was estimated at the grant date using the Black-Scholes option valuation model, considering the terms and conditions upon which options were granted, with the following weighted-average assumptions: At December 31, 2023 2022 2021 Expected volatility 43.69 % 41.70 % 41.05 % Expected terms (in years) 6.16 6.11 6.16 Risk-free interest rate 4.04 % 2.13 % 1.06 % Expected dividend yield — — — Exercise price (GBP) 2.22 2.04 3.34 Underlying stock price (GBP) 2.22 2.04 3.34 These assumptions resulted in an estimated weighted-average grant-date fair value per share of stock options granted during the years ended December 31, 2023, 2022 and 2021 of $1.37 ,$1.15 and $1.87, respectively. The Group incurred share-based payment expense for the stock options of $3,310, $8,351 and $6,158 for the years ended December 31, 2023, 2022 and 2021, respectively. For shares outstanding as of December 31, 2023, the range of exercise prices is detailed as follows: Range of Exercise Prices (GBP) Options Wtd Wtd Average of 0.01 439,490 — 5.76 1.00 to 2.00 4,989,572 1.54 5.64 2.00 to 3.00 6,664,028 2.25 8.55 3.00 to 4.00 4,863,500 3.33 7.10 Total 16,956,590 2.29 7.20 Subsidiary Plans Certain subsidiaries of the Group have adopted stock option plans. A summary of stock option activity by number of shares in these subsidiaries is presented in the following table: Outstanding as of January 1, 2023 Granted During the Year Exercised During the Year Expired During the Year Forfeited During the Year Deconsolidation During the Year Outstanding as of December 31, 2023 Entrega 344,500 — — — — — 344,500 Follica 2,776,120 — — (2,170,547) (605,573) — — Vedanta 1,824,576 — — (1,313) (29,607) (1,793,656) — Outstanding as of January 1, 2022 Granted During the Year Exercised During the Year Expired During the Year Forfeited During the Year Deconsolidation During the Year Outstanding as of December 31, 2022 Entrega 349,500 45,000 — (50,000) — — 344,500 Follica 2,686,120 90,000 — — — — 2,776,120 Sonde 2,049,004 — — — — (2,049,004) — Vedanta 1,991,637 490,506 (400,000) (65,235) (192,332) — 1,824,576 Outstanding as of January 1, 2021 Granted During the Year Exercised During the Year Expired During the Year Forfeited During the Year Deconsolidation During the Year Outstanding as of December 31, 2021 Alivio 3,888,168 197,398 (2,373,750) (506,260) (1,205,556) — — Entrega 962,000 — (525,000) (87,500) — — 349,500 Follica 1,309,040 1,383,080 — (6,000) — — 2,686,120 Sonde 2,192,834 — — (51,507) (92,323) — 2,049,004 Vedanta 1,741,888 451,532 (52,938) (76,491) (72,354) — 1,991,637 The weighted-average exercise prices and remaining contractual life for the options outstanding as of December 31, 2023, were as follows: Outstanding at December 31, 2023 Number of options Weighted-average exercise price $ Weighted-average contractual life outstanding Entrega 344,500 1.91 3.92 There were no grants in 2023 under any of the subsidiary option plans. The weighted average exercise prices for the options granted for the years ended December 31, 2022 and 2021, were as follows: For the years ended December 31, 2022 $ 2021 $ Entrega 0.02 — Follica 1.86 1.86 Vedanta 14.94 19.69 The weighted average exercise prices for options forfeited during the year ended December 31, 2023, were as follows: Forfeited during the year ended December 31, 2023 Number of options Weighted-average exercise price $ Follica 605,573 1.86 Vedanta 29,607 17.06 The weighted average exercise prices for options exercisable as of December 31, 2023, were as follows: Exercisable at December 31, 2023 Number of Options Weighted-average exercise price $ Exercise Price Range Entrega 329,500 1.99 0.02-2.36 There were no subsidiary options exercised during the year ended December 31, 2023.

Finance Income_(Costs), net

Finance Income/(Costs), net	12 Months Ended
	Dec. 31, 2023
Finance Cost Net [Abstract]
Finance Income/(Costs), net	Finance Income/(Costs), net The following table shows the breakdown of finance income and costs: 2023 $ 2022 $ 2021 $ For the years ended December 31, Finance income Interest income from financial assets 16,012 5,799 214 Total finance income 16,012 5,799 214 Finance costs Contractual interest expense on notes payable (1,422) (212) (1,031) Interest expense on other borrowings (363) (1,759) (1,502) Interest expense on lease liability (1,544) (1,982) (2,181) Gain/(loss) on foreign currency exchange (94) 14 (56) Total finance cost – contractual (3,424) (3,939) (4,771) Gain/(loss) from change in fair value of warrant liability 33 6,740 1,419 Gain/(loss) from change in fair value of preferred shares 2,617 130,825 8,362 Gain/(loss) from change in fair value of convertible debt — (502) (175) Total finance income/(costs) – fair value accounting 2,650 137,063 9,606 Total finance costs - non cash interest expense related to sale of future royalties (10,159) — — Finance income/(costs), net 5,078 138,924 5,050

Earnings_(Loss) per Share

Earnings/(Loss) per Share	12 Months Ended
	Dec. 31, 2023
Earnings per share [abstract]
Earnings/(Loss) per Share	Earnings/(Loss) per Share Basic earnings/(loss) per share is calculated by dividing the Group's net income or loss for the year attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding, net of treasury shares. Diluted EPS is calculated by dividing the Group's net income or loss for the year by the weighted average number of ordinary shares outstanding, net of treasury shares, plus the weighted average number of ordinary shares that would be issued at conversion of all the dilutive potential ordinary shares into ordinary shares. Dilutive effects arise from equity-settled shares from the Group's share-based plans. For the years ended December 31, 2023, 2022 and 2021, the Group incurred a net loss and therefore all outstanding potential securities were considered anti-dilutive. The amount of potential securities that were excluded from the diluted calculation amounted to 1,509,900, 3,134,131 and 6,553,905 shares, respectively. Earnings/(Loss) Attributable to Owners of the Group: 2023 2022 2021 Basic $ Diluted $ Basic $ Diluted $ Basic $ Diluted $ Income/(loss) for the year, attributable to the owners of the Group (65,697) (65,697) (50,354) (50,354) (60,558) (60,558) Weighted-Average Number of Ordinary Shares: 2023 2022 2021 Basic Diluted Basic Diluted Basic Diluted Issued ordinary shares at January 1, 278,566,306 278,566,306 287,796,585 287,796,585 285,885,025 285,885,025 Effect of shares issued & treasury shares purchased (2,263,773) (2,263,773) (3,037,150) (3,037,150) 705,958 705,958 Weighted average number of ordinary shares at December 31, 276,302,533 276,302,533 284,759,435 284,759,435 286,590,983 286,590,983 Earnings/(Loss) per Share: 2023 2022 2021 Basic $ Diluted $ Basic $ Diluted $ Basic $ Diluted $ Basic and diluted earnings/(loss) per share (0.24) (0.24) (0.18) (0.18) (0.21) (0.21)

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2023
Property, plant and equipment [abstract]
Property and Equipment	Property and Equipment Cost Laboratory and Manufacturing Equipment $ Furniture and Fixtures $ Computer Equipment and Software $ Leasehold Improvements $ Construction in process $ Total $ Balance as of January 1, 2022 11,733 1,452 1,329 18,485 8,116 41,115 Additions, net of transfers 390 — 11 412 1,362 2,176 Disposals (118) — — — (77) (195) Deconsolidation of subsidiaries — — (58) — — (58) Reclassifications 1,336 58 137 5,067 (6,598) — Balance as of December 31, 2022 13,341 1,510 1,419 23,964 2,803 43,037 Additions, net of transfers — — — — 87 87 Disposals/Impairment (2,886) — (137) — — (3,023) Deconsolidation of subsidiaries (5,092) (438) (365) (8,799) (2,871) (17,565) Reclassifications — — — — (18) (18) Balance as of December 31, 2023 5,363 1,072 917 15,165 1 22,518 Accumulated depreciation and impairment loss Laboratory and Manufacturing Equipment $ Furniture and Fixtures $ Computer Equipment and Software $ Leasehold Improvements $ Construction in process $ Total $ Balance as of January 1, 2022 (5,686) (663) (1,190) (6,806) — (14,344) Depreciation (2,082) (212) (107) (3,444) — (5,845) Disposals 57 — — — — 57 Deconsolidation of subsidiaries — — 53 — — 53 Balance as of December 31, 2022 (7,711) (875) (1,244) (10,250) — (20,080) Depreciation (892) (162) (45) (1,856) — (2,955) Disposals 543 — 38 — — 581 Deconsolidation of subsidiaries 3,917 339 357 4,858 — 9,472 Balance as of December 31, 2023 (4,142) (698) (894) (7,248) — (12,982) Property and Equipment, net Laboratory and Manufacturing Equipment $ Furniture and Fixtures $ Computer Equipment and Software $ Leasehold Improvements $ Construction in process $ Total $ Balance as of December 31, 2022 5,630 635 174 13,714 2,803 22,957 Balance as of December 31, 2023 1,221 375 23 7,917 1 9,536 Depreciation of property and equipment is included in the general and administrative expenses and research and development expenses in the Consolidated Statement of Comprehensive Income/(Loss). The Group recorded depreciation expense of $2,955, $5,845 and $4,347 for the years ended December 31, 2023, 2022 and 2021, respectively.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2023
Disclosure of detailed information about intangible assets [abstract]
Intangible Assets	Intangible Assets Intangible assets consist of licenses of intellectual property acquired by the Group through various agreements with third parties and are recorded at the value of the consideration transferred. Information regarding the cost and accumulated amortization of intangible assets is as follows: Cost Licenses $ Balance as of January 1, 2022 990 Additions 25 Impairment (163) Deconsolidation of subsidiary (21) Balance as of December 31, 2022 831 Additions 200 Impairment (105) Deconsolidation of subsidiaries (19) Balance as of December 31, 2023 906 Accumulated amortization Licenses $ Balance as of January 1, 2022 (3) Amortization (1) Deconsolidation of subsidiary 4 Balance as of December 31, 2022 — Amortization — Deconsolidation of subsidiary — Balance as of December 31, 2023 — Intangible assets, net Licenses $ Balance as of December 31, 2022 831 Balance as of December 31, 2023 906 Substantially all the intangible asset licenses represent in-process-research-and-development assets since they are still being developed and not ready for their intended use. As such, these assets are not amortized but tested for impairment annually. During the year ended December 31, 2023, the Group wrote off two of its research intangible assets for which research was ceased in the amount of $105. During the year ended December 31, 2023, Vedanta , Inc. was deconsolidated and as such, $19 net in intangible assets were derecognized. During the year ended December 31,2022, the Group wrote off one of its research intangible assets for which research was ceased in the amount of $163. During the year ended December 31, 2022, Sonde Health, Inc. was deconsolidated and as such, $18 net intangible assets were derecognized. The Group tested all intangible assets for impairment as of the balance sheet date and concluded that none of such assets were impaired.

Other Financial Assets

Other Financial Assets	12 Months Ended
	Dec. 31, 2023
Other Financial Assets [Abstract]
Other Financial Assets	Other Financial Assets Other financial assets consist primarily of restricted cash reserved as collateral against a letter of credit with a bank that is issued for the benefit of a landlord in lieu of a security deposit for office space leased by the Group. The restricted cash was $1,628 and $2,124 as of December 31, 2023 and 2022, respectively.

Equity

Equity	12 Months Ended
	Dec. 31, 2023
Equity [abstract]
Equity	Equity Total equity for the Group as of December 31, 2023, and 2022, was as follows: December 31, 2023 $ December 31, 2022 $ Equity Share capital, £0.01 par value, issued and paid 271,853,731 and 278,566,306 as of December 31, 2023 and 2022, respectively 5,461 5,455 Share premium 290,262 289,624 Treasury shares, 17,614,428 and 10,595,347 as of December 31, 2023 and 2022, respectively (44,626) (26,492) Merger Reserve 138,506 138,506 Translation reserve 182 89 Other reserves (9,538) (14,478) Retained earnings/(accumulated deficit) 83,820 149,516 Equity attributable to owners of the Group 464,066 542,220 Non-controlling interests (5,835) 5,369 Total equity 458,232 547,589 Changes in share capital and share premium relate primarily to incentive options exercises during the period. Shareholders are entitled to vote on all matters submitted to shareholders for a vote. Each ordinary share is entitled to one vote and is entitled to receive dividends when and if declared by the Group’s Directors. On June 18, 2015, the Group acquired the entire issued share capital of PureTech LLC in return for 159,648,387 ordinary shares. This was accounted for as a common control transaction at cost. It was deemed that the share capital was issued in line with movements in share capital as shown prior to the transaction taking place. In addition, the merger reserve records amounts previously recorded as share premium. Other reserves comprise the cumulative credit to share-based payment reserves corresponding to share-based payment expenses recognized through Consolidated Statement of Comprehensive Income/(Loss), settlements of vested stock awards as well as other additions that flow directly through equity such as the excess or deficit from changes in ownership of subsidiaries while control is maintained by the Group. On May 9, 2022, the Group announced the commencement of a $50,000 share repurchase program (the "Program") of its ordinary shares of one pence each (the “Ordinary Shares”). The Group executed the Program in two equal tranches. The Group entered into an irrevocable non-discretionary instruction with Jefferies International Limited (“Jefferies”) in relation to the purchase by Jefferies of the Ordinary Shares for an aggregate consideration (excluding expenses) of no greater than $25,000 for each tranche, and the simultaneous on-sale of such Ordinary Shares by Jefferies to the Group, subject to certain volume and price restrictions. Jefferies made its trading decisions in relation to the Ordinary Shares independently of, and uninfluenced by, the Group. Purchases could continue during any close period to which the Group was subject. The instruction to Jeffries could be amended or withdrawn so long as the Group was not in a close period or otherwise in possession of inside information. Any purchases of the Ordinary Shares under the Program were carried out on the London Stock Exchange and could be carried out on any other UK recognized investment exchange in accordance with pre-set parameters and subject to limits prescribed by the Group’s general authority to repurchase the Ordinary Shares granted by its shareholders at its annual general meeting on May 27, 2021, and relevant Rules and Regulations. All Ordinary Shares repurchased under the Program are held in treasury and re-issued for settlement of share-based awards. As of December 31, 2023, the Group had repurchased an aggregate of 18,278,873 Ordinary Shares under the share repurchase program with 7,683,526 shares repurchased in 2023. The Program was completed during the month ended February 2024. As of December 31, 2023, the Group’s issued share capital was 289,468,159 shares, including 17,614,428 shares repurchased under the Program and were held by the Group in treasury. The Group does not have a limited amount of authorized share capital.

Subsidiary Preferred Shares

Subsidiary Preferred Shares	12 Months Ended
	Dec. 31, 2023
Subsidiary Preferred Shares [Abstract]
Subsidiary Preferred Shares	Subsidiary Preferred Shares Preferred shares issued by subsidiaries often contain redemption and conversion features that are assessed under IFRS 9 in conjunction with the host preferred share instrument. This balance represents subsidiary preferred shares issued to third parties. The subsidiary preferred shares are redeemable upon the occurrence of a contingent event, other than full liquidation of the Group, that is not considered to be within the control of the Group. Therefore these subsidiary preferred shares are classified as liabilities. These liabilities are measured at fair value through profit and loss. The preferred shares are convertible into ordinary shares of the subsidiaries at the option of the holders and are mandatorily convertible into ordinary shares under certain circumstances. Under certain scenarios, the number of ordinary shares receivable on conversion will change and therefore, the number of shares that will be issued is not fixed. As such the conversion feature is considered to be an embedded derivative that normally would require bifurcation. However, since the preferred share liabilities are measured at fair value through profit and loss, as mentioned above, no bifurcation is required. The preferred shares are entitled to vote with holders of common shares on an as converted basis. The fair value of all subsidiary preferred shares as of December 31, 2023 and December 31, 2022, is as follows: 2023 $ 2022 $ As of December 31, Entrega 169 169 Follica — 350 Vedanta Biosciences — 26,820 Total subsidiary preferred share balance 169 27,339 As is customary, in the event of any voluntary or involuntary liquidation, dissolution or winding up of a subsidiary, the holders of subsidiary preferred shares which are outstanding shall be entitled to be paid out of the assets of the subsidiary available for distribution to shareholders and before any payment shall be made to holders of ordinary shares. A merger, acquisition, sale of voting control or other transaction of a subsidiary in which the shareholders of the subsidiary immediately before the transaction do not own a majority of the outstanding shares of the surviving company shall be deemed to be a liquidation event. Additionally, a sale, lease, transfer or other disposition of all or substantially all of the assets of the subsidiary shall also be deemed a liquidation event. As of December 31, 2023 and December 31, 2022, the minimum liquidation preference reflecting the amounts that would be payable to the subsidiary preferred holders upon a liquidation event of the subsidiaries, is as follows: 2023 $ 2022 $ As of December 31, Entrega 2,216 2,216 Follica 6,405 6,405 Vedanta Biosciences — 149,568 Total minimum liquidation preference 8,621 158,189 For the years ended December 31, 2023 and 2022, the Group recognized the following changes in the value of subsidiary preferred shares: $ Balance as of January 1, 2022 174,017 Decrease in value of preferred shares measured at fair value – finance costs (income) (130,825) Deconsolidation of subsidiary - (Sonde) (15,853) Balance as of December 31, 2022 27,339 Decrease in value of preferred shares measured at fair value – finance costs (income) (2,617) Deconsolidation of subsidiary – (Vedanta) (24,554) Balance as of December 31, 2023 169

Sale of Future Royalties Liabil

Sale of Future Royalties Liability	12 Months Ended
	Dec. 31, 2023
Disclosure of financial liabilities [abstract]
Sale of Future Royalties Liability	Sale of Future Royalties Liability On March 4, 2011, the Group entered into a license agreement with Karuna Therapeutics, Inc. (“Karuna”) according to which the Group granted Karuna an exclusive license to research, develop and sell KarXT in exchange for a royalty on annual net sales, development and regulatory milestones and a fixed portion of sublicensing income, if any (hereinafter “License Agreement”). On March 22, 2023, the Group signed an agreement with Royalty Pharma (hereinafter "Royalty Purchase Agreement"), according to which the Group sold Royalty Pharma a partial right to receive royalty payments made by Karuna in respect of net sales of KarXT, if and when received. According to the Royalty Purchase Agreement, all royalties due to the Group under the License Agreement will be paid to Royalty Pharma up until an annual threshold of $60,000, while all royalties above such annual threshold in a given year will be split 33% to Royalty Pharma and 67% to the Group. Under the terms of the Royalty Purchase Agreement, the Group received a non-refundable initial payment of $100,000 at the execution of the Royalty Purchase Agreement and is eligible to receive additional payments in the aggregate of up to an additional $400,000 based on the achievement of certain regulatory and commercial milestones. The Group continues to hold the rights under the License Agreement and has a contractual obligation to deliver cash to Royalty Pharma for a portion of the royalties it receives. Therefore, the Group will continue to account for any royalties and regulatory milestones due to the Group under the License Agreement as revenue in its Consolidated Statement of Comprehensive Income/(Loss) and record the proceeds from the Royalty Purchase Agreement as a financial liability on its Consolidated Statement of Financial Position. In determining the appropriate accounting treatment for the Royalty Purchase Agreement, management applied significant judgement. The acquisition of Karuna by Bristol Meyers Squibb (NYSE: BMY), which closed on March 18, 2024, had no impact on the Group's rights or obligations under the License Agreement or Royalty Purchase Agreement, each of which remains in full force and effect. In order to determine the amortized cost of the sale of future royalties liability, management is required to estimate the total amount of future receipts from and payments to Royalty Pharma under the Royalty Purchase Agreement over the life of the agreement. The $100,000 liability, recorded at execution of the Royalty Purchase Agreement, will be accreted to the total of these receipts and payments as interest expense over the life of the Royalty Purchase Agreement. These estimates contain assumptions that impact both the amortized cost of the liability and the interest expense that will be recognized in future periods. Additional proceeds received from Royalty Pharma will increase the Group’s financial liability. As royalty payments are made to Royalty Pharma, the balance of the liability will be effectively repaid over the life of the Royalty Purchase Agreement. The estimated timing and amount of royalty payments to and proceeds from Royalty Pharma are likely to change over the life of the Royalty Purchase Agreement. A significant increase or decrease in estimated royalty payments, or a significant shift in the timing of cash flows, will materially impact the sale of future royalties liability, interest expense and the time period for repayment. The Group will periodically assess the expected payments to, or proceeds from, Royalty Pharma, and any such changes in amount or timing of cash flows will require the Group to re-calculate the amortized cost of the sale of future royalties liability as the present value of the estimated future cash flows from the Royalty Purchase Agreement that are discounted at the liability’s original effective interest rate. The adjustment is recognized immediately in profit or loss as income or expense. The following shows the activity in respect of the sale of future royalties liability: Sale of future royalties liability $ Balance as of January 1, 2023 — Amounts received at closing 100,000 Non cash interest expense recognized 10,159 Balance as of December 31, 2023 110,159

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2023
Financial Instruments [Abstract]
Financial Instruments	Financial Instruments The Group’s financial instruments consist of financial assets in the form of notes, convertible notes and investment in shares, and financial liabilities, including preferred shares. Many of these financial instruments are presented at fair value, with changes in fair value recorded through profit and loss. Fair Value Process For financial instruments measured at fair value under IFRS 9, the change in the fair value is reflected through profit and loss. Using the guidance in IFRS 13, the total business enterprise value and allocable equity of each entity being valued can be determined using a market backsolve approach through a recent arm’s length financing round (or a future probable arm's length transaction), market/asset probability-weighted expected return method ("PWERM") approach, discounted cash flow approach, or hybrid approaches. The approaches, in order of strongest fair value evidence, are detailed as follows: Valuation Method Description Market – Backsolve The market backsolve approach benchmarks the original issue price (OIP) of the company’s latest funding transaction as current value. Market/Asset – PWERM Under a PWERM, the company value is based upon the probability-weighted present value of expected future investment returns, considering each of the possible future outcomes available to the enterprise. Possible future outcomes can include IPO scenarios, potential SPAC transactions, merger and acquisition transactions as well as other similar exit transactions of the investee. I ncome Based – DCF The income approach is used to estimate fair value based on the income streams, such as cash flows or earnings, that an asset or business can be expected to generate. At each measurement date, investments held at fair value (that are not publicly traded) as well as the fair value of preferred share liabilities, including embedded conversion rights that are not bifurcated, were determined using the following allocation methods: option pricing model (“OPM”), PWERM, or hybrid allocation framework. The methods are detailed as follows: Allocation Method Description OPM The OPM model treats preferred stock as call options on the enterprise’s equity value, with exercise prices based on the liquidation preferences of the preferred stock. PWERM Under a PWERM, share value is based upon the probability-weighted present value of expected future investment returns, considering each of the possible future outcomes available to the enterprise, as well as the rights of each share class. Hybrid The hybrid method is a combination of the PWERM and OPM. Under the hybrid method, multiple liquidity scenarios are weighted based on the probability of the scenario's occurrence, similar to the PWERM, while also utilizing the OPM to estimate the allocation of value in one or more of the scenarios. Valuation policies and procedures are regularly monitored by the Group. Fair value measurements, including those categorized within Level 3, are prepared and reviewed for reasonableness and compliance with the fair value measurements guidance under IFRS accounting standards. The Group measures fair value using the following fair value hierarchy that reflects the significance of the inputs used in making the measurements: Fair Value Description Level 1 Inputs that are quoted market prices (unadjusted) in active markets for identical instruments. Level 2 Inputs other than quoted prices included within Level 1 that are observable either directly (i.e. as prices) or indirectly (i.e. derived from prices). Level 3 Inputs that are unobservable. This category includes all instruments for which the valuation technique includes inputs not based on observable data and the unobservable inputs have a significant effect on the instruments' valuation. Whilst the Group considers the methodologies and assumptions adopted in fair value measurements as supportable and reasonable, because of the inherent uncertainty of valuation, those estimated values may differ significantly from the values that would have been used had a ready market for the investment existed. Subsidiary Preferred Shares Liability and Subsidiary Convertible Notes The following table summarizes the changes in the Group’s subsidiary preferred shares and convertible notes liabilities measured at fair value, which were categorized as Level 3 in the fair value hierarchy: Subsidiary Preferred Shares Subsidiary Convertible Balance at January 1, 2021 118,972 25,000 Value at issuance 37,610 2,215 Conversion to subsidiary preferred shares 25,797 (25,797) Accrued interest - contractual — 867 Change in fair value (8,362) 175 Balance at December 31, 2021 and January 1, 2022 174,017 2,461 Value at issuance — 393 Accrued interest - contractual — 48 Deconsolidation - Sonde (15,853) (3,403) Change in fair value (130,825) 502 Balance at December 31, 2022 and January 1, 2023 27,339 — Change in fair value (2,617) — Deconsolidation - Vedanta (24,554) — Balance at December 31, 2023 169 — The change in fair value of preferred shares and convertible notes liabilities are recorded in finance income/(costs) – fair value accounting in the Consolidated Statement of Comprehensive Income/(Loss). Investments Held at Fair Value Karuna, Vor and Akili Valuation Karuna (Nasdaq: KRTX), Vor (Nasdaq: VOR), Akili (Nasdaq: AKLI) and additional immaterial investments are listed entities on an active exchange, and as such, the fair value as of December 31, 2023, was calculated utilizing the quoted common share price which is categorized as Level 1 in the fair value hierarchy. Vedanta and Sonde As of December 31, 2023, the Group accounts for the following investments under IFRS 9 as investments held at fair value with changes in fair value through the profit and loss: Sonde preferred A-2 and B shares and Vedanta convertible preferred shares (subsequent to the date of deconsolidation). The valuation of the aforementioned investments is categorized as Level 3 in the fair value hierarchy due to the use of significant unobservable inputs to value such assets. During the year ended December 31, 2023, the Group recorded such investments at fair value and recognized a loss of $7,298 for the change in fair value of the investments. In addition, the Group determined that the fair value of its investment in the Gelesis 2023 Warrants was $0 as Gelesis ceased operations in October 2023. The following table summarizes the changes in all the Group’s investments held at fair value, which were categorized as Level 3 in the fair value hierarchy: $ Balance at January 1, 2021 206,892 Cash purchase of Vor preferred shares 500 Reclassification of Vor from level 3 to level 1 (33,365) Gain/(loss) on change in fair value 65,505 Balance at December 31, 2021 239,533 Deconsolidation of Sonde 11,168 Gelesis Earn-out Shares received in the SPAC exchange 14,214 Exchange of Gelesis preferred shares to Gelesis common shares (92,303) Reclassification of Akili to level 1 investment (128,764) Gain/(loss) on change in fair value (31,253) Balance at December 31, 2022 12,593 Deconsolidation of Vedanta - new investment in Vedanta preferred shares 20,456 Investment in Gelesis 2023 Warrants 1,121 Gain/(loss) on changes in fair value (9,299) Balance as of December 31, 2023 24,872 The change in fair value of investments held at fair value is recorded in gain/(loss) on investments held at fair value in the Consolidated Statement of Comprehensive Income/(Loss). At December 31, 2023, the Group’s material investments held at fair value categorized as Level 3 in the fair value hierarchy include the preferred shares of Sonde and Vedanta, with fair value of $10,408 and $14,153, respectively. The significant unobservable inputs used at December 31, 2023 in the fair value measurement of these investments and the sensitivity of the fair value measurements for these investments to changes to these significant unobservable inputs are summarized in the table below. As of December 31, 2023 Investment (Sonde) Measured through Market Backsolve & OPM Unobservable Inputs Input Value Sensitivity Range Investment Fair Value Increase/(Decrease) $ Equity Value 53,242 -5 % (464) +5% 463 Time to Liquidity 2.00 -6 Months 39 + 6 Months (42) Volatility 60 % -10 % 19 +10% (35) As of December 31, 2023 Investment (Vedanta) Measured through Market Backsolve that Leverages a Monte Carlo Simulation Unobservable Inputs Input Value Sensitivity Range Investment Fair Value Increase/(Decrease) $ Equity Value 127,883 -5 % (1,416) +5% 1,069 Time to Liquidity 1.23 - 6 Months (3,907) + 6 Months 1,261 Volatility 120 % -10 % (954) +10% 474 Investments in Notes from Associates As of December 31, 2022, the investment in notes from associates was $16,501 and represents investments the Group made in convertible promissory notes of Gelesis. During the year ended December 31, 2023, the Group invested $10,729 in convertible promissory notes of Gelesis and $5,000 in a convertible note of Vedanta. The Group recorded a loss of $27,630 for the change in fair value of the notes from associates in the gain/(loss) on investments in notes from associates within the Consolidated Statement of Comprehensive Income/Loss. The loss was driven by a reduction in the fair value of the Gelesis convertible promissory notes of $27,230 as Gelesis filed for bankruptcy in October 2023 and a change in the fair value of the Vedanata convertible note of $400. The convertible debt issued by Vedanta was valued using a market backsolve approach that leverages a Monte Carlo simulation. The significant unobservable inputs categorized as Level 3 in the fair value hierarchy used at December 31, 2023, in the fair value measurement of the convertible debt are the same as the inputs disclosed above for Vedanta preferred shares. Fair Value Measurement and Classification The fair value of financial instruments by category as of December 31, 2023 and 2022: 2023 Carrying Amount Fair Value Financial Assets Financial Liabilities Level 1 Level 2 Level 3 Total Financial assets 3 : Money Markets 1,2 156,705 — 156,705 — — 156,705 Investment in notes from associates 4,600 — — — 4,600 4,600 Investments held at fair value 317,841 — 292,970 — 24,872 317,841 Total financial assets 479,146 — 449,675 — 29,472 479,146 Financial liabilities: Subsidiary preferred shares — 169 — — 169 169 Share-based liability awards — 4,782 — — 4,782 4,782 Total financial liabilities — 4,951 — — 4,951 4,951 1 Issued by a diverse group of corporations, largely consisting of financial institutions, virtually all of which are investment grade. 2 Included within cash and cash equivalents. 3. Excluded from the table above are short-term investments of $136,062 that are classified at amortized cost as of December 31, 2023. The cost of these short-term investments approximates current fair value. The Group has a number of financial instruments that are not measured at fair value in the Consolidated Statement of Financial Position. For these instruments the fair values are not materially different from their carrying amounts. 2022 Carrying Amount Fair Value Financial Assets Financial Liabilities Level 1 Level 2 Level 3 Total Financial assets: Money Markets 1,2 95,249 — 95,249 — — 95,249 Short-term investments 1 200,229 — 200,229 — — 200,229 Note from associate 16,501 — — — 16,501 16,501 Investments held at fair value 251,892 — 239,299 — 12,593 251,892 Trade and other receivables 3 11,867 — — 11,867 — 11,867 Total financial assets 575,738 — 534,777 11,867 29,094 575,738 Financial liabilities: Subsidiary warrant liability — 47 — — 47 47 Subsidiary preferred shares — 27,339 — — 27,339 27,339 Subsidiary notes payable — 2,345 — 2,097 248 2,345 Share-based liability awards — 5,932 4,396 — 1,537 5,932 Total financial liabilities — 35,664 4,396 2,097 29,171 35,664 1 Issued by a diverse group of corporations, largely consisting of financial institutions, virtually all of which are investment grade. 2 Included within cash and cash equivalents. 3 Outstanding receivables are owed primarily by government agencies and large corporations, virtually all of which are investment grade.

Subsidiary Notes Payable

Subsidiary Notes Payable	12 Months Ended
	Dec. 31, 2023
Subsidiary Notes Payable [Abstract]
Subsidiary Notes Payable	Subsidiary Notes Payable The subsidiary notes payable are comprised of loans and convertible notes. As of December 31, 2023 and December 31, 2022, the loan in Follica and the convertible notes for Knode and Appeering did not contain embedded derivatives and therefore these instruments continue to be held at amortized cost. The notes payable consist of the following: 2023 $ 2022 $ As of December 31, Loans 3,439 2,097 Convertible notes 260 248 Total subsidiary notes payable 3,699 2,345 Loans In October 2010, Follica entered into a loan and security agreement with Lighthouse Capital Partners VI, L.P. The loan is secured by Follica’s assets, including Follica’s intellectual property and bears interest at a rate of 5.0 percent in the interest only period and 12.0 percent in the repayment period. Convertible Notes Convertible Notes outstanding were as follows: Knode $ Appeering $ Sonde $ Total $ January 1, 2022 94 141 2,461 2,696 Gross principal - issuance of notes - financing activity — — 393 393 Accrued interest on convertible notes - finance costs 5 8 48 60 Change in fair value - finance costs — — 502 502 Deconsolidation — — (3,403) (3,403) December 31, 2022 and January 1, 2023 99 149 — 248 Accrued interest on convertible notes - finance costs 5 8 — 13 December 31, 2023 104 156 — 260 On April 6, 2021, and on November 24, 2021, Sonde issued unsecured convertible promissory notes to its existing shareholders for a combined total of $4,329, of which $2,215 were issued to third-party shareholders (and $2,113 were issued to the Group and eliminated in consolidation). In addition, in March 2022, Sonde issued an additional amount of $921, of which $393 were issued to third parties (and $528 issued to the Group and eliminated in consolidation). The notes bore interest at an annual rate of 6.0 percent and were to mature on the second anniversary of the issuance. The notes were to mandatorily convert in a Qualified Financing, as defined in the note purchase agreement, at a discount of 20.0 percent from the price per share in the Qualified Financing. In addition, the notes allowed for optional conversion concurrently with a discount of 20.0 percent from the price per share in the Non Qualified Equity Financing. Upon the completion of the Preferred B round of financing in Sonde on May 25, 2022, the Group lost control in Sonde and all convertible notes were derecognized as part of the deconsolidation - See Note 5. Investments Held at Fair Value. For Sonde convertible notes, since these notes contained embedded derivatives, the notes were assessed under IFRS 9 and the entire financial instruments were elected to be accounted for as FVTPL. The Sonde notes were deconsolidated in May 2022 as described above.

Non-Controlling Interest

Non-Controlling Interest	12 Months Ended
	Dec. 31, 2023
Non-Controlling Interests [Abstract]
Non-controlling Interest	Non-Controlling Interest As of December 31, 2023, non-controlling interests include Entrega and Follica. Ownership interests of the non-controlling interests in these entities as of December 31, 2023 were 11.7 percent, and 19.9 percent, respectively. As of December 31, 2022, non-controlling interests include Entrega, Follica, and Vedanta. Ownership interests of the non-controlling interests in these entities were 11.7 percent , 19.9 percent, and 12.2 percent, respectively. As of December 31, 2021, non-controlling interests include Entrega, Follica, Sonde, and Vedanta. Ownership interests of the non-controlling interests in these entities were 11.7 percent, 19.9 percent, 6.2 percent and 3.7 percent, respectively. During the year ended December 31, 2023, Vedanta Biosciences, Inc was deconsolidated. During the year ended December 31, 2022, Sonde Health, Inc was deconsolidated. See Note 5. Investments Held at Fair Value. Non-controlling interests include the amounts recorded for subsidiary stock options. On June 11, 2021, the Group acquired the remaining 17.1 percent of the minority non-controlling interests of Alivio (after exercise of all in the money stock options) increasing its ownership to 100.0 percent of Alivio. The consideration for such non-controlling interests amounted to $1,224, to be paid in three equal installments, with the first installment of $408 paid at the effective date of the transaction and two additional installments to be paid upon the occurrence of certain contingent events. The Group recorded a contingent consideration liability of $560 at fair value for the two additional installments, resulting in a total acquisition cost of $968. The excess of the consideration paid over the book value of the non-controlling interest of approximately $9,636 was recorded directly as a charge to shareholders’ equity. The second installment of $408 was paid in July 2021, upon the occurrence of the contingent event specified in the agreement. The contingent consideration liability was adjusted to fair value at the end of each reporting period with changes in fair value recorded in earnings. Changes in fair value of the aforementioned contingent consideration liability were not material. As of December 31, 2022, the remaining contingent liability was reduced to zero as the second contingent event did not occur. On December 1, 2021, option holders in Entrega exercised options into shares of common stock, increasing the NCI interest held from 0.2 percent to 11.7 percent. During 2021, option holders in Vedanta exercised options and increased the NCI interest to 3.7 percent. The exercise of the options resulted in an increase in the NCI share in Entrega and Vedanta shareholder's deficit of $5,887. The amount together with the consideration paid by NCI ($101) amounted to $5,988 and was recorded as a gain directly in shareholders' equity. On February 15, 2022, option holders in Vedanta exercised options into shares of common stock, increasing the NCI interest held from 3.7 percent to 12.2 percent. The exercise of the options resulted in an increase in the NCI share in Vedanta shareholder's deficit of $15,171. The amount together with the consideration paid by NCI ($7) amounted to $15,171 and was recorded as a gain directly in shareholders' equity.

Trade and Other Payables

Trade and Other Payables	12 Months Ended
	Dec. 31, 2023
Trade and other payables [abstract]
Trade and Other Payables	Trade and Other Payables Information regarding Trade and other payables was as follows: As of December 31, 2023 $ 2022 $ Trade payables 14,637 26,504 Accrued expenses 28,187 24,518 Income tax payable — 57 Liability for share-based awards 1,281 1,805 Other 3 1,957 Total trade and other payables 44,107 54,840

Long-term loan

Long-term loan	12 Months Ended
	Dec. 31, 2023
Long-term loan [Abstract]
Long-term loan	Long-term loan In September 2020, Vedanta entered into a $15,000 loan and security agreement with Oxford Finance LLC. The loan is secured by Vedanta's assets, including equipment, inventory and intellectual property. The loan bears a floating interest rate of 7.7 percent plus the greater of (i) 30 day U.S. Dollar LIBOR reported in the Wall Street Journal or (ii) 0.17 percent. The loan matures September 2025 and requires interest-only payments prior to 2023. The loan also carries a final fee upon full repayment of 7.0 percent of the original principal, or $1,050. As part of the loan agreement, Vedanta also issued Oxford Finance LLC 12,886 Series C-2 preferred share warrants with an exercise price of $23.28 per share, expiring September 2030. The outstanding loan balance totaled approximately $15,400 as of December 31, 2022. On March 1, 2023, the Group derecognized the loan in connection with Vedanta's deconsolidation. Refer to Note 5. Investments Held at Fair Value. The following table summarizes long-term loan activity for the years ended December 31, 2023 and 2022: Long-term loan 2023 $ 2022 $ Balance at January 1, 15,400 15,118 Accrued interest 363 1,755 Interest paid (300) (1,436) Other (17) (38) Deconsolidation of subsidiary (15,446) — Balance at December 31, — 15,400 The long-term loan is presented as follows in the Statement of Financial Position as of December 31, 2023 and 2022: Long-term loan 2023 $ 2022 $ Current portion of long-term loan — 5,156 Long-term loan — 10,244 Total Long-term loan — 15,400

Leases and subleases

Leases and subleases	12 Months Ended
	Dec. 31, 2023
Presentation of leases for lessee [abstract]
Leases and subleases	Leases and subleases The activity related to the Group’s right of use asset and lease liability for the years ended December 31, 2023 and 2022 is as follows: Right of use asset, net 2023 $ 2022 $ Balance at January 1, 14,281 17,166 Additions — 163 Depreciation (1,979) (3,047) Deconsolidated (2,477) — Balance at December 31, 9,825 14,281 Total lease liability 2023 $ 2022 $ Balance at January 1, 29,128 32,990 Additions — 163 Cash paid for rent - principal - financing cash flow (3,338) (4,025) Cash paid for rent - interest (1,544) (1,982) Interest expense 1,544 1,982 Deconsolidated (4,146) — Balance at December 31, 21,644 29,128 Depreciation of the right-of-use assets, which virtually all consist of leased real estate, is included in the general and administrative expenses and research and development expenses line items in the Statement of Comprehensive Income/(Loss). The Group recorded depreciation expense of $1,979, $3,047 and $2,938 for the years ended December 31, 2023, 2022 and 2021, respectively. The following table details the short-term and long-term portion of the lease liability as of December 31, 2023 and 2022: Total lease liability 2023 $ 2022 $ Short-term portion of lease liability 3,394 4,972 Long-term portion of lease liability 18,250 24,155 Total lease liability 21,644 29,128 The following table details the future maturities of the lease liability, showing the undiscounted lease payments to be paid after the reporting date: 2023 $ Less than one year 4,689 One to two years 4,644 Two to three years 4,419 Three to four years 4,551 Four to five years 4,687 More than five years 2,796 Total undiscounted lease maturities 25,785 Interest 4,141 Total lease liability 21,644 During the year ended December 31, 2019, the Group entered into a lease agreement for certain premises consisting of 50,858 rentable square feet of space located at 6 Tide Street, Boston, Massachusetts. The lease commenced on April 26, 2019 for an initial term consisting of ten years and three months, and there is an option to extend the lease for two consecutive periods of five years each. The Group assessed at the lease commencement date whether it was reasonably certain to exercise the extension options, and deemed such options were not reasonably certain to be exercised. The Group will reassess whether it is reasonably certain to exercise the options only if there is a significant event or significant change in circumstances within its control. On June 26, 2019, the Group executed a sublease agreement with Gelesis. The lease is for 9,446 rentable square feet located on the sixth floor of the Group’s former office at 501 Boylston Street, Boston, Massachusetts. The sublease was set to expire on August 31, 2025, and was determined to be a finance lease. Gelesis ceased operations and filed for bankruptcy on October 30, 2023. As a result, the Group wrote off its receivable in the lease of $1,266 in 2023. Rental income recognized by the Group during the year ended December 31, 2023 was $781 which was included in the other income/(expense) line item in the Consolidated Statement of Comprehensive Income/(Loss). In the year ended December 31, 2022, the Group did not recognize any rental income.

Capital and Financial Risk Mana

Capital and Financial Risk Management	12 Months Ended
	Dec. 31, 2023
Capital And Financial Risk Management [Abstract]
Capital and Financial Risk Management	Capital and Financial Risk Management Capital Risk Management The Group's capital and financial risk management policy is to maintain a strong capital base to support its strategic priorities, maintain investor, creditor and market confidence as well as sustain the future development of the business. The Group’s objectives when managing capital are to safeguard its ability to continue as a going concern, to provide returns for shareholders and benefits for other stakeholders, and to maintain an optimal capital structure to reduce the cost of capital. To maintain or adjust the capital structure, the Group may issue new shares or incur new debt. The Group has no material externally imposed capital requirements. The Group’s share capital is set out in Note 15. Equity. Management continuously monitors the level of capital deployed and available for deployment in the Wholly-Owned Programs segment and at Founded Entities. The Directors seek to maintain a balance between the higher returns that might be possible with higher levels of deployed capital and the advantages and security afforded by a sound capital position. The Group’s Directors have overall responsibility for the establishment and oversight of the Group's capital and risk management framework. The Group is exposed to certain risks through its normal course of operations. The Group’s main objective in using financial instruments is to promote the development and commercialization of intellectual property through the raising and investing of funds for this purpose. The nature, amount and timing of investments are determined by planned future investment activity. Due to the nature of activities and with the aim to maintain the investors’ funds as secure and protected, the Group’s policy is to hold any excess funds in highly liquid and readily available financial instruments and maintain minimal exposure to other financial risks. The Group has exposure to the following risks arising from financial instruments: Credit Risk Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet its contractual obligations. Financial instruments that potentially subject the Group to concentrations of credit risk consist principally of cash and cash equivalents, short-term investments, and trade and other receivables. The Group held the following balances (not including the income tax receivable resulting from overpayment of income taxes as of December 31, 2022. See Note 27. Taxation): 2023 $ 2022 $ As of December 31 Cash and cash equivalents 191,081 149,866 Short-term investments 136,062 200,229 Trade and other receivables 2,376 11,867 Total 329,518 361,961 The Group invests its excess cash in U.S. Treasury Bills (presented as short-term investments), and money market accounts, which the Group believes are of high credit quality. Further, the Group's cash and cash equivalents and short-term investments are held at diverse, investment-grade financial institutions. The Group assesses the credit quality of customers on an ongoing basis. The credit quality of financial assets is assessed by historical and recent payment history, counterparty financial position, and reference to credit ratings (if available) or to historical information about counterparty default rates. The Group does not have expected credit losses due to the high credit quality or healthy financial conditions of these counterparties. As of December 31, 2023 and 2022, none of the trade and other receivables were impaired. Liquidity Risk Liquidity risk is the risk that the Group will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Group actively manages its liquidity risk by closely monitoring the maturity of its financial assets and liabilities and projected cash flows from operations, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Group’s reputation. Due to the nature of these financial liabilities, the funds are available on demand to provide optimal financial flexibility. The table below summarizes the maturity profile of the Group’s financial liabilities, including subsidiary preferred shares that have customary liquidation preferences, as of December 31, 2023 and 2022, based on contractual undiscounted payments: As of December 31 2023 Carrying Amount Within Three Months Three to Twelve Months One to Five Years Total Subsidiary notes payable 3,699 3,699 — — 3,699 Trade and other payables 44,107 44,107 — — 44,107 Subsidiary preferred shares (Note 16) 1 169 169 — — 169 Total 47,975 47,975 — — 47,975 As of December 31 2022 Carrying Amount Within Three Months Three to Twelve Months One to Five Years Total Long-term loan 15,400 1,838 5,281 11,413 18,531 Subsidiary notes payable 2,345 2,345 — — 2,345 Trade and other payables 54,840 54,840 — — 54,840 Warrants 2 47 47 — — 47 Subsidiary preferred shares (Note 16) 1 27,339 27,339 — — 27,339 Total 99,971 86,409 5,281 11,413 103,103 1 Redeemable only upon a liquidation or deemed liquidation event, as defined in the applicable shareholder documents. 2 Warrants issued by subsidiaries to third parties to purchase preferred shares. * Does not include payments in respect of lease obligations. For the contractual future payments related to lease obligation s, see Note 23. Leases and subleases. Interest Rate Sensitivity As of December 31, 2023, the Group had cash and cash equivalents of $191,081, and short-term investments of $136,062. The Group's exposure to interest rate sensitivity is impacted by changes in the underlying U.K. and U.S. bank interest rates. The Group has not entered into investments for trading or speculative purposes. Due to the conservative nature of the Group's investment portfolio, which is predicated on capital preservation and investments in short duration, high-quality U.S. Treasury Bills and related money market accounts, a change in interest rates would not have a material effect on the fair market value of the Group's portfolio, and therefore, the Group does not expect operating results or cash flows to be significantly affected by changes in market interest rates. Controlled Founded Entity Investments The Group maintains investments in certain Controlled Founded Entities. The Group’s investments in Controlled Founded Entities are eliminated as intercompany transactions upon financial consolidation. The Group is, however, exposed to a preferred share liability owing to the terms of existing preferred shares and the ownership of Controlled Founded Entities preferred shares by third parties. As discussed in Note 16. Subsidiary Preferred Shares, certain of the Group’s subsidiaries have issued preferred shares that include the right to receive a payment in the event of any voluntary or involuntary liquidation, dissolution or winding up of a subsidiary, including in the event of "deemed liquidation" as defined in the incorporation documents of the entities, which shall be paid out of the assets of the subsidiary available for distribution to shareholders, and before any payment shall be made to holders of ordinary shares. The liability of preferred shares is maintained at fair value through the profit and loss. The Group’s cash position supports the business activities of the Controlled Founded Entities. Accordingly, the Group views exposure to the third party preferred share liability as low. Deconsolidated Founded Entity Investments The Group maintains certain debt or equity holdings in Founded Entities that are deconsolidated. These holdings are deemed either as investments and accounted for as investments held at fair value, or as associates and accounted for under the equity method. The Group's exposure to investments held at fair value is $317,841 as of December 31, 2023, and the Group may or may not be able to realize the value in the future. Accordingly, the Group views the risk as high. The Group’s exposure to investments in associates is limited to the carrying amount of the investment in an associate. The Group is not exposed to further contractual obligations or contingent liabilities beyond the value of the initial investments. Accordingly, the Group does not view this as a high risk. As of December 31, 2023, Sonde is the only associate, and the carrying amount of the investment as associate is $3,185. Equity Price Risk As of December 31, 2023, the Group held 886,885 common shares of Karuna, 2,671,800 common shares of Vor and 12,527,477 common shares of Akili. The fair value of these investments in Karuna, Vor and Akili was $292,831, of which approximately 96% is related to the Karuna common shares. The investments in Karuna, Vor and Akili are exposed to fluctuations in the market price of these common shares. The effect of a 10.0 percent adverse change in the market price of Karuna, Vor and Akili common shares would cause a loss of approximately $29,283 to be recognized as a component of other income (expense) in the Consolidated Statement of Comprehensive Income/(Loss). However, the Group views exposure to equity price risk as low due to the definitive merger agreement Karuna entered into with Bristol Myers Squibb "BMS") in December 2023 under which Karuna common shares were acquired by Bristol Myers Squibb for $330 per share in March 2024. Foreign Exchange Risk The Group maintains consolidated financial statements in the Group's functional currency, which is the U.S. dollar. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at exchange rates prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net income (loss) for the respective periods. Such foreign currency gains or losses were not material for all reported periods. The Group does not currently engage in currency hedging activities since its foreign currency risk is limited, but the Group may begin to do so in the future if and when its foreign currency risk exposure changes.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Commitments And Contingencies [Abstract]
Commitments and Contingencies	Commitments and Contingencies The Group is a party to certain licensing agreements where the Group is licensing IP from third parties. In consideration for such licenses, the Group has made upfront payments and may be required to make additional contingent payments based on developmental and sales milestones and/or royalty on future sales. As of December 31, 2023, certain milestone events have not yet occurred, and therefore, the Group does not have a present obligation to make the related payments in respect of the licenses. Such milestones are dependent on events that are outside of the control of the Group, and many of these milestone events are remote of occurring. As of December 31, 2023 and December 31, 2022, payments in respect of developmental milestones that are dependent on events that are outside the control of the Group but are reasonably possible to occur amounted to approximately $7,371 and $8,666, respectively. These milestone amounts represent an aggregate of multiple milestone payments depending on different milestone events in multiple agreements. The probability that all such milestone events will occur in the aggregate is remote. Payments made to license IP represent the acquisition cost of intangible assets. The Group was a party to certain sponsored research arrangements and is a party to arrangements with contract manufacturing and contract research organizations, whereby the counterparty provides the Group with research and/or manufacturing services. As of December 31, 2023 and 2022, the noncancellable commitments in respect of such contracts amounted to approximately $16,422 and $11,288, respectively. In March 2024, a complaint was filed in Massachusetts District Court against the Group alleging breach of contract with respect to certain payments alleged to be owed to a previous employee of a Group subsidiary based on purported terms of a contract between such individual and the Group. The Group intends to defend itself vigorously though the ultimate outcome of this matter and the timing for resolution remains uncertain. No determination has been made that a loss, if any, arising from this matter is probable or that the amount of any such loss, or range of loss, is reasonably estimable. The Group is involved from time-to-time in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, the Group does not expect the resolution of such legal proceedings to have a material adverse effect on its financial position or results of operations. The Group did not book any provisions and did not identify any contingent liabilities requiring disclosure for any legal proceedings other than already included above for the years ended December 31, 2023 and 2022.

Related Parties Transactions

Related Parties Transactions	12 Months Ended
	Dec. 31, 2023
Related party transactions [abstract]
Related Parties Transactions	Related Parties Transactions Related Party Subleases and Royalties During 2019, the Group executed a sublease agreement with a related party, Gelesis. As of December 31, 2022, the sublease receivable amounted to $1,285. During 2023, the sublease receivable was written down to $0 as Gelesis ceased operations and filed for bankruptcy. The Group recorded $23, $89 and $113 of interest income with respect to the sublease during the years ended December 31, 2023, 2022, and 2021, respectively, which is presented within finance income in the Consolidated Statement of Comprehensive Income/(Loss). The Group received royalties from Gelesis on its product sales. The Group recorded zero, $509, and $231 of royalty revenue during the years ended December 31, 2023, 2022, 2021, respectively, which is presented in contract revenue in the Consolidated Statement of Comprehensive Income/(Loss). Key Management Personnel Compensation Key management includes executive directors and members of the executive management team of the Group (not including non-executive directors). The key management personnel compensation of the Group was as follows for the years ended December 31: 2023 $ 2022 $ 2021 $ As of December 31 Short-term employee benefits 9,714 4,162 4,612 Post-employment benefits 41 55 54 Termination Benefits 417 152 — Share-based payment expense 599 2,741 4,045 Total 10,772 7,109 8,711 Short-term employee benefits include salaries, health care and other non-cash benefits. Post-employment benefits include 401K contributions from the Group. Termination benefits include severance pay. Share-based payments are generally subject to vesting terms over future periods. See Note 9. Share-based Payments. As of 12/31/2023, the payable due to the key management employees was $4,732. In addition the Group paid remuneration to non-executive directors in the amounts of $475, $655 and $605 for the years ended December 31, 2023, 2022 and 2021, respectively. Also, the Group incurred $373, $365, and $161 of stock based compensation expense for such non-executive directors for the years ended December 31, 2023, 2022, and 2021, respectively. During the years ended December 31, 2023 and 2022, the Group incurred $46, and $51, respectively, of expenses paid to related parties. Convertible Notes Issued to Directors Certain related parties of the Group have invested in convertible notes issued by the Group’s subsidiaries. As of December 31, 2023 and December 31, 2022, the outstanding related party notes payable totaled $104 and $99, respectively, including principal and interest. The notes issued to related parties bear interest rates, maturity dates, discounts and other contractual terms that are the same as those issued to outside investors during the same issuances. Directors’ and Senior Managers’ Shareholdings and Share Incentive Awards The Directors and senior managers hold beneficial interests in shares in the following businesses and sourcing companies as of December 31, 2023: Business name (share class) Number of shares held as of December 31, 2023 Number of options held as of December 31, 2023 Number of RSUs held as of December 31, 2023 Ownership Directors: Dr Robert Langer Entrega (Common) 250,000 82,500 — 4.09 % Dr Raju Kucherlapati Enlight (Class B Common) — 30,000 — 3.00 % Dr John LaMattina 2 Akili (Common) 56,554 — — 0.07 % Vedanta Biosciences (Common) 25,000 15,000 — 0.24 % Senior Managers: Dr Bharatt Chowrira Karuna (Common) 5,000 — — 0.01 % 1 Ownership interests as of December 31, 2023 are calculated on a diluted basis, including issued and outstanding shares, warrants and options (and written commitments to issue options) but excluding unallocated shares authorized to be issued pursuant to equity incentive plans and any shares issuable upon conversion of outstanding convertible promissory notes. 2 Dr John LaMattina holds convertible notes issued by Appeering in the aggregate principal amount of $50,000. Directors and senior managers hold 23,547,554 ordinary shares and 11.5 percent voting rights of the Group as of December 31, 2023. This amount excludes options to purchase 2,262,500 ordinary shares. This amount also excludes 7,301,547 shares, which are issuable based on the terms of performance based RSU awards granted to certain senior managers covering the financial years 2023, 2022 and 2021, and 102,732 shares, which are issuable to directors immediately prior to the Group's 2024 Annual General Meeting of Stockholders, based on the terms of the RSU awards granted to non-executive directors in 2023. Such shares will be issued to such senior managers and non-executive directors in future periods provided that performance and/or service conditions are met, and certain of the shares will be withheld for payment of customary withholding taxes. Other See Note 7. Investment in Notes from Associates for details on the notes issued by Gelesis and Vedanta to the Group. As of December 31, 2023, the Group has a receivable from Sonde and Vedanta in the amount of $1,569. See Note 6. Investments in Associates for details on the execution and termination of Merger Agreement with Gelesis.

Taxation

Taxation	12 Months Ended
	Dec. 31, 2023
Taxation [Abstract]
Taxation	Taxation Tax on the profit or loss for the year comprises current and deferred income tax. Tax is recognized in the Consolidated Statement of Comprehensive Income/(Loss) except to the extent that it relates to items recognized directly in equity. For the years ended December 31, 2023, 2022 and 2021, the Group filed a consolidated U.S. federal income tax return which included all subsidiaries in which the Group owned greater than 80 percent of the vote and value. For the years ended December 31, 2023, 2022 and 2021, the Group filed certain consolidated state income tax returns which included all subsidiaries in which the Group owned greater than 50 percent of the vote and value. The remaining subsidiaries file separate U.S. tax returns. Amounts recognized in Consolidated Statement of Comprehensive Income/(Loss): 2023 $ 2022 $ 2021 $ For the year ended December 31 Income/(loss) for the year (66,628) (37,065) (62,709) Income tax expense/(benefit) 30,525 (55,719) 3,756 Income/(loss) before taxes (36,103) (92,783) (58,953) Recognized Income Tax Expense/(Benefit): 2023 $ 2022 $ 2021 $ For the year ended December 31 Federal - current (2,246) 13,065 22,138 State - current (46) 1,336 109 Total current income tax expense/(benefit) (2,292) 14,401 22,247 Federal - deferred 29,294 (48,240) (15,416) State - deferred 3,523 (21,880) (3,075) Total deferred income tax expense/(benefit) 32,817 (70,120) (18,491) Total income tax expense/(benefit), recognized 30,525 (55,719) 3,756 The income tax expense/(benefit) was $30,525, $(55,719) and $3,756 in 2023, 2022 and 2021 respectively. The increase in tax expense for the year ended December 31, 2023 was primarily attributable to a lower pre-tax loss in the tax consolidated U.S. group, the tax in respect of the sale of future royalties to Royalty Pharma and the tax impact of derecognizing previously recognized deferred tax assets that are no longer expected to be utilized. Reconciliation of Effective Tax Rate The Group is primarily subject to taxation in the U.S. A reconciliation of the U.S. federal statutory tax rate to the effective tax rate is as follows: 2023 2022 2021 For the year ended December 31 $ % $ % $ % US federal statutory rate (7,573) 21.00 (19,486) 21.00 (12,380) 21.00 State taxes, net of federal effect (3,974) 11.01 (8,043) 8.67 (4,484) 7.61 Tax credits (9,167) 25.39 (6,876) 7.41 (5,056) 8.58 Stock-based compensation 589 (1.63) 788 (0.85) 555 (0.94) Finance income/(costs) – fair value accounting (556) 1.54 (28,783) 31.02 (2,017) 3.42 Loss with respect to associate for which no deferred tax asset is recognized 249 (0.69) 1,413 (1.52) 11,542 (19.58) Revaluation of deferred due to rate change — 0.00 (8,856) 9.54 — — Nondeductible compensation 872 (2.42) 300 (0.32) 746 (1.27) Recognition of deferred tax assets and tax benefits not previously recognized (433) 1.20 (184) 0.20 (414) 0.70 Unrecognized deferred tax asset 83,984 (232.63) 17,287 (18.63) 14,375 (24.38) Deconsolidation of subsidiary (17,506) 48.49 (3,572) 3.85 — — Other 1,321 (3.65) 293 (0.32) 889 (1.51) Worthless stock deduction (17,281) 47.87 — — — — 30,525 (84.52) (55,719) 60.05 3,756 (6.37) The Group is also subject to taxation in the UK, but to date, no taxable income has been generated in the UK. Changes in corporate tax rates can change both the current tax expense (benefit) as well as the deferred tax expense (benefit). Deferred Tax Assets and Liabilities Deferred tax assets have been recognized in the U.S. jurisdiction in respect of the following items: 2023 $ 2022 $ For the year ended December 31 Operating tax losses 3,849 48,317 Tax credits 2,425 11,101 Share-based payments 5,210 8,423 Capitalized research & development expenditures 39,422 36,084 Investment in Associates — 13,036 Lease liability 5,133 7,143 Sale of future royalties 35,920 — Other temporary differences 1,770 2,957 Deferred tax assets 93,729 127,061 Investments held at fair value (53,411) (47,877) Right of use assets (2,330) (3,519) Property and equipment, net (1,637) (2,348) Investment in Associates (755) — Deferred tax liabilities (58,133) (53,744) Deferred tax assets (liabilities), net 35,596 73,317 Deferred tax liabilities, net, recognized (52,462) (19,645) Deferred tax assets (liabilities), net, not recognized 88,058 92,962 The Group has recognized deferred tax assets due to future reversals of existing taxable temporary differences that will be sufficient to recover the deferred tax assets. Our unrecognized deferred tax assets of $88,058 are primarily related to tax credits, capitalized research & development expenditures and deferred tax asset related to the sale of future royalties to Royalty Pharma. The Group does not believe it is probable that future taxable profit will be available to support the realizability of these unrecognized deferred tax assets. Unrecognized Deferred Tax Assets Deferred tax assets have not been recognized in respect of the following carryforward losses, credits and temporary differences, because it is not probable that future taxable profit will be available against which the Group can use the benefits therefrom. 2023 $ 2022 $ For the year ended December 31 Gross Amount Tax Effected Gross Amount Tax Effected Deductible temporary difference 353,323 83,741 132,145 33,544 Tax losses 13,681 3,849 219,466 48,317 Tax credits 468 468 11,101 11,101 Total 367,472 88,058 362,712 92,962 Tax Losses and Tax Credits Carryforwards Tax losses and tax credits for which no deferred tax asset was recognized are presented below: As of December 31 2023 $ 2022 $ Gross Amount Tax Effected Gross Amount Tax Effected Tax losses expiring: Within 10 years 4,741 1,284 23,930 5,387 More than 10 years 6,635 1,455 42,822 10,509 Available Indefinitely 2,305 1,110 152,714 32,421 Total 13,681 3,849 219,466 48,317 Tax credits expiring: Within 10 years 43 43 43 43 More than 10 years 425 425 11,058 11,058 Available indefinitely — — — — Total 468 468 11,101 11,101 The Group had U.S. federal net operating losses carry forwards (“NOLs”) of $13,681, $219,466 and $215,400 as of December 31, 2023, 2022 and 2021, respectively, which are available to offset future taxable income. These NOLs expire through 2037 with the exception of $2,305 which is not subject to expiration. The Group had U.S. federal research and development tax credits of approximately $1,396, $4,500 and $3,900 as of December 31, 2023, 2022 and 2021, respectively, which are available to offset future taxes that expire at various dates through 2043. The Group also had Federal Orphan Drug credits of approximately $930 and $6,100 as of December 31, 2023, and 2022, which are available to offset future taxes that expire at various dates through 2043. A portion of these federal NOLs and credits can only be used to offset the profits from the Group’s subsidiaries who file separate federal tax returns. These NOLs and credits are subject to review and possible adjustment by the Internal Revenue Service. The Group had state net operating losses carry forwards (“NOLs”) of approximately $111,446, $71,700 and $27,900 for the years ended December 31, 2023, 2022 and 2021, respectively, which are available to offset future taxable income. These NOLs expire at various dates beginning in 2030. The Group had Massachusetts research and development tax credits of approximately $98, $600 and $1,300 for the years ended December 31, 2023, 2022 and 2021, respectively, which are available to offset future taxes and expire at various dates through 2038. These NOLs and credits are subject to review and possible adjustment by state taxing authority. Utilization of the NOLs and research and development credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes may limit the amount of NOL and research and development credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Group has performed a Section 382 analysis through December 31, 2023. The results of this analysis concluded that certain net operating losses were subject to limitation under Section 382 of the Internal Revenue Code. None of the Group’s net operating losses which are subject to a Section 382 limitation has been recognized in the financial statements. Tax Balances The tax related balances presented in the Statement of Financial Position are as follows: For the year ended December 31 2023 $ 2022 $ Income tax receivable – current 11,746 10,040 Trade and other payables — (57) Uncertain Tax Positions The Group has no uncertain tax positions as of December 31, 2023. U.S. corporations are routinely subject to audit by federal and state tax authorities in the normal course of business.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2023
Disclosure of non-adjusting events after reporting period [abstract]
Subsequent Events	Subsequent Events The Group has evaluated subsequent events after December 31, 2023, up to the date of issuance, April 25, 2024, of the Consolidated Financial Statements, and has not identified any recordable or disclosable events not otherwise reported in these Consolidated Financial Statements or notes thereto, except for the following: In January 2024, the Group launched two new Founded Entities (Seaport Therapeutics and Gallop Oncology) to advance certain programs from the Wholly-Owned Programs segment. Seaport Therapeutics ("Seaport") will advance certain central nervous system programs and relevant Glyph intellectual property. Gallop Oncology will advance LYT-200 and other galectin-9 intellectual property. The financial results of these programs were included in the Wholly-Owned Programs segment in the footnotes to the Consolidated Financial Statements, as of December 31, 2023 and 2022, and for the three years ended December 31, 2023, 2022 and 2021, respectively. Upon raising dilutive third-party financing, the financial results of these two entities will be included in the Controlled Founded Entities segment to the extent that the Group maintains control over these entities. On May 9, 2022, the Group announced the commencement of a $50,000 share repurchase program ( the "Program") of its ordinary shares of one pence each. In February 2024, the Group completed the Program and has repurchased an aggregate of 20,182,863 ordinary shares under the Program. These shares have been held as treasury shares and are being used to settle the vesting of restricted stock units or exercise of options. In March 2024, Karuna was acquired by Bristol Myers Squibb (“BMS”) in accordance with a definitive merger agreement signed in December 2023. As a result of this transaction, the Group received total proceeds of In March 2024, the Group announced a proposed capital return of $100,000 to its shareholders by way of a tender offer (the "Tender Offer"). The Tender Offer is expected to be launched in early May, subject to market conditions and shareholder approval. If the full $100,000 is not returned, then the Group intends to return any remainder following the completion of the Tender Offer, by way of a special dividend. In April 2024, Seaport Therapeutics, the Group's latest Founded Entity, raised $100,000 in a Series A financing, out of which $32,000 was invested by the Group. Following the Series A financing, the Group holds equity ownership in Seaport of 61.5 percent on a diluted basis. In April 2024, the Gelesis' Chapter 7 Trustee provided notice that a third party bid to purchase the assets subject to the bankruptcy had been accepted as a stalking horse bid, subject to Bankruptcy Court approval. If such sale of the assets is ultimately approved by the Bankruptcy Court and consummated, it is expected that PureTech could recover a portion of its investment in Gelesis senior secured convertible promissory notes. The ultimate resolution of this matter, any potential recovery, and the associated timing remain uncertain. The Group has not recorded any amount in its Consolidated Financial Statements related to amounts that may be received as a result of the bankruptcy process.

Material Accounting Policies (P

Material Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies 1 [Abstract]
Basis of Presentation	For presentation of the Consolidated Statement of Comprehensive Income/(Loss), the Group uses a classification based on the function of expenses, rather than based on their nature, as it is more representative of the format used for internal reporting and management purposes and is consistent with international practice. Certain amounts in the Consolidated Financial Statements and accompanying notes may not add due to rounding. All percentages have been calculated using unrounded amounts.
Basis of Measurement	Basis of Measurement
Use of Judgments and Estimates	Use of Judgments and Estimates In preparing the Consolidated Financial Statements, management has made judgements, estimates and assumptions that affect the application of the Group’s accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an on-going basis. Significant estimation is applied in determining the following: • Financial instruments valuations (see Note 18. Financial Instruments): In accordance with IFRS 9, the Group carries certain financial assets and financial liabilities at fair value, with changes in fair value through profit and loss ("FVTPL"). Valuation of the aforementioned financial instruments (assets and liabilities) includes making significant estimates, specifically determining the appropriate valuation methodology and making certain estimates such as the future expected returns on the financial instrument in different scenarios, appropriate discount rate, volatility, and term to exit. Significant judgement is also applied in determining the following: • Whether financial instruments should be classified as liability or equity (see Note 16. Subsidiary Preferred Shares.). The judgement includes an assessment of whether the financial instruments include contractual obligations of the Group to deliver cash or other financial assets or to exchange financial assets or financial liabilities with another party, and whether those obligations could be settled by the Group exchanging a fixed amount of cash or other financial assets for a fixed number of its own equity instruments. Further information about these critical judgements and estimates is included below under Financial Instruments. • Whether the power to control investees exists (see Note 5. Investments Held at Fair Value and Note 6. Investments in Associates and accounting policy with regard to Subsidiaries below). The judgement includes an assessment of whether the Group has (i) power over the investee; (ii) exposure, or rights, to variable returns from its involvement with the investee; and (iii) the ability to use its power over the investee to affect the amount of its own returns. The Group considers among others its voting shares, shareholder agreements, ability to appoint board members, representation on the board, rights to appoint management, de facto control, investee dependence on the Group, etc. If the power to control the investee exists, it consolidates the financial statements of such investee in the Consolidated Financial Statements of the Group. Upon issuance of new shares in an investee and/or a change in any shareholders or governance agreements, the Group reassesses its ability to control the investee based on the revised voting interest, revised board composition and revised subsidiary governance and management structure. When such new circumstances result in the Group losing its power to control the investee, the investee is deconsolidated. On March 1 2023 Vedanta was deconsolidated. Although the Group holds 47% of the voting rights and the other shareholders are widely dispersed, the Group does not have de facto control because the investor rights agreement stipulates that the relevant activities of Vedanta are directed by Vedanta's Board and the Group does not control Vedanta's Board decision making. Voting rights are not the dominant factor for directing Vedanta's relevant activities. • Whether the Group has significant influence over financial and operating policies of investees in order to determine if the Group should account for its investment as an associate based on IAS 28 or a financial instrument based on IFRS 9. (refer to Note 5. Investments Held at Fair Value and Note 6. Investments in Associates ). This judgement includes, among others, an assessment whether the Group has representation on the board of directors of the investee, whether the Group participates in the policy making processes of the investee, whether there is any interchange of managerial personnel, whether there is any essential technical information provided to the investee and if there are any transactions between the Group and the investee. • Upon determining that the Group does have significant influence over the financial and operating policies of an investee, if the Group holds more than a single instrument issued by its equity-accounted investee, judgement is required to determine whether the additional instrument forms part of the investment in the associate, which is accounted for under IAS 28 and scoped out of IFRS 9, or it is a separate financial instrument that falls in the scope of IFRS 9. This judgement includes an assessment of the characteristics of the financial instrument of the investee held by the Group and whether such financial instrument provides access to returns underlying an ownership interest. • When the Group has other investments in an equity accounted investee that are not accounted for under IAS 28, judgement is required in determining if such investments constitute long-term interests ("LTI") for the purposes of IAS 28. This determination is based on the individual facts and circumstances and characteristics of each investment, but is driven, among other factors, by the intention and likelihood to settle the instrument through redemption or repayment in the foreseeable future, and whether or not the investment is likely to be converted to common stock or other equity instruments. After considering the individual facts and circumstances of the Group’s investment in its associate's preferred stock in the manner described above, including the long-term nature of such investment, the ability of the Group to convert its preferred stock investment to an investment in common shares and the likelihood of such conversion, the Group concluded that such investment was considered a long term interest. • In determining the appropriate accounting treatment for the Royalty Purchase Agreement, management applied significant judgement (refer to Note 17. Sale of Future Royalties Liability).
Going Concern	Considering the Group’s financial position as of December 31, 2023, and its principal risks and opportunities, the Group prepared a going concern analysis covering a period of at least the twelve-month period from the date of signing the Consolidated Financial Statements ("the going concern period") utilizing realistic scenarios and applying a severe but plausible downside scenario. Even under the downside scenario, the analysis demonstrates the Group continues to maintain sufficient liquidity headroom and continues to comply with all financial obligations. The Board of Directors believe the Group and the Parent is adequately resourced to continue in operational existence for at least the twelve-month period from the date of signing the Consolidated Financial Statements. Accordingly, the Board of Directors considered it appropriate to adopt the going concern basis of accounting in preparing the Consolidated Financial Statements and the PureTech Health plc Financial Statements.
Basis of consolidation	Basis of consolidation The Consolidated Financial Statements as of December 31, 2023 and 2022, and for each of the years ended December 31, 2023, 2022 and 2021, comprises PureTech Health plc and its consolidated subsidiaries. Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated.
Subsidiaries and Change in Subsidiary Ownership and Loss of Control	Subsidiaries As used in these financial statements, the term subsidiaries refers to entities that are controlled by the Group. Under applicable accounting rules, the Group controls an entity when it is exposed to, or has the rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. In assessing control, the Group takes into consideration potential voting rights, board representation, shareholders' agreements, ability to appoint board of directors and management, de facto control and other related factors. The financial statements of subsidiaries are included in the Consolidated Financial Statements from the date that control commences until the date that control ceases. Losses applicable to the non-controlling interests in a subsidiary are allocated to the non-controlling interests even if doing so causes the non-controlling interests to have a deficit balance. Change in Subsidiary Ownership and Loss of Control Changes in the Group’s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. Where the Group loses control of a subsidiary, the assets and liabilities are derecognized along with any related non-controlling interest (“NCI”). Any interest retained in the former subsidiary is measured at fair value when control is lost. Any resulting gain or loss is recognized as profit or loss in the Consolidated Statement of Comprehensive Income/(Loss).
Associates	Associates As used in these financial statements, the term associates are those entities in which the Group has no control but maintains significant influence over the financial and operating policies. Significant influence is presumed to exist when the Group holds between 20 and 50 percent of the voting power of an entity, unless it can be clearly demonstrated that this is not the case. The Group evaluates if it maintains significant influence over associates by assessing if the Group has the power to participate in the financial and operating policy decisions of the associate. Application of the Equity Method to Associates Associates are accounted for using the equity method (equity accounted investees) and are initially recognized at cost, or if recognized upon deconsolidation, they are initially recorded at fair value at the date of deconsolidation. The Consolidated Financial Statements include the Group’s share of the total comprehensive income or loss of equity accounted investees, from the date that significant influence commences until the date that significant influence ceases. To the extent the Group holds interests in associates that are not providing access to returns underlying ownership interests, the instrument is accounted for in accordance with IFRS 9 as investments held at fair value. When the Group’s share of losses exceeds its equity method investment in the investee, losses are applied against long-term interests, which are investments accounted for under IFRS 9. Investments are determined to be long-term interests when they are long-term in nature and in substance they form part of the Group's net investment in that associate. This determination is impacted by many factors, among others, whether settlement by the investee through redemption or repayment is planned or likely in the foreseeable future, whether the investment can be converted and/or is likely to be converted to common stock or other equity instrument and other factors regarding the nature of the investment. Whilst this assessment is dependent on many specific facts and circumstances of each investment, typically conversion features whereby the investment is likely to convert to common stock or other equity instruments would point to the investment being a long-term interest. Similarly, where the investment is not planned or likely to be settled through redemption or repayment in the foreseeable future, this would indicate that the investment is a long-term interest. When the net investment in the associate, which includes the Group’s investments in other long-term interests, is reduced to nil, recognition of further losses is discontinued except to the extent that the Group has incurred legal or constructive obligations or made payments on behalf of an investee. The Group has adopted the amendments to IAS 28 Investments in Associates that addresses the dual application of IAS 28 and IFRS 9 when equity method losses are applied against long-term interests. The amendments provide the annual sequence in which both standards are to be applied in such a case. The Group has applied the equity method losses to the long-term interests presented as part of Investments held at fair value subsequent to remeasuring such investments to their fair value at balance sheet date.
Sale of Future Royalties Liability	Sale of Future Royalties Liability The Group accounts for the sale of future royalties liability as a financial liability, as it continues to hold the rights under the royalty bearing licensing agreement and has a contractual obligation to deliver cash to an investor for a portion of the royalty it receives. Interest on the sale of future royalties liability is recognized using the effective interest rate over the life of the related royalty stream. The sale of future royalties liability and the related interest expense are based on the Group’s current estimates of future royalties expected to be paid over the life of the arrangement. Forecasts are updated periodically as new data is obtained. Any increases, decreases or a shift in timing of estimated cash flows require the Group to re-calculate the amortized cost of the sale of future royalties liability as the present value of the estimated future contractual cash flows that are discounted at the liability’s original effective interest rate. The adjustment is recognized immediately in profit or loss as income or expense.
Financial Instruments	Financial Instruments Classification The Group classifies its financial assets in the following measurement categories: • Those to be measured subsequently at fair value either through other comprehensive income "FVOCI", or through profit or loss "FVTPL", and • Those to be measured at amortized cost. The classification depends on the Group’s business model for managing the financial assets and the contractual terms of the cash flows. For assets measured at fair value, gains and losses are recorded in profit or loss. Measurement At initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset not at FVTPL, transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets that are carried at FVTPL are expensed. Impairment The Group assesses on a forward-looking basis the expected credit losses associated with its debt instruments carried at amortized cost. For trade receivables, the Group applies the simplified approach permitted by IFRS 9, which requires expected lifetime losses to be recognized from initial recognition of the receivables.
Financial Assets	Financial Assets The Group’s financial assets consist of cash and cash equivalents, investments in debt securities, trade and other receivables, notes, restricted cash deposits and investments in equity securities. The Group’s financial assets are virtually all classified into the following categories: investments held at fair value, notes, trade and other receivables, short-term investments and cash and cash equivalents. The Group determines the classification of financial assets at initial recognition depending on the purpose for which the financial assets were acquired. Investments held at fair value are investments in equity instruments. Such investments consist of the Group's minority interest holdings where the Group has no significant influence or preferred share investments that are not providing access to returns underlying ownership interests and are categorized as debt instruments that are presented at fair value through profit and loss because the amounts receivable do not represent solely payments of principal and interest. These financial assets are initially measured at fair value and subsequently re-measured at fair value at each reporting date. The Group has elected to record the changes in fair values for the financial assets falling under this category through profit and loss. Please refer to Note 5. Investments Held at Fair Value. Changes in the fair value of financial assets at FVTPL are recognized in other income/(expense) in the Consolidated Statement of Comprehensive Income/(Loss) as applicable. The notes from an associate, since their contractual terms do not consist solely of cash flow payments of principal and interest on the principal amount outstanding, are initially and subsequently measured at fair value, with changes in fair value recognized through profit and loss. Cash and cash equivalents consist of demand deposits with banks and other financial institutions and highly liquid instruments with original maturities of three months or less at the date of purchase. Cash and cash equivalents are carried at cost, which approximates their fair value. Short-term investments consist of short-term US treasury bills that are held to maturity. The contractual terms consist solely of payment of the principal and interest and the Group's business model is to hold the treasury bills to maturity. As such, such short-term investments are recorded at amortized cost. As of balance sheet date, amortized cost approximated the fair value of such short-term investments. Trade and other receivables are non-derivative financial assets with fixed and determinable payments that are not quoted on active markets. These financial assets are carried at the amounts expected to be received less any expected lifetime losses. Such losses are determined taking into account previous experience, credit rating and economic stability of counterparty and economic conditions. When a trade receivable is determined to be uncollectible, it is written off against the available provision. As of balance sheet date, the Group did not record any such expected lifetime losses related to the outstanding trade and other receivable balances. Trade and other receivables are included in current assets, unless maturities are greater than 12 months after the end of the reporting period.
Financial Liabilities	Financial Liabilities The Group’s financial liabilities primarily consist of trade and other payables, and preferred shares. The majority of the Group’s subsidiaries have preferred shares and certain notes payable with embedded derivatives, which are classified as current liabilities. When the Group has preferred shares and notes with embedded derivatives that qualify for bifurcation, the Group has elected to account for the entire instrument as FVTPL after determining under IFRS 9 that the instrument qualifies to be accounted for under such FVTPL method. The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled or expire.
Equity Instruments Issued by the Group	Equity Instruments Issued by the Group Financial instruments issued by the Group are treated as equity only to the extent that they meet the following two conditions, in accordance with IAS 32: 1. They include no contractual obligations upon the Group to deliver cash or other financial assets or to exchange financial assets or financial liabilities with another party under conditions that are potentially unfavorable to the Group; and 2. Where the instrument will or may be settled in the Group’s own equity instruments, it is either a non-derivative that includes no obligation to deliver a variable number of the Group’s own equity instruments or is a derivative that will be settled by the Group exchanging a fixed amount of cash or other financial assets for a fixed number of its own equity instruments. To the extent that this definition is not met, the financial instrument is classified as a financial liability. Where the instrument so classified takes the legal form of the Group’s own shares, the amounts presented in the Group's shareholders' equity exclude amounts in relation to those shares.
IFRS 15, Revenue from Contracts with Customers	IFRS 15, Revenue from Contracts with Customers The standard establishes a five-step principle-based approach for revenue recognition and is based on the concept of recognizing an amount that reflects the consideration for performance obligations only when they are satisfied and the control of goods or services is transferred. The majority of the Group’s contract revenue is generated from licenses and services, some of which are part of collaboration arrangements. Management reviewed contracts where the Group received consideration in order to determine whether or not they should be accounted for in accordance with IFRS 15. To date, the Group has entered into transactions that generate revenue and meet the scope of either IFRS 15 or IAS 20 Accounting for Government Grants. Contract revenue is recognized at either a point-in-time or over time, depending on the nature of the performance obligations. The Group accounts for agreements that meet the definition of IFRS 15 by applying the following five step model: • Identify the contract(s) with a customer – A contract with a customer exists when (i) the Group enters into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to those goods or services, (ii) the contract has commercial substance and, (iii) the Group determines that collection of substantially all consideration for goods or services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration. • Identify the performance obligations in the contract – Performance obligations promised in a contract are identified based on the goods or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the good or service either on its own or together with other resources that are readily available from third parties or from the Group, and are distinct in the context of the contract, whereby the transfer of the goods or services is separately identifiable from other promises in the contract. • Determine the transaction price – The transaction price is determined based on the consideration to which the Group will be entitled in exchange for transferring goods or services to the customer. To the extent the transaction price includes variable consideration, the Group estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in the Group’s judgement, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. • Allocate the transaction price to the performance obligations in the contract – If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price basis. • Recognize revenue when (or as) the Group satisfies a performance obligation – The Group satisfies performance obligations either over time or at a point in time as discussed in further detail below. Revenue is recognized at the time the related performance obligation is satisfied by transferring a promised good or service to a customer. Revenue generated from services agreements (typically where licenses and related services were combined into one performance obligation) is determined to be recognized over time when it can be determined that the services meet one of the following: (a) the customer simultaneously receives and consumes the benefits provided by the entity’s performance as the entity performs; (b) the entity’s performance creates or enhances an asset that the customer controls as the asset is created or enhanced; or (c) the entity’s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. It was determined that the Group has contracts that meet criteria (a), since the customer simultaneously receives and consumes the benefits provided by the Group’s performance as the Group performs. Therefore revenue is recognized over time using the input method based on costs incurred to date as compared to total contract costs. The Group believes that in research and development service type agreements using costs incurred to date represents the most faithful depiction of the entity’s performance towards complete satisfaction of a performance obligation. Revenue from licenses that are not part of a combined performance obligation are recognized at a point in time due to the licenses relating to intellectual property that has significant stand-alone functionality and as such represent a right to use the entity's intellectual property as it exists at the point in time at which the license is granted. Royalty income received in respect of licensing agreements when the license of intellectual property is the predominant item in the arrangement is recognized as the related third-party sales in the licensee occur. Amounts that are receivable or have been received per contractual terms but have not been recognized as revenue since performance has not yet occurred or has not yet been completed are recorded as deferred revenue. The Group classifies as non-current deferred revenue amounts received for which performance is expected to occur beyond one year or one operating cycle.
Grant Revenue	Grant Revenue The Group recognizes grants from governmental agencies as grant revenue in the Consolidated Statement of Comprehensive Income/(Loss), gross of the expenditures that were related to obtaining the grant, when there is reasonable assurance that the Group will comply with the conditions within the grant agreement and there is reasonable assurance that payments under the grants will be received. The Group evaluates the conditions of each grant as of each reporting date to ensure that the Group has reasonable assurance of meeting the conditions of each grant arrangement and that it is expected that the grant payment will be received as a result of meeting the necessary conditions. The Group submits qualifying expenses for reimbursement after the Group has incurred the research and development expense. The Group records an unbilled receivable upon incurring such expenses. In cases in which the grant revenue is received prior to the expenses being incurred or recognized, the amounts received are deferred until the related expense is incurred and/or recognized. Grant revenue is recognized in the Consolidated Statement of Comprehensive Income/(Loss) at the time in which the Group recognizes the related reimbursable expense for which the grant is intended to compensate.
Functional and Presentation Currency	Functional and Presentation Currency The Consolidated Financial Statements are presented in United States dollars (“US dollars”). The functional currency of all members of the Group is the U.S. dollar. The Group's share in foreign exchange differences in associates were reported in other comprehensive income/(loss).
Foreign Currency	Foreign Currency
Share Capital	Share Capital Ordinary shares are classified as equity. The Group's equity is comprised of share capital, share premium, merger reserve, other reserve, translation reserve, and retained earnings/accumulated deficit.
Treasury Shares	Treasury Shares Treasury shares are recognized at cost and are deducted from shareholders' equity. No gain or loss is recognized in profit and loss for the purchase, sale, re-issue or cancellation of the Group's own equity shares.
Property and Equipment	Property and Equipment Property and equipment is stated at cost less accumulated depreciation and any accumulated impairment losses. Cost includes expenditures that are directly attributable to the acquisition of the asset. Assets under construction represent leasehold improvements and machinery and equipment to be used in operations or research and development activities. When parts of an item of property and equipment have different useful lives, they are accounted for as separate items (major components) of property and equipment. Depreciation is calculated using the straight-line method over the estimated useful life of the related asset: Laboratory and manufacturing equipment 2-8 years Furniture and fixtures 7 years Computer equipment and software 1-5 years Leasehold improvements 5-10 years, or the remaining term of the lease, if shorter Depreciation methods, useful lives and residual values are reviewed at each balance sheet date.
Intangible Assets	Intangible Assets Intangible assets, which include purchased patents and licenses with finite useful lives, are carried at historical cost less accumulated amortization, if amortization has commenced. Intangible assets with finite lives are amortized from the time they are available for their intended use. Amortization is calculated using the straight-line method to allocate the costs of patents and licenses over their estimated useful lives. Research and development intangible assets, which are still under development and have accordingly not yet obtained marketing approval, are presented as In-Process Research and Development (IPR&D). The cost of IPR&D represents upfront payments as well as additional contingent payments based on development, regulatory and sales milestones related to certain license agreement where the Group licenses IP from a third party. These milestones are capitalized as the milestone is triggered. See Note 25. Commitments and Contingencies. IPR&D is not amortized since it is not yet available for its intended use, but it is evaluated for potential impairment on an annual basis or more frequently when facts and circumstances warrant.
Impairment of Non-Financial Assets	Impairment of Non-Financial Assets The Group reviews the carrying amounts of its property and equipment and intangible assets at each reporting date to determine whether there are indicators of impairment. If any such indicators of impairment exist, then an asset’s recoverable amount is estimated. The recoverable amount is the higher of an asset’s fair value less cost of disposal and value in use. The Group’s IPR&D intangible assets are not yet available for their intended use. As such, they are tested for impairment at least annually. An impairment loss is recognized when an asset’s carrying amount exceeds its recoverable amount. For the purposes of impairment testing, assets are grouped at the lowest levels for which there are largely independent cash flows. If a non- financial asset instrument is impaired, an impairment loss is recognized in the Consolidated Statement of Comprehensive Income/(Loss).
Employee Benefits	Employee Benefits Short-Term Employee Benefits Short-term employee benefit obligations are measured on an undiscounted basis and expensed as the related service is provided. A liability is recognized for the amount expected to be paid if the Group has a present legal or constructive obligation due to past service provided by the employee, and the obligation can be estimated reliably. Defined Contribution Plans
Share-based Payments	Share-based Payments Share-based payment arrangements, in which the Group receives goods or services as consideration for its own equity instruments, are accounted for as equity-settled share-based payment transactions (except certain restricted stock units - see below) in accordance with IFRS 2, regardless of how the equity instruments are obtained by the Group. The grant date fair value of employee share-based payment awards is recognized as an expense with a corresponding increase in equity over the requisite service period related to the awards. The amount recognized as an expense is adjusted to reflect the actual number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that do meet the related service and non-market performance conditions at the vesting date. For share-based payment awards with market conditions, the grant date fair value is measured to reflect such conditions and there is no true-up for differences between expected and actual outcomes. Certain restricted stock units are treated as liability settled awards starting in 2021. Such awards are remeasured at every reporting date until settlement date and are recognized as compensation expense over the requisite service period. Differences in remeasurement are recognized in profit and loss. The cumulative cost that will ultimately be recognized in respect of these awards will equal to the amount at settlement.
Development Costs	Development Costs Expenditures on research activities are recognized as incurred in the Consolidated Statement of Comprehensive Income/(Loss). In accordance with IAS 38, development costs are capitalized only if the expenditure can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, the Group can demonstrate its ability to use or sell the intangible asset, the Group intends to and has sufficient resources to complete development and to use or sell the asset, and it is able to measure reliably the expenditure attributable to the intangible asset during its development. The point at which technical feasibility is determined to have been reached is, generally, when regulatory approval has been received where applicable. Management determines that commercial viability has been reached when a clear market and pricing point have been identified, which may coincide with achieving meaningful recurring sales. Otherwise, the development expenditure is recognized as incurred in the Consolidated Statement of Comprehensive Income/(Loss). As of balance sheet date, the Group has not capitalized any development costs.
Provisions	Provisions A provision is recognized in the Consolidated Statement of Financial Position when the Group has a present legal or constructive obligation due to a past event that can be reliably measured, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects risks specific to the liability.
Leases	Leases The Group leases real estate for use in operations. These leases have lease terms of approximately 10 years. The Group includes options that are reasonably certain to be exercised as part of the determination of the lease term. The group determines if an arrangement is a lease at inception of the contract in accordance with guidance detailed in IFRS 16. Right-of-use (ROU) assets represent the Group’s right to use an underlying asset for the lease term and lease liabilities represent the Group's obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are recognized at commencement date based on the present value of the lease payments over the lease term. As most of the Group's leases do not provide an implicit rate, the Group used its estimated incremental borrowing rate, based on information available at commencement date, in determining the present value of future payments. The Group’s leases are virtually all leases of real estate. The Group has elected to account for lease payments as an expense on a straight-line basis over the life of the lease for: • Leases with a term of 12 months or less and containing no purchase options; and • Leases where the underlying asset has a value of less than $5,000.
Finance Income and Finance Costs	Finance Income and Finance Costs Finance income consists of interest income on funds invested in money market funds and U.S. treasuries. Finance income is recognized as it is earned. Finance costs consist mainly of loan, notes and lease liability interest expenses, interest expense due to accretion of and adjustment to sale of future royalties liability as well as the changes in the fair value of financial liabilities carried at FVTPL (such changes can consist of finance income when the fair value of such financial liabilities decreases).
Taxation	Taxation Tax on the profit or loss for the year comprises current and deferred income tax. In accordance with IAS 12, tax is recognized in the Consolidated Statement of Comprehensive Income/(Loss) except to the extent that it relates to items recognized directly in equity. Current income tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantially enacted at the reporting date, and any adjustment to tax payable in respect of previous years. Deferred tax is recognized due to temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax assets are recognized for unused tax losses, unused tax credits and deductible temporary differences to the extent that it is probable that future taxable profits will be available against which they can be used. Deferred tax assets with respect to investments in associates are recognized only to the extent that it is probable the temporary difference will reverse in the foreseeable future and taxable profit will be available against which the temporary difference can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, using tax rates enacted or substantively enacted at the reporting date. Deferred income tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets against current tax liabilities and when the deferred income tax assets and liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities where there is an intention to settle the balances on a net basis.
Fair Value Measurements	Fair Value Measurements The Group’s accounting policies require that certain financial assets and certain financial liabilities be measured at their fair value. The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows: • Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities. • Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices). • Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs). The Group recognizes transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.
Operating Segments	Operating Segments Operating segments are reported in a manner that is consistent with the internal reporting provided to the chief operating decision maker (“CODM”). The CODM reviews discrete financial information for the operating segments in order to assess their performance and is responsible for making decisions about resources allocated to the segments. The CODM has been identified as the Group’s Board of Directors.
New Standards and Interpretations	New Standards and Interpretations The Group has applied the following amendments for the first time for its annual reporting period commencing January 1, 2023: • IFRS 17 Insurance Contracts • Definition of Accounting Estimates (Amendments to IAS 8) • Deferred Tax related to Assets and Liabilities Arising from a Single Transaction (Amendments to IAS 12) The amendments listed above did not have any impact on the amounts recognized in prior and current periods and are not expected to significantly affect the future periods. Certain new accounting standards, amendments to accounting standards and interpretations have been published that are not mandatory for December 31, 2023 reporting periods and have not been early adopted by the Group. These standards, amendments or interpretations are not expected to have a material impact on the Group in the current or future reporting periods and on foreseeable future transactions.

Material Accounting Policies (T

Material Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Accounting Policies 1 [Abstract]
Schedule of Subsidiaries	All current subsidiaries are domiciled within the United States and conduct business activities solely within the United States. Voting percentage at December 31, through the holdings in 2023 2022 2021 Subsidiary Common Preferred Common Preferred Common Preferred Subsidiary operating companies Alivio Therapeutics, Inc. 2 — 100.0 — 100.0 — 100.0 Entrega, Inc. (indirectly held through Enlight) 2 — 77.3 — 77.3 — 77.3 PureTech LYT, Inc. (formerly Ariya Therapeutics, Inc.) 2 — 100.0 — 100.0 — 100.0 PureTech LYT 100, Inc. 2 — 100.0 — 100.0 — 100.0 PureTech Management, Inc. 3 100.0 — 100.0 — 100.0 — PureTech Health LLC 3 100.0 — 100.0 — 100.0 — Deconsolidated former subsidiary operating companies Sonde Health, Inc. 2,5 — 40.2 — 40.2 — 51.8 Akili Interactive Labs, Inc. 2,6 14.6 — 14.7 — — 26.7 Gelesis, Inc. 1,2 — — 22.8 — 4.8 19.7 Karuna Therapeutics, Inc. 2,6 2.3 — 3.1 — 5.6 — Vedanta Biosciences, Inc. 2, 4 — 47.0 — 47.0 — 48.6 Vedanta Biosciences Securities Corp. (indirectly held through Vedanta) 2, 4 — 47.0 — 47.0 — 48.6 Vor Biopharma Inc .2,6 3.9 — 4.1 — 8.6 — Nontrading holding companies Endra Holdings, LLC (held indirectly through Enlight) 2 86.0 — 86.0 — 86.0 — Ensof Holdings, LLC (held indirectly through Enlight) 2 86.0 — 86.0 — 86.0 — PureTech Securities Corp. 2 100.0 — 100.0 — 100.0 — PureTech Securities II Corp. 2 100.0 — 100.0 — 100.0 — Inactive subsidiaries Appeering, Inc. 2 — 100.0 — 100.0 — 100.0 Commense Inc. 2 — 99.1 — 99.1 — 99.1 Enlight Biosciences, LLC 2 86.0 — 86.0 — 86.0 — Ensof Biosystems, Inc. (held indirectly through Enlight) 2 57.7 28.3 57.7 28.3 57.7 28.3 Follica, LLC 2 28.7 56.7 28.7 56.7 28.7 56.7 Knode Inc. (indirectly held through Enlight) 2 — 86.0 — 86.0 — 86.0 Libra Biosciences, Inc. 2 — 100.0 — 100.0 — 100.0 Mandara Sciences, LLC 2 98.3 — 98.3 — 98.3 — Tal Medical, Inc. 2 — 100.0 — 100.0 — 100.0 1 On October 30, 2023, Gelesis ceased operations and filed a voluntary petition for relief under the United States bankruptcy code. See Note 6. Investments in Associates for details. 2 Registered address is Corporation Trust Center, 1209 Orange St., Wilmington, DE 19801, USA. 3 Registered address is 2711 Centerville Rd., Suite 400, Wilmington, DE 19808, USA. 4 On March 1, 2023, the Group lost control over Vedanta and Vedanta was deconsolidated from the Group’s financial statements, resulting in only the profits and losses generated by Vedanta through the deconsolidation date being included in the Group’s Consolidated Statement of Comprehensive Income/(Loss). See Notes 5. Investments Held at Fair Value for further details about the accounting for the investments in Vedanta subsequent to deconsolidation. 5 On May 25, 2022, the Group lost control over Sonde and Sonde was deconsolidated from the Group’s financial statements, resulting in only the profits and losses generated by Sonde through the deconsolidation date being included in the Group’s Consolidated Statement of Comprehensive Income/(Loss). See Notes 5. Investments Held at Fair Value and 6. Investments in Associates for further details about the accounting for the investments in Sonde subsequent to deconsolidation. 6 See Notes 5. Investments Held at Fair Value and 6. Investments in Associates for additional discussion on the Group's investment held in Akili, Karuna and Vor. 7 Follica became inactive during 2023.
Schedule of Estimated Useful Life of Assets	Depreciation is calculated using the straight-line method over the estimated useful life of the related asset: Laboratory and manufacturing equipment 2-8 years Furniture and fixtures 7 years Computer equipment and software 1-5 years Leasehold improvements 5-10 years, or the remaining term of the lease, if shorter Depreciation methods, useful lives and residual values are reviewed at each balance sheet date.

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Dec. 31, 2023
Revenue [abstract]
Schedule of Revenue	Revenue recorded in the Consolidated Statement of Comprehensive Income/(Loss) consists of the following: For the years ended December 31, 2023 $ 2022 $ 2021 $ Contract revenue 750 2,090 9,979 Grant revenue 2,580 13,528 7,409 Total revenue 3,330 15,618 17,388
Schedule of Disaggregation of Revenue from Contracts with Customers	Timing of contract revenue recognition For the years ended December 31, 2023 $ 2022 $ 2021 $ Transferred at a point in time – Licensing Income — 527 6,809 Transferred over time 750 1,563 3,171 750 2,090 9,979 Customers over 10% of revenue 2023 $ 2022 $ 2021 $ Customer A 750 1,500 1,500 Customer B — — 7,250 Customer C — 509 — 750 2,009 8,750

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2023
Segment Information [Abstract]
Schedule of Operating Segments	For the year ended December 31, 2023 Wholly-Owned Programs $ Controlled Founded Entities $ Parent Company & Other $ Consolidated $ Contract revenue — 750 — 750 Grant revenue 853 — 1,727 2,580 Total revenue 853 750 1,727 3,330 General and administrative expenses (14,020) (562) (38,713) (53,295) Research and development expenses (89,495) (672) (6,068) (96,235) Total operating expense (103,516) (1,233) (44,781) (149,530) Operating income/(loss) (102,662) (483) (43,054) (146,199) Income/expenses not allocated to segments Other income/(expense): Gain on deconsolidation of subsidiary 61,787 Gain/(loss) on investment held at fair value 77,945 Realized loss on sale of investments (122) Gain/(loss) on investment in notes from associates (27,630) Other income/(expense) (908) Total other income/(expense) 111,072 Net finance income/(costs) 5,078 Share of net income/(loss) of associates accounted for using the equity method (6,055) Income/(loss) before taxes (36,103) As of December 31, 2023 Available Funds Cash and cash equivalents 2,140 675 188,266 191,081 Short-term Investments — — 136,062 136,062 Consolidated cash, cash equivalents and short-term investments 2,140 675 324,328 327,143 For the year ended December 31, 2022 Wholly-Owned Programs Controlled Founded Entities $ Parent Company & Other $ Consolidated $ Contract revenue — 1,500 590 2,090 Grant revenue 2,826 — 10,702 13,528 Total revenue 2,826 1,500 11,292 15,618 General and administrative expenses (8,301) (419) (52,272) (60,991) Research and development expenses (116,054) (1,051) (35,328) (152,433) Total Operating expenses (124,355) (1,470) (87,600) (213,425) Operating income/(loss) (121,529) 30 (76,308) (197,807) Income/expenses not allocated to segments Other income/(expense): Gain on deconsolidation 27,251 Gain/(loss) on investment held at fair value (32,060) Realized loss on sale of investments (29,303) Other income/(expense) 8,131 Total other income/(expense) (25,981) Net finance income/(costs) 138,924 Share of net income/(loss) of associate accounted for using the equity method (27,749) Gain on dilution of ownership interest in associate 28,220 Impairment of investment in associates (8,390) Income/(loss) before taxes (92,783) As of December 31, 2022 Available Funds Cash and cash equivalents 7,306 823 141,737 149,866 Short-term Investments — — 200,229 200,229 Consolidated cash, cash equivalents and short-term investments 7,306 823 341,966 350,095 For the year ended December 31, 2021 Wholly-Owned Programs Controlled Founded Entities $ Parent Company & Other $ Consolidated $ Contract revenue 8,129 1,500 350 9,979 Grant revenue 1,253 — 6,156 7,409 Total revenue 9,382 1,500 6,506 17,388 General and administrative expenses (8,673) (365) (48,161) (57,199) Research and development expenses (65,444) (918) (44,108) (110,471) Total operating expense (74,118) (1,284) (92,269) (167,671) Operating income/(loss) (64,736) 216 (85,763) (150,282) Income/expenses not allocated to segments Other income/(expense): Gain/(loss) on investment held at fair value 179,316 Realized loss on sale of investments (20,925) Other income/(expense) 1,592 Other income/(expense) 159,983 Net finance income/(costs) 5,050 Share of net income/(loss) of associate accounted for using the equity method (73,703) Income/(loss) before taxes (58,953)

Investments held at fair value

Investments held at fair value (Tables)	12 Months Ended
	Dec. 31, 2023
Investments held at fair value [Abstract]
Schedule of Investments Held at Fair Value	Activities related to such investments during the periods are shown below: Investments held at fair value $ Balance as of January 1, 2022 493,888 Investment in Sonde preferred shares - Sonde deconsolidation 11,168 Sale of Karuna and Vor shares (118,710) Loss realised on sale of investments as a result of written call option (29,303) Investment in Akili common shares 5,000 Gelesis Earn-out Shares received in the SPAC exchange 14,214 Exchange of Gelesis preferred shares to Gelesis common shares (92,303) Loss – change in fair value through profit and loss (32,060) Balance as of December 31, 2022 and January 1, 2023 251,892 Investment in Vedanta preferred shares – Vedanta deconsolidation 20,456 Investment in Gelesis 2023 Warrants 1,121 Sale of Karuna shares (33,309) Loss realised on sale of investments (265) Gain – change in fair value through profit and loss 77,945 Balance as of December 31, 2023 317,841

Investments in Associates (Tabl

Investments in Associates (Tables)	12 Months Ended
	Dec. 31, 2023
Investment in Associates [Abstract]
Schedule of Investments in Associates	The following table summarizes the activity related to the investment in associates balance for the years ended December 31, 2023 and 2022. Investment in Associates $ As of January 1, 2022 — Cash investment in associates 19,961 Additional investment as a result of settling the Backstop agreement (see above) 8,424 Gain on dilution of interest in associate (*) 13,793 Investment in Sonde - deconsolidation 7,680 Share in net loss of associates (27,749) Reversal of equity method losses recorded against LTI (due to decrease in the fair value of such LTI): (4,406) Share in other comprehensive loss of associates (166) Impairment (8,390) As of December 31, 2022 and January 1, 2023 9,147 Share in net loss of associates (6,055) Share in other comprehensive income of associates 92 As of December 31, 2023 3,185 * Gain on dilution of interest was further increased due to the receipt of Gelesis Earn-out Shares accounted for as investments held at fair value (see above). Following is the activity in respect of investments in notes from associates during the periods . The fair value of the $4,600 note from associate as of December 31, 2023 is determined using unobservable Level 3 inputs. See Note 18. Financial Instruments for additional information. Investment in notes from associates $ Balance as of January 1, 2022 — Investment In Gelesis notes 15,000 Changes in the fair value of the notes 1,501 Balance as of December 31, 2022 and January 1, 2023 16,501 Investment In Gelesis notes 10,729 Investment in Vedanta convertible debt 5,000 Changes in the fair value of the notes and convertible debt (27,630) Balance as of December 31, 2023 4,600
Schedule of Financial Information of Gelesis	The following table summarizes the financial information of Gelesis as of December 31, 2022 and for the years ended December 31, 2022 and 2021, as included in its own financial statements, adjusted for fair value adjustments at deconsolidation and differences in accounting policies. The table also reconciles the summarized financial information to the carrying amount of the Group’s interest in Gelesis. As of December 31, 2023, the Group’s investment in Gelesis is $0 and Gelesis does not represent a significant equity method investment. As a result, such a disclosure for Gelesis is not presented for the year ended December 31, 2023. 2022 $ As of and for the year ended December 31, Percentage ownership interest 22.5 % Non-current assets 333,040 Current assets 23,495 Non-current liabilities (99,053) Current liabilities (80,010) Non-controlling interests and options issued to third parties (46,204) Net assets (deficit) attributable to shareholders of Gelesis Inc. 131,268 Group's share of net assets (net deficit) 29,504 Goodwill 3,858 Impairment (28,452) Investment in associates 4,910 2022 $ 2021 $ Revenue 25,767 11,185 Loss from continuing operations (100%) (111,567) (271,430) Total comprehensive loss (100%) (112,285) (273,005) Group's share in net losses - limited to net investment amount (*) (24,306) (73,703) Group's share of total comprehensive loss - limited to net investment amount (24,472) (73,703) * For the year ended December 31, 2022, the amount includes $4,406 reversal of equity method losses recorded against long-term Interests ("LTI") due to the decrease in fair value of such LTI.

Investment in Notes from Asso_2

Investment in Notes from Associates (Tables)	12 Months Ended
	Dec. 31, 2023
Investment in Notes from Associates [Abstract]
Schedule of Investments in Associates	The following table summarizes the activity related to the investment in associates balance for the years ended December 31, 2023 and 2022. Investment in Associates $ As of January 1, 2022 — Cash investment in associates 19,961 Additional investment as a result of settling the Backstop agreement (see above) 8,424 Gain on dilution of interest in associate (*) 13,793 Investment in Sonde - deconsolidation 7,680 Share in net loss of associates (27,749) Reversal of equity method losses recorded against LTI (due to decrease in the fair value of such LTI): (4,406) Share in other comprehensive loss of associates (166) Impairment (8,390) As of December 31, 2022 and January 1, 2023 9,147 Share in net loss of associates (6,055) Share in other comprehensive income of associates 92 As of December 31, 2023 3,185 * Gain on dilution of interest was further increased due to the receipt of Gelesis Earn-out Shares accounted for as investments held at fair value (see above). Following is the activity in respect of investments in notes from associates during the periods . The fair value of the $4,600 note from associate as of December 31, 2023 is determined using unobservable Level 3 inputs. See Note 18. Financial Instruments for additional information. Investment in notes from associates $ Balance as of January 1, 2022 — Investment In Gelesis notes 15,000 Changes in the fair value of the notes 1,501 Balance as of December 31, 2022 and January 1, 2023 16,501 Investment In Gelesis notes 10,729 Investment in Vedanta convertible debt 5,000 Changes in the fair value of the notes and convertible debt (27,630) Balance as of December 31, 2023 4,600

Operating Expenses (Tables)

Operating Expenses (Tables)	12 Months Ended
	Dec. 31, 2023
Operating Expense [Abstract]
Schedule of Operating Expenses	Total operating expenses were as follows: For the years ending December 31, 2023 $ 2022 $ 2021 $ General and administrative 53,295 60,991 57,199 Research and development 96,235 152,433 110,471 Total operating expenses 149,530 213,425 167,671 Detailed operating expenses were as follows: 2023 $ 2022 $ 2021 $ For the years ending December 31, Salaries and wages 37,084 41,750 36,792 Healthcare and other benefits 2,599 2,908 2,563 Payroll taxes 1,590 2,286 2,084 Share-based payments 4,415 14,699 13,950 Total payroll costs 45,688 61,643 55,388 Amortization 1,979 3,048 2,940 Depreciation 2,955 5,845 4,347 Total amortization and depreciation expenses 4,933 8,893 7,287 Other general and administrative expenses 25,180 31,600 26,714 Other research and development expenses 73,729 111,288 78,282 Total other operating expenses 98,909 142,888 104,996 Total operating expenses 149,530 213,425 167,671
Schedule of Information about Employees	The average number of persons employed by the Group during the year, analyzed by category, was as follows: For the years ending December 31, 2023 2022 2021 General and administrative 40 57 52 Research and development 56 144 119 Total 96 201 171
Schedule of Payroll Costs	The aggregate payroll costs of these persons were as follows: 2023 $ 2022 $ 2021 $ For the years ending December 31, General and administrative 24,586 25,322 26,438 Research and development 21,102 36,321 28,950 Total 45,688 61,643 55,388

Share-based Payments (Tables)

Share-based Payments (Tables)	12 Months Ended
	Dec. 31, 2023
Share-based Payments [Abstract]
Schedule of Share-Based Payment Expense as Reflected in the Consolidated Statement of Income/(Loss)	The following table provides the classification of the Group’s consolidated share-based payment expense as reflected in the Consolidated Statement of Income/(Loss): Year ended December 31, 2023 $ 2022 $ 2021 $ General and administrative 3,185 8,862 9,310 Research and development 1,230 5,837 4,640 Total 4,415 14,699 13,950
Schedule of RSU Activity	RSU activity for the years ended December 31, 2023, 2022 and 2021 is detailed as follows: Number of Shares/Units Weighted Average Grant Date Fair Value (GBP) (*) Outstanding (Non-vested) at January 1, 2021 3,422,582 2.46 RSUs Granted in Period 2,195,133 2.15 Vested (1,176,695) 2.93 Forfeited (808,305) 2.25 Outstanding (Non-vested) at December 31, 2021 and January 1, 2022 3,632,715 1.91 RSUs Granted in Period 4,309,883 1.76 Vested (696,398) 2.80 Forfeited (1,155,420) 2.67 Outstanding (Non-vested) at December 31, 2022 and January 1, 2023 6,090,780 1.74 RSUs Granted in Period 3,679,669 1.28 Vested (716,029) 2.00 Forfeited (1,880,274) 1.94 Outstanding (Non-vested) at December 31, 2023 7,174,146 1.10 * For liability awards - based on fair value at reporting date.
Schedule of Stock Option Activity	Stock option activity for the years ended December 31, 2023, 2022 and 2021, is detailed as follows: Number of Options Wtd Average Exercise Price (GBP) Wtd Average of Wtd Average Stock Price at Exercise (GBP) Outstanding at January 1, 2021 10,916,086 1.81 8.38 Granted 5,424,000 3.34 Exercised (2,238,187) 0.70 3.63 Forfeited and expired (687,781) 2.53 Options Exercisable at December 31, 2021 and January 1, 2022 4,773,873 1.42 6.50 Outstanding at December 31, 2021 and January 1, 2022 13,414,118 2.58 8.29 Granted 8,881,000 2.04 Exercised (577,022) 0.50 2.43 Forfeited and expired (3,924,215) 2.89 Options Exercisable at December 31, 2022 and January 1, 2023 6,185,216 2.03 6.21 Outstanding at December 31, 2022 and January 1, 2023 17,793,881 2.31 8.03 Granted 3,120,975 2.22 Exercised (534,034) 1.71 2.46 Forfeited and expired (3,424,232) 2.40 Options Exercisable at December 31, 2023 9,065,830 2.19 6.01 Outstanding at December 31, 2023 16,956,590 2.29 7.20
Schedule of Terms and Conditions of Share-Based Payment Arrangement	The fair value of the stock options awarded by the Group was estimated at the grant date using the Black-Scholes option valuation model, considering the terms and conditions upon which options were granted, with the following weighted-average assumptions: At December 31, 2023 2022 2021 Expected volatility 43.69 % 41.70 % 41.05 % Expected terms (in years) 6.16 6.11 6.16 Risk-free interest rate 4.04 % 2.13 % 1.06 % Expected dividend yield — — — Exercise price (GBP) 2.22 2.04 3.34 Underlying stock price (GBP) 2.22 2.04 3.34
Schedule of Range of Exercise Prices of Outstanding Share Options	For shares outstanding as of December 31, 2023, the range of exercise prices is detailed as follows: Range of Exercise Prices (GBP) Options Wtd Wtd Average of 0.01 439,490 — 5.76 1.00 to 2.00 4,989,572 1.54 5.64 2.00 to 3.00 6,664,028 2.25 8.55 3.00 to 4.00 4,863,500 3.33 7.10 Total 16,956,590 2.29 7.20
Schedule of Subsidiary Share-Based Payments	A summary of stock option activity by number of shares in these subsidiaries is presented in the following table: Outstanding as of January 1, 2023 Granted During the Year Exercised During the Year Expired During the Year Forfeited During the Year Deconsolidation During the Year Outstanding as of December 31, 2023 Entrega 344,500 — — — — — 344,500 Follica 2,776,120 — — (2,170,547) (605,573) — — Vedanta 1,824,576 — — (1,313) (29,607) (1,793,656) — Outstanding as of January 1, 2022 Granted During the Year Exercised During the Year Expired During the Year Forfeited During the Year Deconsolidation During the Year Outstanding as of December 31, 2022 Entrega 349,500 45,000 — (50,000) — — 344,500 Follica 2,686,120 90,000 — — — — 2,776,120 Sonde 2,049,004 — — — — (2,049,004) — Vedanta 1,991,637 490,506 (400,000) (65,235) (192,332) — 1,824,576 Outstanding as of January 1, 2021 Granted During the Year Exercised During the Year Expired During the Year Forfeited During the Year Deconsolidation During the Year Outstanding as of December 31, 2021 Alivio 3,888,168 197,398 (2,373,750) (506,260) (1,205,556) — — Entrega 962,000 — (525,000) (87,500) — — 349,500 Follica 1,309,040 1,383,080 — (6,000) — — 2,686,120 Sonde 2,192,834 — — (51,507) (92,323) — 2,049,004 Vedanta 1,741,888 451,532 (52,938) (76,491) (72,354) — 1,991,637
Schedule of Weighted Average Exercise Prices for Options Outstanding	The weighted-average exercise prices and remaining contractual life for the options outstanding as of December 31, 2023, were as follows: Outstanding at December 31, 2023 Number of options Weighted-average exercise price $ Weighted-average contractual life outstanding Entrega 344,500 1.91 3.92
Schedule of Weighted Average Exercise Prices for Options Granted	The weighted average exercise prices for the options granted for the years ended December 31, 2022 and 2021, were as follows: For the years ended December 31, 2022 $ 2021 $ Entrega 0.02 — Follica 1.86 1.86 Vedanta 14.94 19.69
Schedule of Weighted Average Exercise Prices for Options Forfeited	The weighted average exercise prices for options forfeited during the year ended December 31, 2023, were as follows: Forfeited during the year ended December 31, 2023 Number of options Weighted-average exercise price $ Follica 605,573 1.86 Vedanta 29,607 17.06
Schedule of Weighted Average Exercise Prices for Options Exercisable	The weighted average exercise prices for options exercisable as of December 31, 2023, were as follows: Exercisable at December 31, 2023 Number of Options Weighted-average exercise price $ Exercise Price Range Entrega 329,500 1.99 0.02-2.36

Finance Income_(Costs), net (Ta

Finance Income/(Costs), net (Tables)	12 Months Ended
	Dec. 31, 2023
Finance Cost Net [Abstract]
Schedule of Finance Income (Cost)	Finance Income/(Costs), net The following table shows the breakdown of finance income and costs: 2023 $ 2022 $ 2021 $ For the years ended December 31, Finance income Interest income from financial assets 16,012 5,799 214 Total finance income 16,012 5,799 214 Finance costs Contractual interest expense on notes payable (1,422) (212) (1,031) Interest expense on other borrowings (363) (1,759) (1,502) Interest expense on lease liability (1,544) (1,982) (2,181) Gain/(loss) on foreign currency exchange (94) 14 (56) Total finance cost – contractual (3,424) (3,939) (4,771) Gain/(loss) from change in fair value of warrant liability 33 6,740 1,419 Gain/(loss) from change in fair value of preferred shares 2,617 130,825 8,362 Gain/(loss) from change in fair value of convertible debt — (502) (175) Total finance income/(costs) – fair value accounting 2,650 137,063 9,606 Total finance costs - non cash interest expense related to sale of future royalties (10,159) — — Finance income/(costs), net 5,078 138,924 5,050

Earnings_(Loss) per Share (Tabl

Earnings/(Loss) per Share (Tables)	12 Months Ended
	Dec. 31, 2023
Earnings per share [abstract]
Schedule of Earnings/(Loss) Attributable to Owners of Company	Earnings/(Loss) Attributable to Owners of the Group: 2023 2022 2021 Basic $ Diluted $ Basic $ Diluted $ Basic $ Diluted $ Income/(loss) for the year, attributable to the owners of the Group (65,697) (65,697) (50,354) (50,354) (60,558) (60,558)
Schedule of Weighted-Average Number of Ordinary Shares	Weighted-Average Number of Ordinary Shares: 2023 2022 2021 Basic Diluted Basic Diluted Basic Diluted Issued ordinary shares at January 1, 278,566,306 278,566,306 287,796,585 287,796,585 285,885,025 285,885,025 Effect of shares issued & treasury shares purchased (2,263,773) (2,263,773) (3,037,150) (3,037,150) 705,958 705,958 Weighted average number of ordinary shares at December 31, 276,302,533 276,302,533 284,759,435 284,759,435 286,590,983 286,590,983
Schedule of Earnings/(Loss) per Share	Earnings/(Loss) per Share: 2023 2022 2021 Basic $ Diluted $ Basic $ Diluted $ Basic $ Diluted $ Basic and diluted earnings/(loss) per share (0.24) (0.24) (0.18) (0.18) (0.21) (0.21)

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2023
Property, plant and equipment [abstract]
Schedule of Cost	Cost Laboratory and Manufacturing Equipment $ Furniture and Fixtures $ Computer Equipment and Software $ Leasehold Improvements $ Construction in process $ Total $ Balance as of January 1, 2022 11,733 1,452 1,329 18,485 8,116 41,115 Additions, net of transfers 390 — 11 412 1,362 2,176 Disposals (118) — — — (77) (195) Deconsolidation of subsidiaries — — (58) — — (58) Reclassifications 1,336 58 137 5,067 (6,598) — Balance as of December 31, 2022 13,341 1,510 1,419 23,964 2,803 43,037 Additions, net of transfers — — — — 87 87 Disposals/Impairment (2,886) — (137) — — (3,023) Deconsolidation of subsidiaries (5,092) (438) (365) (8,799) (2,871) (17,565) Reclassifications — — — — (18) (18) Balance as of December 31, 2023 5,363 1,072 917 15,165 1 22,518
Schedule of Accumulated Depreciation and Impairment Loss	Accumulated depreciation and impairment loss Laboratory and Manufacturing Equipment $ Furniture and Fixtures $ Computer Equipment and Software $ Leasehold Improvements $ Construction in process $ Total $ Balance as of January 1, 2022 (5,686) (663) (1,190) (6,806) — (14,344) Depreciation (2,082) (212) (107) (3,444) — (5,845) Disposals 57 — — — — 57 Deconsolidation of subsidiaries — — 53 — — 53 Balance as of December 31, 2022 (7,711) (875) (1,244) (10,250) — (20,080) Depreciation (892) (162) (45) (1,856) — (2,955) Disposals 543 — 38 — — 581 Deconsolidation of subsidiaries 3,917 339 357 4,858 — 9,472 Balance as of December 31, 2023 (4,142) (698) (894) (7,248) — (12,982)
Schedule of Property and Equipment, Net	Property and Equipment, net Laboratory and Manufacturing Equipment $ Furniture and Fixtures $ Computer Equipment and Software $ Leasehold Improvements $ Construction in process $ Total $ Balance as of December 31, 2022 5,630 635 174 13,714 2,803 22,957 Balance as of December 31, 2023 1,221 375 23 7,917 1 9,536

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of detailed information about intangible assets [abstract]
Schedule of Cost and Accumulated Amortization of Intangible Assets	Information regarding the cost and accumulated amortization of intangible assets is as follows: Cost Licenses $ Balance as of January 1, 2022 990 Additions 25 Impairment (163) Deconsolidation of subsidiary (21) Balance as of December 31, 2022 831 Additions 200 Impairment (105) Deconsolidation of subsidiaries (19) Balance as of December 31, 2023 906
Schedule of Accumulated Amortization	Accumulated amortization Licenses $ Balance as of January 1, 2022 (3) Amortization (1) Deconsolidation of subsidiary 4 Balance as of December 31, 2022 — Amortization — Deconsolidation of subsidiary — Balance as of December 31, 2023 —
Schedule of Intangible Assets, Net	Intangible assets, net Licenses $ Balance as of December 31, 2022 831 Balance as of December 31, 2023 906

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2023
Equity [abstract]
Schedule of Equity	Total equity for the Group as of December 31, 2023, and 2022, was as follows: December 31, 2023 $ December 31, 2022 $ Equity Share capital, £0.01 par value, issued and paid 271,853,731 and 278,566,306 as of December 31, 2023 and 2022, respectively 5,461 5,455 Share premium 290,262 289,624 Treasury shares, 17,614,428 and 10,595,347 as of December 31, 2023 and 2022, respectively (44,626) (26,492) Merger Reserve 138,506 138,506 Translation reserve 182 89 Other reserves (9,538) (14,478) Retained earnings/(accumulated deficit) 83,820 149,516 Equity attributable to owners of the Group 464,066 542,220 Non-controlling interests (5,835) 5,369 Total equity 458,232 547,589

Subsidiary Preferred Shares (Ta

Subsidiary Preferred Shares (Tables)	12 Months Ended
	Dec. 31, 2023
Subsidiary Preferred Shares [Abstract]
Schedule of Subsidiary Preferred Share Balances	The fair value of all subsidiary preferred shares as of December 31, 2023 and December 31, 2022, is as follows: 2023 $ 2022 $ As of December 31, Entrega 169 169 Follica — 350 Vedanta Biosciences — 26,820 Total subsidiary preferred share balance 169 27,339
Schedule of Subsidiary Preferred Shares, Minimum Liquidation Preference	As of December 31, 2023 and December 31, 2022, the minimum liquidation preference reflecting the amounts that would be payable to the subsidiary preferred holders upon a liquidation event of the subsidiaries, is as follows: 2023 $ 2022 $ As of December 31, Entrega 2,216 2,216 Follica 6,405 6,405 Vedanta Biosciences — 149,568 Total minimum liquidation preference 8,621 158,189
Schedule of Changes in the Value of Subsidiary Preferred Shares	For the years ended December 31, 2023 and 2022, the Group recognized the following changes in the value of subsidiary preferred shares: $ Balance as of January 1, 2022 174,017 Decrease in value of preferred shares measured at fair value – finance costs (income) (130,825) Deconsolidation of subsidiary - (Sonde) (15,853) Balance as of December 31, 2022 27,339 Decrease in value of preferred shares measured at fair value – finance costs (income) (2,617) Deconsolidation of subsidiary – (Vedanta) (24,554) Balance as of December 31, 2023 169

Sale of Future Royalties Liab_2

Sale of Future Royalties Liability (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of financial liabilities [abstract]
Schedule of Sale of Future Royalties Liability	The following shows the activity in respect of the sale of future royalties liability: Sale of future royalties liability $ Balance as of January 1, 2023 — Amounts received at closing 100,000 Non cash interest expense recognized 10,159 Balance as of December 31, 2023 110,159

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2023
Financial Instruments [Abstract]
Schedule of Fair Value Measurement Methods	The approaches, in order of strongest fair value evidence, are detailed as follows: Valuation Method Description Market – Backsolve The market backsolve approach benchmarks the original issue price (OIP) of the company’s latest funding transaction as current value. Market/Asset – PWERM Under a PWERM, the company value is based upon the probability-weighted present value of expected future investment returns, considering each of the possible future outcomes available to the enterprise. Possible future outcomes can include IPO scenarios, potential SPAC transactions, merger and acquisition transactions as well as other similar exit transactions of the investee. I ncome Based – DCF The income approach is used to estimate fair value based on the income streams, such as cash flows or earnings, that an asset or business can be expected to generate. Allocation Method Description OPM The OPM model treats preferred stock as call options on the enterprise’s equity value, with exercise prices based on the liquidation preferences of the preferred stock. PWERM Under a PWERM, share value is based upon the probability-weighted present value of expected future investment returns, considering each of the possible future outcomes available to the enterprise, as well as the rights of each share class. Hybrid The hybrid method is a combination of the PWERM and OPM. Under the hybrid method, multiple liquidity scenarios are weighted based on the probability of the scenario's occurrence, similar to the PWERM, while also utilizing the OPM to estimate the allocation of value in one or more of the scenarios. Fair Value Description Level 1 Inputs that are quoted market prices (unadjusted) in active markets for identical instruments. Level 2 Inputs other than quoted prices included within Level 1 that are observable either directly (i.e. as prices) or indirectly (i.e. derived from prices). Level 3 Inputs that are unobservable. This category includes all instruments for which the valuation technique includes inputs not based on observable data and the unobservable inputs have a significant effect on the instruments' valuation.
Schedule of Changes in Financial Liabilities, Level 3 Fair Value, Subsidiary Preferred Shares	The following table summarizes the changes in the Group’s subsidiary preferred shares and convertible notes liabilities measured at fair value, which were categorized as Level 3 in the fair value hierarchy: Subsidiary Preferred Shares Subsidiary Convertible Balance at January 1, 2021 118,972 25,000 Value at issuance 37,610 2,215 Conversion to subsidiary preferred shares 25,797 (25,797) Accrued interest - contractual — 867 Change in fair value (8,362) 175 Balance at December 31, 2021 and January 1, 2022 174,017 2,461 Value at issuance — 393 Accrued interest - contractual — 48 Deconsolidation - Sonde (15,853) (3,403) Change in fair value (130,825) 502 Balance at December 31, 2022 and January 1, 2023 27,339 — Change in fair value (2,617) — Deconsolidation - Vedanta (24,554) — Balance at December 31, 2023 169 —
Schedule of Changes in Assets, Level 3 Fair Value, Investments Held at Fair Value	The following table summarizes the changes in all the Group’s investments held at fair value, which were categorized as Level 3 in the fair value hierarchy: $ Balance at January 1, 2021 206,892 Cash purchase of Vor preferred shares 500 Reclassification of Vor from level 3 to level 1 (33,365) Gain/(loss) on change in fair value 65,505 Balance at December 31, 2021 239,533 Deconsolidation of Sonde 11,168 Gelesis Earn-out Shares received in the SPAC exchange 14,214 Exchange of Gelesis preferred shares to Gelesis common shares (92,303) Reclassification of Akili to level 1 investment (128,764) Gain/(loss) on change in fair value (31,253) Balance at December 31, 2022 12,593 Deconsolidation of Vedanta - new investment in Vedanta preferred shares 20,456 Investment in Gelesis 2023 Warrants 1,121 Gain/(loss) on changes in fair value (9,299) Balance as of December 31, 2023 24,872
Schedule of Sensitivity Analysis of Fair Value Measurement to Changes in Unobservable Inputs, Liabilities	The significant unobservable inputs used at December 31, 2023 in the fair value measurement of these investments and the sensitivity of the fair value measurements for these investments to changes to these significant unobservable inputs are summarized in the table below. As of December 31, 2023 Investment (Sonde) Measured through Market Backsolve & OPM Unobservable Inputs Input Value Sensitivity Range Investment Fair Value Increase/(Decrease) $ Equity Value 53,242 -5 % (464) +5% 463 Time to Liquidity 2.00 -6 Months 39 + 6 Months (42) Volatility 60 % -10 % 19 +10% (35) As of December 31, 2023 Investment (Vedanta) Measured through Market Backsolve that Leverages a Monte Carlo Simulation Unobservable Inputs Input Value Sensitivity Range Investment Fair Value Increase/(Decrease) $ Equity Value 127,883 -5 % (1,416) +5% 1,069 Time to Liquidity 1.23 - 6 Months (3,907) + 6 Months 1,261 Volatility 120 % -10 % (954) +10% 474
Schedule of Fair Value Measurement and Classification	The fair value of financial instruments by category as of December 31, 2023 and 2022: 2023 Carrying Amount Fair Value Financial Assets Financial Liabilities Level 1 Level 2 Level 3 Total Financial assets 3 : Money Markets 1,2 156,705 — 156,705 — — 156,705 Investment in notes from associates 4,600 — — — 4,600 4,600 Investments held at fair value 317,841 — 292,970 — 24,872 317,841 Total financial assets 479,146 — 449,675 — 29,472 479,146 Financial liabilities: Subsidiary preferred shares — 169 — — 169 169 Share-based liability awards — 4,782 — — 4,782 4,782 Total financial liabilities — 4,951 — — 4,951 4,951 1 Issued by a diverse group of corporations, largely consisting of financial institutions, virtually all of which are investment grade. 2 Included within cash and cash equivalents. 3. Excluded from the table above are short-term investments of $136,062 that are classified at amortized cost as of December 31, 2023. The cost of these short-term investments approximates current fair value. 2022 Carrying Amount Fair Value Financial Assets Financial Liabilities Level 1 Level 2 Level 3 Total Financial assets: Money Markets 1,2 95,249 — 95,249 — — 95,249 Short-term investments 1 200,229 — 200,229 — — 200,229 Note from associate 16,501 — — — 16,501 16,501 Investments held at fair value 251,892 — 239,299 — 12,593 251,892 Trade and other receivables 3 11,867 — — 11,867 — 11,867 Total financial assets 575,738 — 534,777 11,867 29,094 575,738 Financial liabilities: Subsidiary warrant liability — 47 — — 47 47 Subsidiary preferred shares — 27,339 — — 27,339 27,339 Subsidiary notes payable — 2,345 — 2,097 248 2,345 Share-based liability awards — 5,932 4,396 — 1,537 5,932 Total financial liabilities — 35,664 4,396 2,097 29,171 35,664 1 Issued by a diverse group of corporations, largely consisting of financial institutions, virtually all of which are investment grade. 2 Included within cash and cash equivalents. 3 Outstanding receivables are owed primarily by government agencies and large corporations, virtually all of which are investment grade.

Subsidiary Notes Payable (Table

Subsidiary Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2023
Subsidiary Notes Payable [Abstract]
Schedule of Notes Payable	The notes payable consist of the following: 2023 $ 2022 $ As of December 31, Loans 3,439 2,097 Convertible notes 260 248 Total subsidiary notes payable 3,699 2,345
Schedule of Convertible Notes Outstanding	Convertible Notes outstanding were as follows: Knode $ Appeering $ Sonde $ Total $ January 1, 2022 94 141 2,461 2,696 Gross principal - issuance of notes - financing activity — — 393 393 Accrued interest on convertible notes - finance costs 5 8 48 60 Change in fair value - finance costs — — 502 502 Deconsolidation — — (3,403) (3,403) December 31, 2022 and January 1, 2023 99 149 — 248 Accrued interest on convertible notes - finance costs 5 8 — 13 December 31, 2023 104 156 — 260

Trade and Other Payables (Table

Trade and Other Payables (Tables)	12 Months Ended
	Dec. 31, 2023
Trade and other payables [abstract]
Schedule of Trade and Other Payables	Information regarding Trade and other payables was as follows: As of December 31, 2023 $ 2022 $ Trade payables 14,637 26,504 Accrued expenses 28,187 24,518 Income tax payable — 57 Liability for share-based awards 1,281 1,805 Other 3 1,957 Total trade and other payables 44,107 54,840

Long-term loan (Tables)

Long-term loan (Tables)	12 Months Ended
	Dec. 31, 2023
Long-term loan [Abstract]
Schedule of Long-Term Loan Activity	The following table summarizes long-term loan activity for the years ended December 31, 2023 and 2022: Long-term loan 2023 $ 2022 $ Balance at January 1, 15,400 15,118 Accrued interest 363 1,755 Interest paid (300) (1,436) Other (17) (38) Deconsolidation of subsidiary (15,446) — Balance at December 31, — 15,400
Schedule of Detailed Information about Borrowings	The long-term loan is presented as follows in the Statement of Financial Position as of December 31, 2023 and 2022: Long-term loan 2023 $ 2022 $ Current portion of long-term loan — 5,156 Long-term loan — 10,244 Total Long-term loan — 15,400

Leases and subleases (Tables)

Leases and subleases (Tables)	12 Months Ended
	Dec. 31, 2023
Presentation of leases for lessee [abstract]
Schedule of Quantitative Information About Right-of-use Assets and Lease Liability	The activity related to the Group’s right of use asset and lease liability for the years ended December 31, 2023 and 2022 is as follows: Right of use asset, net 2023 $ 2022 $ Balance at January 1, 14,281 17,166 Additions — 163 Depreciation (1,979) (3,047) Deconsolidated (2,477) — Balance at December 31, 9,825 14,281
Schedule of Lease Liabilities	Total lease liability 2023 $ 2022 $ Balance at January 1, 29,128 32,990 Additions — 163 Cash paid for rent - principal - financing cash flow (3,338) (4,025) Cash paid for rent - interest (1,544) (1,982) Interest expense 1,544 1,982 Deconsolidated (4,146) — Balance at December 31, 21,644 29,128
Schedule of Short-term and Long-term Portion of Lease Liability	The following table details the short-term and long-term portion of the lease liability as of December 31, 2023 and 2022: Total lease liability 2023 $ 2022 $ Short-term portion of lease liability 3,394 4,972 Long-term portion of lease liability 18,250 24,155 Total lease liability 21,644 29,128
Schedule of Maturity Analysis of Operating Lease Payments	The following table details the future maturities of the lease liability, showing the undiscounted lease payments to be paid after the reporting date: 2023 $ Less than one year 4,689 One to two years 4,644 Two to three years 4,419 Three to four years 4,551 Four to five years 4,687 More than five years 2,796 Total undiscounted lease maturities 25,785 Interest 4,141 Total lease liability 21,644

Capital and Financial Risk Ma_2

Capital and Financial Risk Management (Tables)	12 Months Ended
	Dec. 31, 2023
Capital And Financial Risk Management [Abstract]
Schedule of Credit Risk	The Group held the following balances (not including the income tax receivable resulting from overpayment of income taxes as of December 31, 2022. See Note 27. Taxation): 2023 $ 2022 $ As of December 31 Cash and cash equivalents 191,081 149,866 Short-term investments 136,062 200,229 Trade and other receivables 2,376 11,867 Total 329,518 361,961
Schedule of Liquidity Risk	The table below summarizes the maturity profile of the Group’s financial liabilities, including subsidiary preferred shares that have customary liquidation preferences, as of December 31, 2023 and 2022, based on contractual undiscounted payments: As of December 31 2023 Carrying Amount Within Three Months Three to Twelve Months One to Five Years Total Subsidiary notes payable 3,699 3,699 — — 3,699 Trade and other payables 44,107 44,107 — — 44,107 Subsidiary preferred shares (Note 16) 1 169 169 — — 169 Total 47,975 47,975 — — 47,975 As of December 31 2022 Carrying Amount Within Three Months Three to Twelve Months One to Five Years Total Long-term loan 15,400 1,838 5,281 11,413 18,531 Subsidiary notes payable 2,345 2,345 — — 2,345 Trade and other payables 54,840 54,840 — — 54,840 Warrants 2 47 47 — — 47 Subsidiary preferred shares (Note 16) 1 27,339 27,339 — — 27,339 Total 99,971 86,409 5,281 11,413 103,103 1 Redeemable only upon a liquidation or deemed liquidation event, as defined in the applicable shareholder documents. 2 Warrants issued by subsidiaries to third parties to purchase preferred shares. * Does not include payments in respect of lease obligations. For the contractual future payments related to lease obligation s, see Note 23. Leases and subleases.

Related Parties Transactions (T

Related Parties Transactions (Tables)	12 Months Ended
	Dec. 31, 2023
Related party transactions [abstract]
Schedule of Key Management Personnel Compensation	The key management personnel compensation of the Group was as follows for the years ended December 31: 2023 $ 2022 $ 2021 $ As of December 31 Short-term employee benefits 9,714 4,162 4,612 Post-employment benefits 41 55 54 Termination Benefits 417 152 — Share-based payment expense 599 2,741 4,045 Total 10,772 7,109 8,711
Schedule of Directors’ and Senior Managers’ Shareholdings and Share Incentive Awards	The Directors and senior managers hold beneficial interests in shares in the following businesses and sourcing companies as of December 31, 2023: Business name (share class) Number of shares held as of December 31, 2023 Number of options held as of December 31, 2023 Number of RSUs held as of December 31, 2023 Ownership Directors: Dr Robert Langer Entrega (Common) 250,000 82,500 — 4.09 % Dr Raju Kucherlapati Enlight (Class B Common) — 30,000 — 3.00 % Dr John LaMattina 2 Akili (Common) 56,554 — — 0.07 % Vedanta Biosciences (Common) 25,000 15,000 — 0.24 % Senior Managers: Dr Bharatt Chowrira Karuna (Common) 5,000 — — 0.01 % 1 Ownership interests as of December 31, 2023 are calculated on a diluted basis, including issued and outstanding shares, warrants and options (and written commitments to issue options) but excluding unallocated shares authorized to be issued pursuant to equity incentive plans and any shares issuable upon conversion of outstanding convertible promissory notes. 2 Dr John LaMattina holds convertible notes issued by Appeering in the aggregate principal amount of $50,000.

Taxation (Tables)

Taxation (Tables)	12 Months Ended
	Dec. 31, 2023
Taxation [Abstract]
Schedule of Income Taxes Recognized in Comprehensive Income	Amounts recognized in Consolidated Statement of Comprehensive Income/(Loss): 2023 $ 2022 $ 2021 $ For the year ended December 31 Income/(loss) for the year (66,628) (37,065) (62,709) Income tax expense/(benefit) 30,525 (55,719) 3,756 Income/(loss) before taxes (36,103) (92,783) (58,953)
Schedule of Recognized Income Tax Expense	Recognized Income Tax Expense/(Benefit): 2023 $ 2022 $ 2021 $ For the year ended December 31 Federal - current (2,246) 13,065 22,138 State - current (46) 1,336 109 Total current income tax expense/(benefit) (2,292) 14,401 22,247 Federal - deferred 29,294 (48,240) (15,416) State - deferred 3,523 (21,880) (3,075) Total deferred income tax expense/(benefit) 32,817 (70,120) (18,491) Total income tax expense/(benefit), recognized 30,525 (55,719) 3,756
Schedule of Reconciliation of Effective Tax Rate	The Group is primarily subject to taxation in the U.S. A reconciliation of the U.S. federal statutory tax rate to the effective tax rate is as follows: 2023 2022 2021 For the year ended December 31 $ % $ % $ % US federal statutory rate (7,573) 21.00 (19,486) 21.00 (12,380) 21.00 State taxes, net of federal effect (3,974) 11.01 (8,043) 8.67 (4,484) 7.61 Tax credits (9,167) 25.39 (6,876) 7.41 (5,056) 8.58 Stock-based compensation 589 (1.63) 788 (0.85) 555 (0.94) Finance income/(costs) – fair value accounting (556) 1.54 (28,783) 31.02 (2,017) 3.42 Loss with respect to associate for which no deferred tax asset is recognized 249 (0.69) 1,413 (1.52) 11,542 (19.58) Revaluation of deferred due to rate change — 0.00 (8,856) 9.54 — — Nondeductible compensation 872 (2.42) 300 (0.32) 746 (1.27) Recognition of deferred tax assets and tax benefits not previously recognized (433) 1.20 (184) 0.20 (414) 0.70 Unrecognized deferred tax asset 83,984 (232.63) 17,287 (18.63) 14,375 (24.38) Deconsolidation of subsidiary (17,506) 48.49 (3,572) 3.85 — — Other 1,321 (3.65) 293 (0.32) 889 (1.51) Worthless stock deduction (17,281) 47.87 — — — — 30,525 (84.52) (55,719) 60.05 3,756 (6.37)
Schedule of Deferred Taxes	Deferred tax assets have been recognized in the U.S. jurisdiction in respect of the following items: 2023 $ 2022 $ For the year ended December 31 Operating tax losses 3,849 48,317 Tax credits 2,425 11,101 Share-based payments 5,210 8,423 Capitalized research & development expenditures 39,422 36,084 Investment in Associates — 13,036 Lease liability 5,133 7,143 Sale of future royalties 35,920 — Other temporary differences 1,770 2,957 Deferred tax assets 93,729 127,061 Investments held at fair value (53,411) (47,877) Right of use assets (2,330) (3,519) Property and equipment, net (1,637) (2,348) Investment in Associates (755) — Deferred tax liabilities (58,133) (53,744) Deferred tax assets (liabilities), net 35,596 73,317 Deferred tax liabilities, net, recognized (52,462) (19,645) Deferred tax assets (liabilities), net, not recognized 88,058 92,962
Schedule of Unrecognized Deferred Tax Assets	Deferred tax assets have not been recognized in respect of the following carryforward losses, credits and temporary differences, because it is not probable that future taxable profit will be available against which the Group can use the benefits therefrom. 2023 $ 2022 $ For the year ended December 31 Gross Amount Tax Effected Gross Amount Tax Effected Deductible temporary difference 353,323 83,741 132,145 33,544 Tax losses 13,681 3,849 219,466 48,317 Tax credits 468 468 11,101 11,101 Total 367,472 88,058 362,712 92,962
Schedule of Unrecognized Tax Losses and Tax Credits Carryforwards	Tax losses and tax credits for which no deferred tax asset was recognized are presented below: As of December 31 2023 $ 2022 $ Gross Amount Tax Effected Gross Amount Tax Effected Tax losses expiring: Within 10 years 4,741 1,284 23,930 5,387 More than 10 years 6,635 1,455 42,822 10,509 Available Indefinitely 2,305 1,110 152,714 32,421 Total 13,681 3,849 219,466 48,317 Tax credits expiring: Within 10 years 43 43 43 43 More than 10 years 425 425 11,058 11,058 Available indefinitely — — — — Total 468 468 11,101 11,101
Schedule of Tax Balances as Presented in Statement of Financial Position	Tax Balances The tax related balances presented in the Statement of Financial Position are as follows: For the year ended December 31 2023 $ 2022 $ Income tax receivable – current 11,746 10,040 Trade and other payables — (57)

Material Accounting Policies -

Material Accounting Policies - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Mar. 01, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Investments held at fair value [Line Items]
Cash and cash equivalents	$ 191,081		$ 149,866	$ 465,708	$ 403,881
Short-term investments	$ 136,062		$ 200,229
Lease, term of contract	10 years
Vedanta
Investments held at fair value [Line Items]
Percent voting rights		47%

Material Accounting Policies _2

Material Accounting Policies - Subsidiaries (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Subsidiary operating companies | Alivio Therapeutics, Inc. | Common
Accounting Policies
Voting percentage through the holdings	0%	0%	0%
Subsidiary operating companies | Alivio Therapeutics, Inc. | Preferred
Accounting Policies
Voting percentage through the holdings	100%	100%	100%
Subsidiary operating companies | Entrega, Inc. (indirectly held through Enlight) | Common
Accounting Policies
Voting percentage through the holdings	0%	0%	0%
Subsidiary operating companies | Entrega, Inc. (indirectly held through Enlight) | Preferred
Accounting Policies
Voting percentage through the holdings	77.30%	77.30%	77.30%
Subsidiary operating companies | PureTech LYT, Inc. (formerly Ariya Therapeutics, Inc.) | Common
Accounting Policies
Voting percentage through the holdings	0%	0%	0%
Subsidiary operating companies | PureTech LYT, Inc. (formerly Ariya Therapeutics, Inc.) | Preferred
Accounting Policies
Voting percentage through the holdings	100%	100%	100%
Subsidiary operating companies | PureTech LYT 100, Inc. | Common
Accounting Policies
Voting percentage through the holdings	0%	0%	0%
Subsidiary operating companies | PureTech LYT 100, Inc. | Preferred
Accounting Policies
Voting percentage through the holdings	100%	100%	100%
Subsidiary operating companies | PureTech Management, Inc. | Common
Accounting Policies
Voting percentage through the holdings	100%	100%	100%
Subsidiary operating companies | PureTech Management, Inc. | Preferred
Accounting Policies
Voting percentage through the holdings	0%	0%	0%
Subsidiary operating companies | PureTech Health LLC | Common
Accounting Policies
Voting percentage through the holdings	100%	100%	100%
Subsidiary operating companies | PureTech Health LLC | Preferred
Accounting Policies
Voting percentage through the holdings	0%	0%	0%
Deconsolidated former subsidiary operating companies | Vedanta Biosciences | Common
Accounting Policies
Voting percentage through the holdings	0%	0%	0%
Deconsolidated former subsidiary operating companies | Vedanta Biosciences | Preferred
Accounting Policies
Voting percentage through the holdings	47%	47%	48.60%
Deconsolidated former subsidiary operating companies | Vedanta Biosciences Securities Corp. (indirectly held through Vedanta) | Common
Accounting Policies
Voting percentage through the holdings	0%	0%	0%
Deconsolidated former subsidiary operating companies | Vedanta Biosciences Securities Corp. (indirectly held through Vedanta) | Preferred
Accounting Policies
Voting percentage through the holdings	47%	47%	48.60%
Deconsolidated former subsidiary operating companies | Sonde Health, Inc. | Common
Accounting Policies
Voting percentage through the holdings	0%	0%	0%
Deconsolidated former subsidiary operating companies | Sonde Health, Inc. | Preferred
Accounting Policies
Voting percentage through the holdings	40.20%	40.20%	51.80%
Deconsolidated former subsidiary operating companies | Akili Interactive Labs, Inc. | Common
Accounting Policies
Voting percentage through the holdings	14.60%	14.70%	0%
Deconsolidated former subsidiary operating companies | Akili Interactive Labs, Inc. | Preferred
Accounting Policies
Voting percentage through the holdings	0%	0%	26.70%
Deconsolidated former subsidiary operating companies | Gelesis, Inc. | Common
Accounting Policies
Voting percentage through the holdings	0%	22.80%	4.80%
Deconsolidated former subsidiary operating companies | Gelesis, Inc. | Preferred
Accounting Policies
Voting percentage through the holdings	0%	0%	19.70%
Deconsolidated former subsidiary operating companies | Karuna Therapeutics, Inc. | Common
Accounting Policies
Voting percentage through the holdings	2.30%	3.10%	5.60%
Deconsolidated former subsidiary operating companies | Karuna Therapeutics, Inc. | Preferred
Accounting Policies
Voting percentage through the holdings	0%	0%	0%
Deconsolidated former subsidiary operating companies | Vor Biopharma Inc. | Common
Accounting Policies
Voting percentage through the holdings	3.90%	4.10%	8.60%
Deconsolidated former subsidiary operating companies | Vor Biopharma Inc. | Preferred
Accounting Policies
Voting percentage through the holdings	0%	0%	0%
Nontrading holding companies | Endra Holdings, LLC (held indirectly through Enlight) | Common
Accounting Policies
Voting percentage through the holdings	86%	86%	86%
Nontrading holding companies | Endra Holdings, LLC (held indirectly through Enlight) | Preferred
Accounting Policies
Voting percentage through the holdings	0%	0%	0%
Nontrading holding companies | Ensof Holdings, LLC (held indirectly through Enlight) | Common
Accounting Policies
Voting percentage through the holdings	86%	86%	86%
Nontrading holding companies | Ensof Holdings, LLC (held indirectly through Enlight) | Preferred
Accounting Policies
Voting percentage through the holdings	0%	0%	0%
Nontrading holding companies | PureTech Securities Corp. | Common
Accounting Policies
Voting percentage through the holdings	100%	100%	100%
Nontrading holding companies | PureTech Securities Corp. | Preferred
Accounting Policies
Voting percentage through the holdings	0%	0%	0%
Nontrading holding companies | PureTech Securities II Corp. | Common
Accounting Policies
Voting percentage through the holdings	100%	100%	100%
Nontrading holding companies | PureTech Securities II Corp. | Preferred
Accounting Policies
Voting percentage through the holdings	0%	0%	0%
Inactive subsidiaries | Appeering Inc. | Common
Accounting Policies
Voting percentage through the holdings	0%	0%	0%
Inactive subsidiaries | Appeering Inc. | Preferred
Accounting Policies
Voting percentage through the holdings	100%	100%	100%
Inactive subsidiaries | Commense Inc. | Common
Accounting Policies
Voting percentage through the holdings	0%	0%	0%
Inactive subsidiaries | Commense Inc. | Preferred
Accounting Policies
Voting percentage through the holdings	99.10%	99.10%	99.10%
Inactive subsidiaries | Enlight Biosciences, LLC | Common
Accounting Policies
Voting percentage through the holdings	86%	86%	86%
Inactive subsidiaries | Enlight Biosciences, LLC | Preferred
Accounting Policies
Voting percentage through the holdings	0%	0%	0%
Inactive subsidiaries | Ensof Biosystems, Inc. (held indirectly through Enlight) | Common
Accounting Policies
Voting percentage through the holdings	57.70%	57.70%	57.70%
Inactive subsidiaries | Ensof Biosystems, Inc. (held indirectly through Enlight) | Preferred
Accounting Policies
Voting percentage through the holdings	28.30%	28.30%	28.30%
Inactive subsidiaries | Follica, Incorporated | Common
Accounting Policies
Voting percentage through the holdings	28.70%	28.70%	28.70%
Inactive subsidiaries | Follica, Incorporated | Preferred
Accounting Policies
Voting percentage through the holdings	56.70%	56.70%	56.70%
Inactive subsidiaries | Knode Inc. (indirectly held through Enlight) | Common
Accounting Policies
Voting percentage through the holdings	0%	0%	0%
Inactive subsidiaries | Knode Inc. (indirectly held through Enlight) | Preferred
Accounting Policies
Voting percentage through the holdings	86%	86%	86%
Inactive subsidiaries | Libra Biosciences, Inc. | Common
Accounting Policies
Voting percentage through the holdings	0%	0%	0%
Inactive subsidiaries | Libra Biosciences, Inc. | Preferred
Accounting Policies
Voting percentage through the holdings	100%	100%	100%
Inactive subsidiaries | Mandara Sciences, LLC | Common
Accounting Policies
Voting percentage through the holdings	98.30%	98.30%	98.30%
Inactive subsidiaries | Mandara Sciences, LLC | Preferred
Accounting Policies
Voting percentage through the holdings	0%	0%	0%
Inactive subsidiaries | Tal Medical, Inc. | Common
Accounting Policies
Voting percentage through the holdings	0%	0%	0%
Inactive subsidiaries | Tal Medical, Inc. | Preferred
Accounting Policies
Voting percentage through the holdings	100%	100%	100%

Material Accounting Policies _3

Material Accounting Policies - Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2023
Laboratory and manufacturing equipment | Minimum
Accounting Policies
Useful life measured as period of time, property, plant and equipment	2 years
Laboratory and manufacturing equipment | Maximum
Accounting Policies
Useful life measured as period of time, property, plant and equipment	8 years
Furniture and fixtures
Accounting Policies
Useful life measured as period of time, property, plant and equipment	7 years
Computer equipment and software | Minimum
Accounting Policies
Useful life measured as period of time, property, plant and equipment	1 year
Computer equipment and software | Maximum
Accounting Policies
Useful life measured as period of time, property, plant and equipment	5 years
Leasehold improvements | Minimum
Accounting Policies
Useful life measured as period of time, property, plant and equipment	5 years
Leasehold improvements | Maximum
Accounting Policies
Useful life measured as period of time, property, plant and equipment	10 years

Revenue - Disclosure of Revenue

Revenue - Disclosure of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue [abstract]
Contract revenue	$ 750	$ 2,090	$ 9,979
Grant revenue	2,580	13,528	7,409
Total revenue	$ 3,330	$ 15,618	$ 17,388

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue [Line Items]
Contract revenue	$ 750	$ 2,090	$ 9,979
Imbrium Therapeutics L.P.
Revenue [Line Items]
Contract revenue			6,500
Gelesis | Associates
Revenue [Line Items]
Royalty income	$ 0	$ 509	$ 231

Revenue - Disaggregation of Rev

Revenue - Disaggregation of Revenue, Timing of Contract (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of disaggregation of revenue from contracts with customers [line items]
Contract revenue	$ 750	$ 2,090	$ 9,979
Transferred at a point in time – Licensing Income
Disclosure of disaggregation of revenue from contracts with customers [line items]
Contract revenue	0	527	6,809
Transferred over time
Disclosure of disaggregation of revenue from contracts with customers [line items]
Contract revenue	$ 750	$ 1,563	$ 3,171

Revenue - Disaggregation of R_2

Revenue - Disaggregation of Revenue, Customers Over 10% of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of disaggregation of revenue from contracts with customers [line items]
Contract revenue	$ 750	$ 2,090	$ 9,979
Over 10 percent of revenue
Disclosure of disaggregation of revenue from contracts with customers [line items]
Contract revenue	750	2,009	8,750
Customer A | Over 10 percent of revenue
Disclosure of disaggregation of revenue from contracts with customers [line items]
Contract revenue	750	1,500	1,500
Customer B | Over 10 percent of revenue
Disclosure of disaggregation of revenue from contracts with customers [line items]
Contract revenue	0	0	7,250
Customer C | Over 10 percent of revenue
Disclosure of disaggregation of revenue from contracts with customers [line items]
Contract revenue	$ 0	$ 509	$ 0

Revenue - Contract Balances (De

Revenue - Contract Balances (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Contract Balances [Table]
Accounts receivables related to contract revenue	$ 555	$ 606

Segment Information - Narrative

Segment Information - Narrative (Details)	Jan. 31, 2024 entity	Dec. 31, 2023 segment
Wholly-Owned Programs
Disclosure of operating segments [line items]
Number of reportable segments		1
Controlled founded entities
Disclosure of operating segments [line items]
Number of reportable segments		1
Establishment of new entities
Disclosure of operating segments [line items]
Number of entities established | entity	2

Segment Information - Schedule

Segment Information - Schedule of Operating Segments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Consolidated Statement of Comprehensive Income/(Loss)
Contract revenue	$ 750	$ 2,090	$ 9,979
Grant revenue	2,580	13,528	7,409
Total revenue	3,330	15,618	17,388
General and administrative expenses	(53,295)	(60,991)	(57,199)
Research and development expenses	(96,235)	(152,433)	(110,471)
Total operating expense	(149,530)	(213,425)	(167,671)
Operating income/(loss)	(146,199)	(197,807)	(150,282)
Other income/(expense):
Gain on deconsolidation	61,787	27,251	0
Gain/(loss) on investments held at fair value	77,945	(32,060)	179,316
Realized gain/(loss) on sale of investments	(122)	(29,303)	(20,925)
Gain/(loss) on investments in notes from associates	(27,630)	0	0
Other income/(expense)	(908)	8,131	1,592
Other income/(expense)	111,072	(25,981)	159,983
Net finance income/(costs)	5,078	138,924	5,050
Share of net income/(loss) of associates accounted for using the equity method	(6,055)	(27,749)	(73,703)
Gain on dilution of ownership interest in associate	0	28,220	0
Impairment of investment in associates	0	(8,390)	0
Income/(loss) before taxes	(36,103)	(92,783)	(58,953)
Available Funds
Cash and cash equivalents	191,081	149,866	465,708	$ 403,881
Short-term investments	136,062	200,229
Wholly-Owned Programs
Consolidated Statement of Comprehensive Income/(Loss)
Contract revenue	0	0	8,129
Grant revenue	853	2,826	1,253
Total revenue	853	2,826	9,382
General and administrative expenses	(14,020)	(8,301)	(8,673)
Research and development expenses	(89,495)	(116,054)	(65,444)
Total operating expense	(103,516)	(124,355)	(74,118)
Operating income/(loss)	(102,662)	(121,529)	(64,736)
Available Funds
Cash and cash equivalents	2,140	7,306
Short-term investments	0	0
Consolidated cash, cash equivalents and short-term investments	2,140	7,306
Controlled Founded Entities
Consolidated Statement of Comprehensive Income/(Loss)
Contract revenue	750	1,500	1,500
Grant revenue	0	0	0
Total revenue	750	1,500	1,500
General and administrative expenses	(562)	(419)	(365)
Research and development expenses	(672)	(1,051)	(918)
Total operating expense	(1,233)	(1,470)	(1,284)
Operating income/(loss)	(483)	30	216
Available Funds
Cash and cash equivalents	675	823
Short-term investments	0	0
Consolidated cash, cash equivalents and short-term investments	675	823
Parent Company & Other
Consolidated Statement of Comprehensive Income/(Loss)
Contract revenue	0	590	350
Grant revenue	1,727	10,702	6,156
Total revenue	1,727	11,292	6,506
General and administrative expenses	(38,713)	(52,272)	(48,161)
Research and development expenses	(6,068)	(35,328)	(44,108)
Total operating expense	(44,781)	(87,600)	(92,269)
Operating income/(loss)	(43,054)	(76,308)	(85,763)
Available Funds
Cash and cash equivalents	188,266	141,737
Short-term investments	136,062	200,229
Consolidated cash, cash equivalents and short-term investments	324,328	341,966
Operating segments
Consolidated Statement of Comprehensive Income/(Loss)
Contract revenue	750	2,090	9,979
Grant revenue	2,580	13,528	7,409
Total revenue	3,330	15,618	17,388
General and administrative expenses	(53,295)	(60,991)	(57,199)
Research and development expenses	(96,235)	(152,433)	(110,471)
Total operating expense	(149,530)	(213,425)	(167,671)
Operating income/(loss)	(146,199)	(197,807)	(150,282)
Other income/(expense):
Gain on deconsolidation	61,787	27,251
Gain/(loss) on investments held at fair value	77,945	(32,060)	179,316
Realized gain/(loss) on sale of investments	(122)	(29,303)	(20,925)
Gain/(loss) on investments in notes from associates	(27,630)
Other income/(expense)	(908)	8,131	1,592
Other income/(expense)	111,072	(25,981)	159,983
Net finance income/(costs)	5,078	138,924	5,050
Share of net income/(loss) of associates accounted for using the equity method	(6,055)	(27,749)	(73,703)
Gain on dilution of ownership interest in associate		28,220
Impairment of investment in associates		(8,390)
Income/(loss) before taxes	(36,103)	(92,783)	$ (58,953)
Available Funds
Cash and cash equivalents	191,081	149,866
Short-term investments	136,062	200,229
Consolidated cash, cash equivalents and short-term investments	$ 327,143	$ 350,095

Investments held at fair valu_2

Investments held at fair value - Schedule of Investments Held at Fair Value (Details) - USD ($) $ in Thousands	2 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Investments held at fair value [Line Items]
Beginning balance		$ 251,892	$ 493,888
Loss realised on sale of investments as a result of written call option		(265)	(29,303)
Cash purchase of Vor preferred shares		0	5,000	$ 500
Loss – change in fair value through profit and loss			(32,060)
Gain – change in fair value through profit and loss		77,945
Ending balance		317,841	251,892	493,888
Gelesis
Investments held at fair value [Line Items]
Gelesis Earn-out Shares received in the SPAC exchange			14,214
Exchange of Gelesis preferred shares to Gelesis common shares			(92,303)
Investment in Gelesis 2023 Warrants		1,121
Vedanta
Investments held at fair value [Line Items]
Investment in Vedanta preferred shares – Vedanta deconsolidation		20,456
Sonde
Investments held at fair value [Line Items]
Investment in Vedanta preferred shares – Vedanta deconsolidation			11,168
Karuna and Vor
Investments held at fair value [Line Items]
Sale of Karuna and Vor shares			(118,710)
Karuna
Investments held at fair value [Line Items]
Sale of Karuna and Vor shares		$ (33,309)
Loss realised on sale of investments as a result of written call option	$ (29,303)			$ (20,925)
Akili
Investments held at fair value [Line Items]
Cash purchase of Vor preferred shares			$ 5,000

Investments held at fair valu_3

Investments held at fair value - Narrative (Details) - USD ($)												1 Months Ended		2 Months Ended	5 Months Ended	12 Months Ended
	May 26, 2023	May 01, 2023	Feb. 21, 2023	Aug. 19, 2022	Jan. 13, 2022	Nov. 09, 2021	May 25, 2021	May 24, 2021	Feb. 10, 2021	Feb. 09, 2021	Jan. 08, 2021	May 31, 2023	Feb. 21, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Aug. 08, 2022	May 25, 2022	Dec. 31, 2020
Investments held at fair value [Line Items]
Gain/(loss) on deconsolidation of subsidiary																$ 61,787,000	$ 27,251,000	$ 0
Financial assets															$ 575,738,000	479,146,000	575,738,000
Sale of investments held at fair value																33,309,000	118,710,000	218,125,000
Losses on disposals of investments																265,000	29,303,000
Cash purchase of Vor preferred shares																$ 0	5,000,000	500,000
Bristol Myers Squibb | Karuna
Investments held at fair value [Line Items]
Business combination, share price paid (in dollars per share)																$ 330
Series D | Akili
Investments held at fair value [Line Items]
Proceeds from the issuance of shares and subsidiary preferred shares							$ 110,000,000
Number of shares issued by investee (in shares)							13,053,508
Vedanta
Investments held at fair value [Line Items]
Investment in Vedanta preferred shares – Vedanta deconsolidation																$ 20,456,000
Gelesis
Investments held at fair value [Line Items]
Gains (losses) on change in fair value of equity investments																(1,264,000)	(18,476,000)	34,566,000
Investments in associates accounted for using equity method																0		0			$ 0
Share of associate loss recorded against long-term interest																		$ 73,703,000
Number of earnout shares received from SPAC exchange (in shares)					4,526,622
Gelesis Earn out shares received in SPAC exchange					$ 14,214,000
Number of warrants (in shares)	43,133,803	192,307,692	23,688,047									235,441,495	23,688,047
Exercise price of warrants (in usd per share)	$ 0.0142	$ 0.0182	$ 0.2744										$ 0.2744
Expiring term after issuance			5 years
Warrants fair value												$ 1,121,000				0
Percentage of voting equity interests acquired					22.80%													42%
Sonde
Investments held at fair value [Line Items]
Gains (losses) on change in fair value of equity investments																(994,000)	$ 235,000
Financial assets																10,408,000
Investments in associates accounted for using equity method																3,185,000
Fair value of equity investment																				$ 11,168,000
Percentage of voting equity interests acquired															40.17%		40.17%			48.20%
Vedanta
Investments held at fair value [Line Items]
Gain/(loss) on deconsolidation of subsidiary																61,787,000
Gains (losses) on change in fair value of equity investments																(6,303,000)
Financial assets																14,153,000
Karuna
Investments held at fair value [Line Items]
Gains (losses) on change in fair value of equity investments																107,079,000	$ 134,952,000	$ 109,987,000
Financial assets																280,708,000
Sale of investments held at fair value						$ 100,125,000				$ 118,000,000				$ 115,457,000		$ 33,309,000
Losses on disposals of investments														$ 29,303,000				20,925,000
Number of associate's common stock held at fair value																886,885
Proportion of ownership interest in investee																2.30%
Karuna | Common
Investments held at fair value [Line Items]
Sale of equity instruments in other entities (in shares)						750,000				1,000,000						167,579			125,000
Exercise of call options, maximum number of common stocks to be purchased (in shares)																			477,100
Vor
Investments held at fair value [Line Items]
Gains (losses) on change in fair value of equity investments																$ (11,756,000)	$ (16,247,000)	3,903,000
Financial assets																$ 6,012,000
Sale of equity instruments in other entities (in shares)															535,400		535,400
Number of associate's common stock held at fair value																2,671,800
Proportion of ownership interest in investee									8.60%
Cash purchase of Vor preferred shares											$ 500,000
Share purchase price (in dollars per share)										$ 18
Proceeds from sale of equity investment															$ 3,253,000
Acquisition of equity instruments in other entities											961,538
Vor | Common
Investments held at fair value [Line Items]
Number of shares held (in shares)									3,207,200
Number of shares issued by investee (in shares)										9,828,017
Capstar
Investments held at fair value [Line Items]
SPAC exchange, PIPE transaction, amount					$ 15,000,000
Business combination, investment in common share					$ 4,961,000
Akili
Investments held at fair value [Line Items]
Gains (losses) on change in fair value of equity investments																$ (8,681,000)	$ (131,419,000)	$ 32,151,000
Proportion of ownership interest in investee							27.50%	41.90%
Cash purchase of Vor preferred shares																	$ 5,000,000
Number of shares held (in shares)				12,527,477
Number of earnout shares received from SPAC exchange (in shares)				1,433,914
Gelesis Earn out shares received in SPAC exchange																$ 6,422,000
Acquisition of equity instruments in other entities				500,000
Cash Investment (Akili)				$ 5,000,000

Investments in Associates - Nar

Investments in Associates - Narrative (Details) - USD ($)					1 Months Ended		12 Months Ended
	May 26, 2023	May 01, 2023	Feb. 21, 2023	Jan. 13, 2022	May 31, 2023	Feb. 21, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	May 25, 2022	Jan. 14, 2022	Dec. 30, 2021
Disclosure of associates [line items]
Gain on dilution of ownership interest in associate							$ 0	$ 28,220,000	$ 0
Impairment of investment in associates							0	8,390,000	0
Investment in associates – equity method							3,185,000	9,147,000	0
Capstar
Disclosure of associates [line items]
Stock committed to acquire during period (in dollars per share)													$ 10
SPAC exchange, PIPE transaction, amount				$ 15,000,000
Business combination, number of additional shares received at no additional cost (in shares)				1,322,500
Business combination, number of additional shares received, additional cost				$ 0
Business combination, additional shares to be received at no additional cost, fair value							11,200,000
Business combination, additional shares to be received at no additional cost, transaction cost							0
Business combination, number of shares received for additional cost (in shares)				496,145
Business combination, investment in common share				$ 4,961,000
Capstar | Derivative Asset, Backstop Agreement
Disclosure of associates [line items]
Amortization of deferred gain								10,400,000	800,000
Loss on change in fair value of derivatives								2,776,000
Gain (loss) on derivative assets recognized through profit or loss								$ 7,624,000
Derivative financial assets				$ 8,424,000
Gelesis Holdings Inc.
Disclosure of associates [line items]
Number of shares in entity held by entity or by its subsidiaries or associates (in shares)												16,727,582
Percentage of voting equity interests acquired												23.20%
Gelesis
Disclosure of associates [line items]
Investments in associates accounted for using equity method							0		0	$ 0
Unrecognized equity method losses									38,101,000
Unrecognised share of losses of associates, other comprehensive loss									$ 709,000
Percentage ownership interest								22.50%	42%	47.90%
Percentage of voting equity interests acquired				22.80%					42%
Gain on dilution of ownership interest in associate				$ 28,255,000
Investment in associates – equity method							4,910,000
Number of warrants (in shares)	43,133,803	192,307,692	23,688,047		235,441,495	23,688,047
Exercise price of warrants (in usd per share)	$ 0.0142	$ 0.0182	$ 0.2744			$ 0.2744
Gelesis | Top of range
Disclosure of associates [line items]
Exercise price of warrants (in usd per share)		$ 0.0182
Gelesis | Bottom of range
Disclosure of associates [line items]
Exercise price of warrants (in usd per share)	$ 0.0142
Sonde
Disclosure of associates [line items]
Investments in associates accounted for using equity method							3,185,000
Percentage of voting equity interests acquired								40.17%			48.20%
Share of loss of associates accounted for using equity method							$ 1,052,000	$ 3,443,000
Sonde | Preferred A-1 Shares
Disclosure of associates [line items]
Investments in associates accounted for using equity method											$ 7,716,000

Investments in Associates - Sch

Investments in Associates - Schedule of Investments in Associates (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of associates [Line Items]
Beginning balance	$ 9,147	$ 0
Cash investment in associate	0	19,961	$ 0
Additional investment as a result of backstop settlement (see above)		8,424
Gain/(loss) on dilution of ownership interest in associates		13,793
Share in net loss of associates	(6,055)	(27,749)	(73,703)
Reversal of equity method losses recorded against LTIs (due to decrease in LTI fair value)		(4,406)
Impairment	0	(8,390)	0
Ending balance	3,185	9,147	$ 0
Gelesis
Disclosure of associates [Line Items]
Share in other comprehensive income of associates	92	(166)
Ending balance	$ 4,910
Sonde
Disclosure of associates [Line Items]
Investment in Sonde - deconsolidation		$ 7,680

Investments in Associates - S_2

Investments in Associates - Schedule of Financial Information of Gelesis (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of associates [Line Items]
Non-current assets	$ 346,771	$ 316,454
Current assets	347,201	386,192
Non-current liabilities	(184,371)	(58,172)
Current liabilities	(51,370)	(96,885)
Investment in associates – equity method	3,185	9,147	$ 0
Revenue	3,330	15,618	17,388
Total comprehensive income/(loss) for the year	(66,535)	(37,444)	$ (62,709)
Reversal of equity method losses recorded against LTIs (due to decrease in LTI fair value)		$ 4,406
Gelesis
Disclosure of associates [Line Items]
Percentage ownership interest		22.50%	42%	47.90%
Non-current assets		$ 333,040
Current assets		23,495
Non-current liabilities		(99,053)
Current liabilities		(80,010)
Non-controlling interests and options issued to third parties		(46,204)
Net assets (deficit) attributable to shareholders of Gelesis Inc.		131,268
Group's share of net assets (net deficit)		29,504
Goodwill		3,858
Impairment		(28,452)
Investment in associates – equity method	$ 4,910
Revenue		25,767	$ 11,185
Loss from continuing operations (100%)		(111,567)	(271,430)
Total comprehensive income/(loss) for the year		(112,285)	(273,005)
Group's share in net losses - limited to net investment amount		(24,306)	(73,703)
Group's share of total comprehensive loss - limited to net investment amount		$ (24,472)	$ (73,703)

Investment in Notes from Asso_3

Investment in Notes from Associates - Narrative (Details) $ in Thousands			1 Months Ended	12 Months Ended
	Apr. 24, 2023 USD ($)	Jul. 27, 2022 USD ($) business_day	Oct. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Disclosure of associates [Line Items]
Financial assets, at fair value				$ 479,146	$ 575,738
Gain/(loss) on investments in notes from associates				(27,630)	0	$ 0
Vedanta
Disclosure of associates [Line Items]
Proceeds from issue of convertible notes	$ 18,000
Borrowings, interest rate	9%
Convertible note, percentage of equity price trigger	80%
Number of days after debt incurred from a certain investor	60 days
Unsecured promissory note
Disclosure of associates [Line Items]
Number of business days following the consummation of a qualified financing | business_day		5
Gelesis | Unsecured promissory note
Disclosure of associates [Line Items]
Short-term note from associate		$ 15,000
Current receivable due from associates, interest rate		15%
Financial assets, at fair value				0	16,501
Gain (loss) on change in fair value				(16,501)	539
Interest income					$ 963
Gelesis | Senior secured convertible promissory note
Disclosure of associates [Line Items]
Financial assets, at fair value				0
Cash investment in associate				11,850
Fair value of warrants				1,121
Gelesis | Convertible note receivable
Disclosure of associates [Line Items]
Gain/(loss) on investments in notes from associates			$ (27,230)	(10,729)
Vedanta
Disclosure of associates [Line Items]
Gain (loss) on change in fair value				(400)
Vedanta | Convertible note receivable
Disclosure of associates [Line Items]
Gain/(loss) on investments in notes from associates				$ (400)
Receivables due from associates	$ 5,000

Investment in Notes from Asso_4

Investment in Notes from Associates - Schedule of Investments in Notes from Associates (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of associates [Line Items]
Balance at beginning of period	$ 575,738
Balance at end of period	479,146	$ 575,738
Note receivable
Disclosure of associates [Line Items]
Balance at beginning of period	16,501	0
Changes in the fair value of the notes and convertible debt	(27,630)	1,501
Balance at end of period	4,600	16,501
Gelesis | Note receivable
Disclosure of associates [Line Items]
Investment In Gelesis Notes and Vedanta convertible debt	10,729	$ 15,000
Vedanta | Note receivable
Disclosure of associates [Line Items]
Investment In Gelesis Notes and Vedanta convertible debt	$ 5,000

Operating Expenses - Schedule o

Operating Expenses - Schedule of Operating Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating Expense [Abstract]
General and administrative expenses	$ 53,295	$ 60,991	$ 57,199
Research and development expenses	96,235	152,433	110,471
Total operating expenses	$ 149,530	$ 213,425	$ 167,671

Operating Expenses - Schedule_2

Operating Expenses - Schedule of Information about Employees (Details) - employee	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of information of employees [Line Items]
Total	96	201	171
General and administrative
Disclosure of information of employees [Line Items]
Total	40	57	52
Research and development
Disclosure of information of employees [Line Items]
Total	56	144	119

Operating Expenses - Schedule_3

Operating Expenses - Schedule of Payroll Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of information of employees [Line Items]
Total	$ 45,688	$ 61,643	$ 55,388
General and administrative
Disclosure of information of employees [Line Items]
Total	24,586	25,322	26,438
Research and development
Disclosure of information of employees [Line Items]
Total	$ 21,102	$ 36,321	$ 28,950

Operating Expenses - Schedule_4

Operating Expenses - Schedule of Other Operating Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating Expense [Abstract]
Salaries and wages	$ 37,084	$ 41,750	$ 36,792
Healthcare and other benefits	2,599	2,908	2,563
Payroll taxes	1,590	2,286	2,084
Share-based payment expense	4,415	14,699	13,950
Total payroll costs	45,688	61,643	55,388
Amortization	1,979	3,048	2,940
Depreciation	2,955	5,845	4,347
Total amortization and depreciation expenses	4,933	8,893	7,287
Other general and administrative expenses	25,180	31,600	26,714
Other research and development expenses	73,729	111,288	78,282
Total other operating expenses	98,909	142,888	104,996
Total operating expenses	$ 149,530	$ 213,425	$ 167,671

Share-based Payments - Narrativ

Share-based Payments - Narrative - Share-based Payment Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Payments [Abstract]
Share-based payment expense	$ 4,415	$ 14,699	$ 13,950

Share-based Payments - Schedule

Share-based Payments - Schedule of Share-Based Payment Expense as Reflected in the Consolidated Statement of Income/(Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Payment [Line Items]
Share-based payment expense	$ 4,415	$ 14,699	$ 13,950
General and administrative
Share-based Payment [Line Items]
Share-based payment expense	3,185	8,862	9,310
Research and development
Share-based Payment [Line Items]
Share-based payment expense	$ 1,230	$ 5,837	$ 4,640

Share-based Payments - Narrat_2

Share-based Payments - Narrative - Performance Share Plan (Details)	1 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2023 shares	Dec. 31, 2022 shares	Dec. 31, 2021 shares
Performance Share Plan [Line Items]
Number of share options granted in share-based payment arrangement (in shares)		3,120,975	8,881,000	5,424,000
Minimum
Performance Share Plan [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period		1 year
Maximum
Performance Share Plan [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period		4 years
Performance share plan
Performance Share Plan [Line Items]
Number of share options granted in share-based payment arrangement (in shares)		27,384,777
2015 Performance Share Plan
Performance Share Plan [Line Items]
Share-based awards expiration period		10 years
2023 Performance Share Plan
Performance Share Plan [Line Items]
Share-based payment arrangements, percentage of common shares outstanding	0.10
Share-based awards expiration period		5 years

Share-based Payments - Schedu_2

Share-based Payments - Schedule of RSU Activity (Details) - RSU	12 Months Ended
	Dec. 31, 2023 shares £ / shares	Dec. 31, 2022 shares £ / shares	Dec. 31, 2021 shares £ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding (Non-vested), beginning of year (in shares) | shares	6,090,780	3,632,715	3,422,582
Granted (in shares) | shares	3,679,669	4,309,883	2,195,133
Vested (in shares) | shares	(716,029)	(696,398)	(1,176,695)
Forfeited (in shares) | shares	(1,880,274)	(1,155,420)	(808,305)
Outstanding (Non-vested), end of year (in shares) | shares	7,174,146	6,090,780	3,632,715
Weighted average grant date fair value, RSU outstanding beginning balance (in GBP per share) | £ / shares	£ 1.74	£ 1.91	£ 2.46
Weighted average grant date fair value, RSU granted (in GBP per share) | £ / shares	1.28	1.76	2.15
Weighted average grant date fair value, RSU vested (in GBP per share) | £ / shares	2	2.80	2.93
Weighted average grant date fair value, RSU forfeited (in GBP per share) | £ / shares	1.94	2.67	2.25
Weighted average grant date fair value, RSU Ending balance (in GBP per share) | £ / shares	£ 1.10	£ 1.74	£ 1.91

Share-based Payments - Narrat_3

Share-based Payments - Narrative - RSU (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) pence simulation shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
RSU [Line Items]
Number of common shares redeemable from each RSU (in shares) | shares	1
Share-based payment expense	$ 4,415	$ 14,699	$ 13,950
Liability for share-based awards	3,501	4,128
Restricted Share Units
RSU [Line Items]
Share-based payment expense	827	1,637	1,540
Expense in respect of RSU liability award	402	$ 1,131	$ 589
Liability for share-based awards	4,782
Current liabilities from share based payment transactions	1,281
Liability for share-based awards	3,501
Liabilities from share based payment transactions, performance and market conditions met	$ 1,283
Performance, market and service based RSU
RSU [Line Items]
Award settlement, price per share | pence	1
Performance based RSU
RSU [Line Items]
Number of simulations | simulation	100,000
Minimum
RSU [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period	1 year
Minimum | Performance, market and service based RSU
RSU [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period	1 year
Maximum
RSU [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period	4 years
Maximum | Performance, market and service based RSU
RSU [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period	3 years

Share-based Payments - Schedu_3

Share-based Payments - Schedule of Stock Option Activity (Details)	12 Months Ended
	Dec. 31, 2023 shares £ / shares	Dec. 31, 2022 shares £ / shares	Dec. 31, 2021 shares £ / shares	Dec. 31, 2020 shares £ / shares
Share-based Payments [Abstract]
Outstanding at beginning of period (in shares) | shares	17,793,881	13,414,118	10,916,086
Granted (in shares) | shares	3,120,975	8,881,000	5,424,000
Exercised (in shares) | shares	(534,034)	(577,022)	(2,238,187)
Forfeited and expired (in shares) | shares	(3,424,232)	(3,924,215)	(687,781)
Options exercisable (in shares) | shares	9,065,830	6,185,216	4,773,873
Outstanding at end of period (in shares) | shares	16,956,590	17,793,881	13,414,118	10,916,086
Weighted-average exercise price, beginning of year (in GBP per share)	£ 2.31	£ 2.58	£ 1.81
Weighted average exercise price, options granted (in GBP per share)	2.22	2.04	3.34
Weighted average exercise price, options exercised (in GBP per share)	1.71	0.50	0.70
Weighted average exercise price, options forfeited and expired (in GBP per share)	2.40	2.89	2.53
Weighted average exercise price of, options exercisable (in GBP per share)	2.19	2.03	1.42
Weighted-average exercise price, end of year (in GBP per share)	£ 2.29	£ 2.31	£ 2.58	£ 1.81
Weighted average remaining contractual life of outstanding share options	7 years 2 months 12 days	8 years 10 days	8 years 3 months 14 days	8 years 4 months 17 days
Weighted average remaining contractual life of options excisable	6 years 3 days	6 years 2 months 15 days	6 years 6 months
Weighted average stock price of share options exercised in share-based payment arrangement (in GBP per share)	£ 2.46	£ 2.43	£ 3.63

Share-based Payments - Schedu_4

Share-based Payments - Schedule of Assumptions for Option Fair Value (Details)	12 Months Ended
	Dec. 31, 2023 USD ($) yr $ / shares	Dec. 31, 2023 £ / shares	Dec. 31, 2022 USD ($) yr $ / shares	Dec. 31, 2022 £ / shares	Dec. 31, 2021 USD ($) yr $ / shares	Dec. 31, 2021 £ / shares
Share-based Payments [Abstract]
Expected volatility	43.69%		41.70%		41.05%
Expected terms (in years) | yr	6.16		6.11		6.16
Risk-free interest rate	4.04%		2.13%		1.06%
Expected dividend yield | $	$ 0		$ 0		$ 0
Exercise price (GBP) (in GBP per share) | £ / shares		£ 2.22		£ 2.04		£ 3.34
Underlying stock price (GBP) (in GBP per share) | (per share)	$ 1.37	£ 2.22	$ 1.15	£ 2.04	$ 1.87	£ 3.34

Share-based Payments - Narrat_4

Share-based Payments - Narrative - Stock Options (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) shares $ / shares	Dec. 31, 2023 £ / shares	Dec. 31, 2022 USD ($) shares $ / shares	Dec. 31, 2022 £ / shares	Dec. 31, 2021 USD ($) shares $ / shares	Dec. 31, 2021 £ / shares
Share-based Payments Table [Line Items]
Share price at grant date | (per share)	$ 1.37	£ 2.22	$ 1.15	£ 2.04	$ 1.87	£ 3.34
Share-based payment expense	$ 4,415		$ 14,699		$ 13,950
Number of share options granted in share-based payment arrangement (in shares) | shares	3,120,975		8,881,000		5,424,000
Stock options
Share-based Payments Table [Line Items]
Share-based payment expense	$ 3,310		$ 8,351		$ 6,158

Share-based Payments - Schedu_5

Share-based Payments - Schedule of Range of Exercise Prices of Outstanding Share Options (Details)	12 Months Ended
	Dec. 31, 2023 shares £ / shares	Dec. 31, 2022 shares £ / shares	Dec. 31, 2021 shares £ / shares	Dec. 31, 2020 shares £ / shares
Disclosure of range of exercise prices of outstanding share options [line items]
Number of share options (in shares) | shares	16,956,590	17,793,881	13,414,118	10,916,086
Wtd Average Exercise Price (in GBP per share)	£ 2.29	£ 2.31	£ 2.58	£ 1.81
Weighted average remaining contractual life of outstanding share options	7 years 2 months 12 days	8 years 10 days	8 years 3 months 14 days	8 years 4 months 17 days
0.01
Disclosure of range of exercise prices of outstanding share options [line items]
Range of Exercise Prices (in GBP per share)	£ 0.01
Number of share options (in shares) | shares	439,490
Wtd Average Exercise Price (in GBP per share)	£ 0
Weighted average remaining contractual life of outstanding share options	5 years 9 months 3 days
1.00 to 2.00
Disclosure of range of exercise prices of outstanding share options [line items]
Number of share options (in shares) | shares	4,989,572
Wtd Average Exercise Price (in GBP per share)	£ 1.54
Weighted average remaining contractual life of outstanding share options	5 years 7 months 20 days
2.00 to 3.00
Disclosure of range of exercise prices of outstanding share options [line items]
Number of share options (in shares) | shares	6,664,028
Wtd Average Exercise Price (in GBP per share)	£ 2.25
Weighted average remaining contractual life of outstanding share options	8 years 6 months 18 days
3.00 to 4.00
Disclosure of range of exercise prices of outstanding share options [line items]
Number of share options (in shares) | shares	4,863,500
Wtd Average Exercise Price (in GBP per share)	£ 3.33
Weighted average remaining contractual life of outstanding share options	7 years 1 month 6 days
Bottom of range | 1.00 to 2.00
Disclosure of range of exercise prices of outstanding share options [line items]
Range of Exercise Prices (in GBP per share)	£ 1
Bottom of range | 2.00 to 3.00
Disclosure of range of exercise prices of outstanding share options [line items]
Range of Exercise Prices (in GBP per share)	2
Bottom of range | 3.00 to 4.00
Disclosure of range of exercise prices of outstanding share options [line items]
Range of Exercise Prices (in GBP per share)	3
Top of range | 1.00 to 2.00
Disclosure of range of exercise prices of outstanding share options [line items]
Range of Exercise Prices (in GBP per share)	2
Top of range | 2.00 to 3.00
Disclosure of range of exercise prices of outstanding share options [line items]
Range of Exercise Prices (in GBP per share)	3
Top of range | 3.00 to 4.00
Disclosure of range of exercise prices of outstanding share options [line items]
Range of Exercise Prices (in GBP per share)	£ 4

Share-based Payments - Schedu_6

Share-based Payments - Schedule of Subsidiary Share-Based Payments (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Subsidiary Plans [Line Items]
Outstanding at beginning of period (in shares)	17,793,881	13,414,118	10,916,086
Granted (in shares)	3,120,975	8,881,000	5,424,000
Exercised (in shares)	(534,034)	(577,022)	(2,238,187)
Outstanding at end of period (in shares)	16,956,590	17,793,881	13,414,118
Alivio
Subsidiary Plans [Line Items]
Outstanding at beginning of period (in shares)		0	3,888,168
Granted (in shares)			197,398
Exercised (in shares)			(2,373,750)
Expired During the Year			(506,260)
Forfeited (in shares)			(1,205,556)
Deconsolidation (in shares)			0
Outstanding at end of period (in shares)			0
Entrega
Subsidiary Plans [Line Items]
Outstanding at beginning of period (in shares)	344,500	349,500	962,000
Granted (in shares)	0	45,000	0
Exercised (in shares)	0	0	(525,000)
Expired During the Year	0	(50,000)	(87,500)
Forfeited (in shares)	0	0	0
Deconsolidation (in shares)	0	0	0
Outstanding at end of period (in shares)	344,500	344,500	349,500
Follica
Subsidiary Plans [Line Items]
Outstanding at beginning of period (in shares)	2,776,120	2,686,120	1,309,040
Granted (in shares)	0	90,000	1,383,080
Exercised (in shares)	0	0	0
Expired During the Year	(2,170,547)	0	(6,000)
Forfeited (in shares)	(605,573)	0	0
Deconsolidation (in shares)	0	0	0
Outstanding at end of period (in shares)	0	2,776,120	2,686,120
Sonde
Subsidiary Plans [Line Items]
Outstanding at beginning of period (in shares)	0	2,049,004	2,192,834
Granted (in shares)		0	0
Exercised (in shares)		0	0
Expired During the Year		0	(51,507)
Forfeited (in shares)		0	(92,323)
Deconsolidation (in shares)		(2,049,004)	0
Outstanding at end of period (in shares)		0	2,049,004
Vedanta
Subsidiary Plans [Line Items]
Outstanding at beginning of period (in shares)	1,824,576	1,991,637	1,741,888
Granted (in shares)	0	490,506	451,532
Exercised (in shares)	0	(400,000)	(52,938)
Expired During the Year	(1,313)	(65,235)	(76,491)
Forfeited (in shares)	(29,607)	(192,332)	(72,354)
Deconsolidation (in shares)	(1,793,656)	0	0
Outstanding at end of period (in shares)	0	1,824,576	1,991,637

Share-based Payments - Schedu_7

Share-based Payments - Schedule of Weighted Average Exercise Prices for Options Outstanding (Details)	12 Months Ended
	Dec. 31, 2023 shares £ / shares	Dec. 31, 2022 shares £ / shares	Dec. 31, 2021 shares £ / shares	Dec. 31, 2020 shares £ / shares	Dec. 31, 2023 shares $ / shares
Weighted Average Options Outstanding [Line Items]
Number of share options (in shares)	16,956,590	17,793,881	13,414,118	10,916,086	16,956,590
Weighted-average exercise price (in dollars per share) | £ / shares	£ 2.29	£ 2.31	£ 2.58	£ 1.81
Weighted average remaining contractual life of outstanding share options	7 years 2 months 12 days	8 years 10 days	8 years 3 months 14 days	8 years 4 months 17 days
Entrega
Weighted Average Options Outstanding [Line Items]
Number of share options (in shares)	344,500	344,500	349,500	962,000	344,500
Weighted-average exercise price (in dollars per share) | $ / shares					$ 1.91
Weighted average remaining contractual life of outstanding share options	3 years 11 months 1 day

Share-based Payments - Schedu_8

Share-based Payments - Schedule of Weighted Average Exercise Prices for Options Granted (Details)	12 Months Ended
	Dec. 31, 2023 £ / shares	Dec. 31, 2022 £ / shares	Dec. 31, 2022 $ / shares	Dec. 31, 2021 £ / shares	Dec. 31, 2021 $ / shares
Weighted Average Options granted [Line Items]
Weighted average exercise price (in dollars per share) | £ / shares	£ 2.22	£ 2.04		£ 3.34
Entrega
Weighted Average Options granted [Line Items]
Weighted average exercise price (in dollars per share)			$ 0.02		$ 0
Follica
Weighted Average Options granted [Line Items]
Weighted average exercise price (in dollars per share)			1.86		1.86
Vedanta
Weighted Average Options granted [Line Items]
Weighted average exercise price (in dollars per share)			$ 14.94		$ 19.69

Share-based Payments - Schedu_9

Share-based Payments - Schedule of Weighted Average Exercise Prices for Options Forfeited (Details)	12 Months Ended
	Dec. 31, 2023 shares $ / shares	Dec. 31, 2022 shares	Dec. 31, 2021 shares
Follica
Weighted Average Options forfeited [Line Items]
Number of share options forfeited (in shares) | shares	605,573	0	0
Weighted average exercise price (in dollars per share) | $ / shares	$ 1.86
Vedanta
Weighted Average Options forfeited [Line Items]
Number of share options forfeited (in shares) | shares	29,607	192,332	72,354
Weighted average exercise price (in dollars per share) | $ / shares	$ 17.06

Share-based Payments - Sched_10

Share-based Payments - Schedule of Weighted Average Exercise Prices for Options Exercisable (Details)	Dec. 31, 2023 shares £ / shares	Dec. 31, 2023 shares $ / shares	Dec. 31, 2022 shares £ / shares	Dec. 31, 2021 shares £ / shares
Weighted Average Options exercisable [Line Items]
Number of options (in shares) | shares	9,065,830	9,065,830	6,185,216	4,773,873
Weighted average exercise price (in dollars per share) | £ / shares	£ 2.19		£ 2.03	£ 1.42
Entrega
Weighted Average Options exercisable [Line Items]
Number of options (in shares) | shares	329,500	329,500
Weighted average exercise price (in dollars per share)		$ 1.99
Entrega | Bottom of range
Weighted Average Options exercisable [Line Items]
Exercise price range (in dollars per share)		0.02
Entrega | Top of range
Weighted Average Options exercisable [Line Items]
Exercise price range (in dollars per share)		$ 2.36

Share-based Payments - Narrat_5

Share-based Payments - Narrative - Significant Subsidiary Plans and Other Plans (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($) shares
Significant Subsidiary Plan [Line Items]
Share-based payment expense | $	$ 4,415	$ 14,699	$ 13,950
Number of share options exercised (in dollars per share) | shares	534,034	577,022	2,238,187
All Subsidiaries | Stock incentive plan
Significant Subsidiary Plan [Line Items]
Share-based payment expense | $	$ 277	$ 4,711	$ 6,252
Number of share options exercised (in dollars per share) | shares	0

Finance Income_(Costs), net - S

Finance Income/(Costs), net - Schedule of Finance Income (Cost) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Finance income
Interest income from financial assets	$ 16,012	$ 5,799	$ 214
Total finance income	16,012	5,799	214
Finance costs
Contractual interest expense on notes payable	(1,422)	(212)	(1,031)
Interest expense on other borrowings	(363)	(1,759)	(1,502)
Interest expense on lease liability	(1,544)	(1,982)	(2,181)
Gain/(loss) on foreign currency exchange	(94)	14	(56)
Total finance cost – contractual	(3,424)	(3,939)	(4,771)
Gain/(loss) from change in fair value of warrant liability	33	6,740	1,419
Gain/(loss) from change in fair value of preferred shares	2,617	130,825	8,362
Gain/(loss) from change in fair value of convertible debt	0	(502)	(175)
Total finance income/(costs) – fair value accounting	2,650	137,063	9,606
Total finance costs - non cash interest expense related to sale of future royalties	(10,159)	0	0
Net finance income/(costs)	$ 5,078	$ 138,924	$ 5,050

Earnings_(Loss) per share - Nar

Earnings/(Loss) per share - Narrative (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Earnings per share [abstract]
Potential securities excluded from diluted EPS calculation (in shares)	1,509,900	3,134,131	6,553,905

Earnings_(Loss) per Share - Sch

Earnings/(Loss) per Share - Schedule of Earnings/(Loss) Attributable to Owners of Company (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Earnings per share [abstract]
Income/(loss) for the year, attributable to the owners of the Group, basic	$ (65,697)	$ (50,354)	$ (60,558)
Income/(loss) for the year, attributable to the owners of the Group, dilutive	$ (65,697)	$ (50,354)	$ (60,558)

Earnings_(Loss) per Share - S_2

Earnings/(Loss) per Share - Schedule of Weighted-Average Number of Ordinary Shares (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Earnings per share [abstract]
Issued ordinary shares at January 1 (in shares)		278,566,306	287,796,585	285,885,025
Effect of shares issued & treasury shares purchased (in shares)	(2,263,773)	(3,037,150)	705,958
Weighted average number of ordinary shareholders to calculate basic earnings per share (in shares)	276,302,533	284,759,435	286,590,983
Weighted average number of ordinary shareholders to calculate diluted earnings per share (in shares)	276,302,533	284,759,435	286,590,983

Earnings_(Loss) per Share - S_3

Earnings/(Loss) per Share - Schedule of Earnings/(Loss) per Share (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Earnings per share [abstract]
Basic earnings/(loss) per share (in dollars per share)	$ (0.24)	$ (0.18)	$ (0.21)
Diluted earnings/(loss) per share (in dollars per share)	$ (0.24)	$ (0.18)	$ (0.21)

Property and Equipment - Schedu

Property and Equipment - Schedule of Cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Property, plant and equipment
Balance at beginning of period	$ 22,957
Balance at end of period	9,536	$ 22,957
Laboratory and manufacturing equipment
Property, plant and equipment
Balance at beginning of period	5,630
Balance at end of period	1,221	5,630
Furniture and fixtures
Property, plant and equipment
Balance at beginning of period	635
Balance at end of period	375	635
Computer equipment and software
Property, plant and equipment
Balance at beginning of period	174
Balance at end of period	23	174
Leasehold improvements
Property, plant and equipment
Balance at beginning of period	13,714
Balance at end of period	7,917	13,714
Construction in progress
Property, plant and equipment
Balance at beginning of period	2,803
Balance at end of period	1	2,803
Cost
Property, plant and equipment
Balance at beginning of period	43,037	41,115
Additions, net of transfers	87	2,176
Disposals/Impairment	(3,023)	(195)
Deconsolidation of subsidiaries	(17,565)	(58)
Reclassifications	(18)	0
Balance at end of period	22,518	43,037
Cost | Laboratory and manufacturing equipment
Property, plant and equipment
Balance at beginning of period	13,341	11,733
Additions, net of transfers	0	390
Disposals/Impairment	(2,886)	(118)
Deconsolidation of subsidiaries	(5,092)	0
Reclassifications	0	1,336
Balance at end of period	5,363	13,341
Cost | Furniture and fixtures
Property, plant and equipment
Balance at beginning of period	1,510	1,452
Additions, net of transfers	0	0
Disposals/Impairment	0	0
Deconsolidation of subsidiaries	(438)	0
Reclassifications	0	58
Balance at end of period	1,072	1,510
Cost | Computer equipment and software
Property, plant and equipment
Balance at beginning of period	1,419	1,329
Additions, net of transfers	0	11
Disposals/Impairment	(137)	0
Deconsolidation of subsidiaries	(365)	(58)
Reclassifications	0	137
Balance at end of period	917	1,419
Cost | Leasehold improvements
Property, plant and equipment
Balance at beginning of period	23,964	18,485
Additions, net of transfers	0	412
Disposals/Impairment	0	0
Deconsolidation of subsidiaries	(8,799)	0
Reclassifications	0	5,067
Balance at end of period	15,165	23,964
Cost | Construction in progress
Property, plant and equipment
Balance at beginning of period	2,803	8,116
Additions, net of transfers	87	1,362
Disposals/Impairment	0	(77)
Deconsolidation of subsidiaries	(2,871)	0
Reclassifications	(18)	(6,598)
Balance at end of period	$ 1	$ 2,803

Property and Equipment - Sche_2

Property and Equipment - Schedule of Accumulated Depreciation and Impairment Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Property, plant and equipment
Balance at beginning of period	$ 22,957
Balance at end of period	9,536	$ 22,957
Laboratory and manufacturing equipment
Property, plant and equipment
Balance at beginning of period	5,630
Balance at end of period	1,221	5,630
Furniture and fixtures
Property, plant and equipment
Balance at beginning of period	635
Balance at end of period	375	635
Computer equipment and software
Property, plant and equipment
Balance at beginning of period	174
Balance at end of period	23	174
Leasehold improvements
Property, plant and equipment
Balance at beginning of period	13,714
Balance at end of period	7,917	13,714
Construction in progress
Property, plant and equipment
Balance at beginning of period	2,803
Balance at end of period	1	2,803
Accumulated depreciation and impairment loss
Property, plant and equipment
Balance at beginning of period	(20,080)	(14,344)
Depreciation	(2,955)	(5,845)
Disposals/Impairment	581	57
Deconsolidation of subsidiaries	9,472	53
Balance at end of period	(12,982)	(20,080)
Accumulated depreciation and impairment loss | Laboratory and manufacturing equipment
Property, plant and equipment
Balance at beginning of period	(7,711)	(5,686)
Depreciation	(892)	(2,082)
Disposals/Impairment	543	57
Deconsolidation of subsidiaries	3,917	0
Balance at end of period	(4,142)	(7,711)
Accumulated depreciation and impairment loss | Furniture and fixtures
Property, plant and equipment
Balance at beginning of period	(875)	(663)
Depreciation	(162)	(212)
Disposals/Impairment	0	0
Deconsolidation of subsidiaries	339	0
Balance at end of period	(698)	(875)
Accumulated depreciation and impairment loss | Computer equipment and software
Property, plant and equipment
Balance at beginning of period	(1,244)	(1,190)
Depreciation	(45)	(107)
Disposals/Impairment	38	0
Deconsolidation of subsidiaries	357	53
Balance at end of period	(894)	(1,244)
Accumulated depreciation and impairment loss | Leasehold improvements
Property, plant and equipment
Balance at beginning of period	(10,250)	(6,806)
Depreciation	(1,856)	(3,444)
Disposals/Impairment	0	0
Deconsolidation of subsidiaries	4,858	0
Balance at end of period	(7,248)	(10,250)
Accumulated depreciation and impairment loss | Construction in progress
Property, plant and equipment
Balance at beginning of period	0	0
Depreciation	0	0
Disposals/Impairment	0	0
Deconsolidation of subsidiaries	0	0
Balance at end of period	$ 0	$ 0

Property and Equipment - Sche_3

Property and Equipment - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Property, plant and equipment
Property and equipment, net	$ 9,536	$ 22,957
Laboratory and manufacturing equipment
Property, plant and equipment
Property and equipment, net	1,221	5,630
Furniture and fixtures
Property, plant and equipment
Property and equipment, net	375	635
Computer equipment and software
Property, plant and equipment
Property and equipment, net	23	174
Leasehold improvements
Property, plant and equipment
Property and equipment, net	7,917	13,714
Construction in progress
Property, plant and equipment
Property and equipment, net	$ 1	$ 2,803

Property and Equipment - Narrat

Property and Equipment - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Property, plant and equipment [abstract]
Depreciation	$ 2,955	$ 5,845	$ 4,347

Intangible Assets - Schedule of

Intangible Assets - Schedule of Cost and Accumulated Amortization of Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Intangible Assets
Balance at beginning of period	$ 831
Impairment		$ (163)
Balance at end of period	906	831
Licenses
Intangible Assets
Balance at beginning of period	831
Balance at end of period	906	831
Cost | Licenses
Intangible Assets
Balance at beginning of period	831	990
Additions	200	25
Impairment	(105)	(163)
Deconsolidation of subsidiaries	(19)	(21)
Balance at end of period	$ 906	$ 831

Intangible Assets - Schedule _2

Intangible Assets - Schedule of Accumulated Amortization (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Intangible Assets
Balance at beginning of period	$ 831
Balance at end of period	906	$ 831
Licenses
Intangible Assets
Balance at beginning of period	831
Balance at end of period	906	831
Accumulated amortization | Licenses
Intangible Assets
Balance at beginning of period	0	(3)
Amortization	0	(1)
Deconsolidation of subsidiaries	0	4
Balance at end of period	$ 0	$ 0

Intangible Assets - Schedule _3

Intangible Assets - Schedule of Intangible Assets, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Intangible Assets
Intangible assets, net	$ 906	$ 831
Licenses
Intangible Assets
Intangible assets, net	$ 906	$ 831

Intangible Assets - Narrative (

Intangible Assets - Narrative (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) asset	Dec. 31, 2022 USD ($)
Intangible Assets
Number of intangible assets wrote-offs | asset	2
Write-off amount		$ 163
Sonde
Intangible Assets
Decrease through loss of control of subsidiary, net assets	$ 19	$ 18

Other Financial Assets - Schedu

Other Financial Assets - Schedule of Other Financial Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Other Financial Assets [Abstract]
Other financial assets	$ 1,628	$ 2,124

Equity - Schedule of Equity (De

Equity - Schedule of Equity (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2023 £ / shares	Dec. 31, 2022 £ / shares	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Equity - Acquired Share capital PureTech LLC [Line Items]
Share capital	$ 5,461	$ 5,455
Share premium	290,262	289,624
Treasury stock	(44,626)	(26,492)
Merger reserve	138,506	138,506
Translation reserve	182	89
Other reserve	(9,538)	(14,478)
Retained earnings/(accumulated deficit)	83,820	149,516
Equity attributable to the owners of the Group	464,066	542,220
Non-controlling interests	(5,835)	5,369
Total equity	$ 458,232	$ 547,589			$ 584,147	$ 653,539
Par value per share (in GBP per share) | £ / shares			£ 0.01	£ 0.01
Number of shares issued and fully paid (in shares) | shares	271,853,731	278,566,306
Common
Equity - Acquired Share capital PureTech LLC [Line Items]
Treasury shares (in shares) | shares	17,614,428	10,595,347

Equity - Narrative (Details)

Equity - Narrative (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 vote shares	Dec. 31, 2022 shares	May 09, 2022 USD ($) tranche pence	Jun. 18, 2015 shares
Equity - Acquired Share capital PureTech LLC [Line Items]
Number of votes per ordinary share | vote	1
Number of shares issued (in shares)	289,468,159
Common
Equity - Acquired Share capital PureTech LLC [Line Items]
Value of shares authorized to be repurchased | $			$ 50,000
Stock repurchase program, purchase price per share | pence			1
Number of tranches | tranche			2
Aggregated number of shares repurchased under share repurchase program (in shares)	18,278,873
Shares repurchased under share repurchase program (in shares)	7,683,526
Purchase of treasury stock (in shares)	17,614,428	10,595,347
Common | Jefferies International Limited
Equity - Acquired Share capital PureTech LLC [Line Items]
Value of shares authorized to be repurchased | $			$ 25,000
PureTech Health LLC | Common
Equity - Acquired Share capital PureTech LLC [Line Items]
Issued share capital acquired (in shares)				159,648,387

Subsidiary Preferred Shares - S

Subsidiary Preferred Shares - Schedule of Subsidiary Preferred Share Balances (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Subsidiary Preferred Shares [Line Items]
Total subsidiary preferred share balance	$ 169	$ 27,339
Entrega
Subsidiary Preferred Shares [Line Items]
Total subsidiary preferred share balance	169	169
Follica
Subsidiary Preferred Shares [Line Items]
Total subsidiary preferred share balance	0	350
Vedanta Biosciences
Subsidiary Preferred Shares [Line Items]
Total subsidiary preferred share balance	$ 0	$ 26,820

Subsidiary Preferred Shares -_2

Subsidiary Preferred Shares - Schedule of Subsidiary Preferred Shares, Minimum Liquidation Preference (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Minimum liquidation preference [Line Items]
Total minimum liquidation preference	$ 8,621	$ 158,189
Entrega
Minimum liquidation preference [Line Items]
Total minimum liquidation preference	2,216	2,216
Follica
Minimum liquidation preference [Line Items]
Total minimum liquidation preference	6,405	6,405
Vedanta Biosciences
Minimum liquidation preference [Line Items]
Total minimum liquidation preference	$ 0	$ 149,568

Subsidiary Preferred Shares -_3

Subsidiary Preferred Shares - Schedule of Changes in the Value of Subsidiary Preferred Shares (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Changes in the value of subsidiary preferred shares [Roll Forward]
Beginning balance	$ 27,339
Ending balance	169	$ 27,339
Subsidiary preferred shares
Changes in the value of subsidiary preferred shares [Roll Forward]
Beginning balance	27,339	174,017
Change in fair value	(2,617)	(130,825)
Deconsolidation of subsidiary	(24,554)	(15,853)
Ending balance	$ 169	$ 27,339

Sale of Future Royalties Liab_3

Sale of Future Royalties Liability - Narrative (Details) - USD ($) $ in Thousands			12 Months Ended
	Mar. 23, 2023	Mar. 22, 2023	Dec. 31, 2023
Sale Of Future Royalties Liability [Line Items]
Percentage of royalties received above annual threshold		67%
Amounts received at closing	$ 100,000	$ 100,000	$ 100,000
Eligibility to receive additional payment amount (up to)		400,000
Royalty Pharma
Sale Of Future Royalties Liability [Line Items]
Annual threshold, amount		$ 60,000
Percentage of royalties received above annual threshold		33%

Sale of Future Royalties Liab_4

Sale of Future Royalties Liability - Schedule of Sale of Future Royalties Liability (Details) - USD ($) $ in Thousands			12 Months Ended
	Mar. 23, 2023	Mar. 22, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of financial liabilities [abstract]
Beginning balance			$ 0
Amounts received at closing	$ 100,000	$ 100,000	100,000
Non cash interest expense recognized			10,159	$ 0	$ 0
Ending balance			$ 110,159	$ 0

Financial Instruments - Schedul

Financial Instruments - Schedule of Changes in Financial Liabilities, Level 3 Fair Value, Subsidiary Preferred Shares (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of financial liabilities [line items]
Balance at beginning of period	$ 35,664
Balance at end of period	4,951	$ 35,664
Subsidiary preferred shares
Disclosure of financial liabilities [line items]
Balance at beginning of period	27,339
Change in fair value	(2,617)	(130,825)
Deconsolidation of subsidiary	(24,554)	(15,853)
Balance at end of period	169	27,339
Subsidiary preferred shares | At fair value
Disclosure of financial liabilities [line items]
Balance at beginning of period	27,339	174,017	$ 118,972
Value at issuance		0	37,610
Conversion to subsidiary preferred shares			25,797
Accrued interest – contractual		0	0
Change in fair value	(2,617)	(130,825)	(8,362)
Deconsolidation of subsidiary	(24,554)	(15,853)
Balance at end of period	169	27,339	174,017
Convertible notes
Disclosure of financial liabilities [line items]
Change in fair value		502
Convertible notes | At fair value
Disclosure of financial liabilities [line items]
Balance at beginning of period	0	2,461	25,000
Value at issuance		393	2,215
Conversion to subsidiary preferred shares			(25,797)
Accrued interest – contractual		48	867
Change in fair value	0	502	175
Deconsolidation of subsidiary	0	(3,403)
Balance at end of period	$ 0	$ 0	$ 2,461

Financial Instruments - Narrati

Financial Instruments - Narrative - Investments Held at Fair Value (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	May 31, 2023	Dec. 31, 2022
Disclosure of financial liabilities [line items]
Gain/(loss) on changes in fair value	$ 77,945
Financial assets	479,146		$ 575,738
Vedanta and Sonde
Disclosure of financial liabilities [line items]
Gain/(loss) on changes in fair value	(7,298)
Sonde
Disclosure of financial liabilities [line items]
Financial assets	10,408
Gelesis
Disclosure of financial liabilities [line items]
Warrants fair value	0	$ 1,121
Level 3 of fair value hierarchy
Disclosure of financial liabilities [line items]
Financial assets	29,472		$ 29,094
Level 3 of fair value hierarchy | Preference shares | Sonde
Disclosure of financial liabilities [line items]
Financial assets	10,408
Level 3 of fair value hierarchy | Preference shares | Vedanta
Disclosure of financial liabilities [line items]
Financial assets	$ 14,153

Financial Instruments - Sched_2

Financial Instruments - Schedule of Changes in Assets, Level 3 Fair Value, Investments Held at Fair Value (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of financial assets [line items]
Balance at beginning of period	$ 575,738
Cash purchase of Vor preferred shares	0	$ 19,961	$ 0
Gain/(loss) on changes in fair value	77,945
Balance at end of period	479,146	575,738
Vor
Disclosure of financial assets [line items]
Balance at end of period	6,012
Vedanta
Disclosure of financial assets [line items]
Balance at end of period	14,153
Level 3 of fair value hierarchy
Disclosure of financial assets [line items]
Balance at beginning of period	29,094
Balance at end of period	29,472	29,094
Investments held at fair value
Disclosure of financial assets [line items]
Balance at beginning of period	251,892
Balance at end of period	317,841	251,892
Investments held at fair value | Level 3 of fair value hierarchy
Disclosure of financial assets [line items]
Balance at beginning of period	12,593	239,533	206,892
Reclassification of Akili to level 1 investment		(128,764)
Gain/(loss) on changes in fair value	(9,299)	(31,253)	65,505
Balance at end of period	24,872	12,593	239,533
Investments held at fair value | Level 3 of fair value hierarchy | Vor
Disclosure of financial assets [line items]
Cash purchase of Vor preferred shares			500
Reclassification of Vor from level 3 to level 1			$ (33,365)
Investments held at fair value | Level 3 of fair value hierarchy | Sonde
Disclosure of financial assets [line items]
Deconsolidation of subsidiary		11,168
Investments held at fair value | Level 3 of fair value hierarchy | Gelesis
Disclosure of financial assets [line items]
Gelesis Earn-out Shares received in the SPAC exchange		14,214
Exchange of Gelesis preferred shares to Gelesis common shares		$ (92,303)
Investment in Gelesis 2023 Warrants	1,121
Investments held at fair value | Level 3 of fair value hierarchy | Vedanta
Disclosure of financial assets [line items]
Deconsolidation of subsidiary	$ 20,456

Financial Instruments - Sched_3

Financial Instruments - Schedule of Sensitivity Analysis of Fair Value Measurement to Changes in Unobservable Inputs, Investments (Details) - Level 3 of fair value hierarchy $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Equity Value | Market Backsolve & OPM | Sonde | Preferred
Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, assets [line items]
Significant unobservable input	53,242
Percentage of reasonably possible decrease in unobservable input, assets	(5.00%)
Percentage of reasonably possible increase in unobservable input, assets	5%
Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, assets	$ (464)
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets	$ 463
Equity Value | Market Backsolve Approach Leverage Monte Carlo Simulation | Vedanta | Preferred
Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, assets [line items]
Significant unobservable input	127,883
Percentage of reasonably possible decrease in unobservable input, assets	(5.00%)
Percentage of reasonably possible increase in unobservable input, assets	5%
Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, assets	$ (1,416)
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets	$ 1,069
Time to Liquidity | Market Backsolve & OPM | Sonde | Preferred
Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, assets [line items]
Significant unobservable input	2
Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, assets	$ 39
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets	$ (42)
Time to Liquidity | Market Backsolve Approach Leverage Monte Carlo Simulation | Sonde
Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, assets [line items]
Sensitivity range, decrease	6 months
Sensitivity range, increase	6 months
Time to Liquidity | Market Backsolve Approach Leverage Monte Carlo Simulation | Vedanta
Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, assets [line items]
Sensitivity range, decrease	6 months
Sensitivity range, increase	6 months
Time to Liquidity | Market Backsolve Approach Leverage Monte Carlo Simulation | Vedanta | Preferred
Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, assets [line items]
Significant unobservable input	1.23
Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, assets	$ (3,907)
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets	$ 1,261
Volatility | Market Backsolve & OPM | Sonde | Preferred
Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, assets [line items]
Significant unobservable input	0.60
Percentage of reasonably possible decrease in unobservable input, assets	10%
Percentage of reasonably possible increase in unobservable input, assets	10%
Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, assets	$ 19
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets	$ (35)
Volatility | Market Backsolve Approach Leverage Monte Carlo Simulation | Vedanta | Preferred
Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, assets [line items]
Significant unobservable input	1.20
Percentage of reasonably possible decrease in unobservable input, assets	(10.00%)
Percentage of reasonably possible increase in unobservable input, assets	10%
Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, assets	$ (954)
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets	$ 474

Financial Instruments - Narra_2

Financial Instruments - Narrative - Investments in notes from associates (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Oct. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Apr. 24, 2023
Short-term note [Line Items]
Loss on investments in notes from associates		$ 27,630	$ 0	$ 0
Note receivable | Gelesis
Short-term note [Line Items]
Receivables due from associates			16,501
Increase (decrease) in financial assets		10,729	$ 15,000
Convertible note receivable | Gelesis
Short-term note [Line Items]
Increase (decrease) in financial assets		10,729
Loss on investments in notes from associates	$ 27,230	10,729
Convertible note receivable | Vedanta
Short-term note [Line Items]
Receivables due from associates					$ 5,000
Increase (decrease) in financial assets		5,000
Loss on investments in notes from associates		$ 400

Financial Instruments - Sched_4

Financial Instruments - Schedule of Fair Value Measurement and Classification (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets	$ 479,146	$ 575,738
Financial liabilities	4,951	35,664
Carrying Amount
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets	479,146	575,738
Financial liabilities	4,951	35,664
Subsidiary warrant liability
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial liabilities		47
Subsidiary warrant liability | Carrying Amount
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial liabilities		47
Subsidiary preferred shares
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial liabilities	169	27,339
Subsidiary preferred shares | Carrying Amount
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial liabilities	169	27,339
Subsidiary notes payable
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial liabilities		2,345
Subsidiary notes payable | Carrying Amount
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial liabilities		2,345
Share-based liability awards
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial liabilities	4,782	5,932
Share-based liability awards | Carrying Amount
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial liabilities	4,782	5,932
Level 1 of fair value hierarchy
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets	449,675	534,777
Financial liabilities	0	4,396
Level 1 of fair value hierarchy | Subsidiary warrant liability
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial liabilities		0
Level 1 of fair value hierarchy | Subsidiary preferred shares
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial liabilities	0	0
Level 1 of fair value hierarchy | Subsidiary notes payable
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial liabilities		0
Level 1 of fair value hierarchy | Share-based liability awards
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial liabilities	0	4,396
Level 2 of fair value hierarchy
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets	0	11,867
Financial liabilities	0	2,097
Level 2 of fair value hierarchy | Subsidiary warrant liability
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial liabilities		0
Level 2 of fair value hierarchy | Subsidiary preferred shares
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial liabilities	0	0
Level 2 of fair value hierarchy | Subsidiary notes payable
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial liabilities		2,097
Level 2 of fair value hierarchy | Share-based liability awards
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial liabilities	0	0
Level 3 of fair value hierarchy
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets	29,472	29,094
Financial liabilities	4,951	29,171
Level 3 of fair value hierarchy | Subsidiary warrant liability
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial liabilities		47
Level 3 of fair value hierarchy | Subsidiary preferred shares
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial liabilities	169	27,339
Level 3 of fair value hierarchy | Subsidiary notes payable
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial liabilities		248
Level 3 of fair value hierarchy | Share-based liability awards
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial liabilities	4,782	1,537
Money Markets
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets	156,705	95,249
Money Markets | Carrying Amount
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets	156,705	95,249
Money Markets | Level 1 of fair value hierarchy
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets	156,705	95,249
Money Markets | Level 2 of fair value hierarchy
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets	0	0
Money Markets | Level 3 of fair value hierarchy
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets	0	0
Short-term Investments
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets		200,229
Short-term Investments | Carrying Amount
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets	136,062	200,229
Short-term Investments | Level 1 of fair value hierarchy
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets		200,229
Short-term Investments | Level 2 of fair value hierarchy
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets		0
Short-term Investments | Level 3 of fair value hierarchy
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets		0
Investment in notes from associates
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets	4,600	16,501
Investment in notes from associates | Carrying Amount
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets	4,600	16,501
Investment in notes from associates | Level 1 of fair value hierarchy
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets	0	0
Investment in notes from associates | Level 2 of fair value hierarchy
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets	0	0
Investment in notes from associates | Level 3 of fair value hierarchy
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets	4,600	16,501
Investments held at fair value
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets	317,841	251,892
Investments held at fair value | Carrying Amount
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets	317,841	251,892
Investments held at fair value | Level 1 of fair value hierarchy
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets	292,970	239,299
Investments held at fair value | Level 2 of fair value hierarchy
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets	0	0
Investments held at fair value | Level 3 of fair value hierarchy
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets	$ 24,872	12,593	$ 239,533	$ 206,892
Trade and other receivables
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets		11,867
Trade and other receivables | Carrying Amount
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets		11,867
Trade and other receivables | Level 1 of fair value hierarchy
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets		0
Trade and other receivables | Level 2 of fair value hierarchy
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets		11,867
Trade and other receivables | Level 3 of fair value hierarchy
Financial Instruments - Fair value Measurement and Classification [Line Items]
Financial assets		$ 0

Subsidiary Notes Payable - Sche

Subsidiary Notes Payable - Schedule of Notes Payable (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Notes Payable [Line Items]
Subsidiary preferred shares	$ 3,699	$ 2,345
Loans
Notes Payable [Line Items]
Subsidiary preferred shares	3,439	2,097
Convertible notes
Notes Payable [Line Items]
Subsidiary preferred shares	$ 260	$ 248	$ 2,696

Subsidiary Notes Payable - Narr

Subsidiary Notes Payable - Narrative - Loans (Details) - Loans - Follica - Lighthouse Capital Partners VI, L.P	Oct. 31, 2010
Subsidiary Notes Payable - Loans [Line Items]
Interest rate, interest only period	5%
Interest rate, repayment period	12%

Subsidiary Notes Payable - Sc_2

Subsidiary Notes Payable - Schedule of Convertible Notes Outstanding (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Convertible Notes [Roll Forward]
Beginning balance	$ 2,345
Ending balance	3,699	$ 2,345
Convertible notes
Convertible Notes [Roll Forward]
Beginning balance	248	2,696
Gross principal - issuance of notes - financing activity		393
Accrued interest on convertible notes - finance costs	13	60
Change in fair value		502
Deconsolidation		(3,403)
Ending balance	260	248
Knode | Convertible notes
Convertible Notes [Roll Forward]
Beginning balance	99	94
Gross principal - issuance of notes - financing activity		0
Accrued interest on convertible notes - finance costs	5	5
Change in fair value		0
Deconsolidation		0
Ending balance	104	99
Appeering | Convertible notes
Convertible Notes [Roll Forward]
Beginning balance	149	141
Gross principal - issuance of notes - financing activity		0
Accrued interest on convertible notes - finance costs	8	8
Change in fair value		0
Deconsolidation		0
Ending balance	156	149
Sonde | Convertible notes
Convertible Notes [Roll Forward]
Beginning balance	0	2,461
Gross principal - issuance of notes - financing activity		393
Accrued interest on convertible notes - finance costs	0	48
Change in fair value		502
Deconsolidation		(3,403)
Ending balance	$ 0	$ 0

Subsidiary Notes Payable - Na_2

Subsidiary Notes Payable - Narrative - Convertible Notes (Details) - Convertible notes - Sonde - USD ($) $ in Thousands	1 Months Ended	8 Months Ended
	Mar. 31, 2022	Nov. 24, 2021	Dec. 31, 2023
Convertible Notes [Line Items]
Borrowings, interest rate			6%
Discount, conversion from notes - qualified financing			20%
Discount, conversion from notes - non qualified financing			20%
PureTech and third-party
Convertible Notes [Line Items]
Proceeds from issue of convertible notes	$ 921	$ 4,329
Outside investors
Convertible Notes [Line Items]
Proceeds from issue of convertible notes	393	2,215
PureTech Health (Company)
Convertible Notes [Line Items]
Proceeds from issue of convertible notes	$ 528	$ 2,113

Non-Controlling Interest (Detai

Non-Controlling Interest (Details) $ in Thousands			12 Months Ended
	Nov. 30, 2021	Jun. 11, 2021 USD ($)	Dec. 31, 2023 USD ($) installment	Dec. 31, 2022	Dec. 31, 2021 USD ($)	Jul. 15, 2021 USD ($)
Non-Controlling Interests [Line Items]
Contingent consideration recognised as of acquisition date		$ 560
Consideration paid (received)		$ 9,636
Alivio
Non-Controlling Interests [Line Items]
Acquired minority non-controlling interest		17.10%
Proportion of ownership interest in subsidiary		100%
Consideration for acquired non-controlling interest		$ 1,224
Number of equal installments | installment			3
Consideration for acquired non-controlling interest, first installment		408
Acquisition cost		$ 968
Consideration for acquired non-controlling interest, second installment						$ 408
Common | Entrega
Non-Controlling Interests [Line Items]
Proportion of ownership interests held by non-controlling interests	0.20%		11.70%	11.70%	11.70%
Common | Follica, Incorporated
Non-Controlling Interests [Line Items]
Proportion of ownership interests held by non-controlling interests			19.90%	19.90%	19.90%
Common | Vedanta
Non-Controlling Interests [Line Items]
Proportion of ownership interests held by non-controlling interests				12.20%	3.70%
Common | Vedanta | Non-controlling interests
Non-Controlling Interests [Line Items]
Increase through conversion of convertible instruments, equity			$ 15,171
Convertible debt, instruments, converted to equity			$ 7
Common | Sonde
Non-Controlling Interests [Line Items]
Proportion of ownership interests held by non-controlling interests					6.20%
Common | Entrega and Vedanta
Non-Controlling Interests [Line Items]
Increase through conversion of convertible instruments, equity					$ 5,988
Common | Entrega and Vedanta | Non-controlling interests
Non-Controlling Interests [Line Items]
Increase through conversion of convertible instruments, equity					5,887
Convertible debt, instruments, converted to equity					$ 101

Trade and Other Payables (Detai

Trade and Other Payables (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Trade and other payables [abstract]
Trade payables	$ 14,637	$ 26,504
Accrued expenses	28,187	24,518
Income tax payable	0	57
Liability for share-based awards	1,281	1,805
Other	3	1,957
Total trade and other payables	$ 44,107	$ 54,840

Long-term loan - Narrative (Det

Long-term loan - Narrative (Details) $ / shares in Units, $ in Thousands	1 Months Ended
	Sep. 30, 2020 USD ($)	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Sep. 21, 2021 $ / shares shares	Sep. 15, 2020
Disclosure of detailed information about borrowings [line items]
Long-term loan		$ 0	$ 15,400	$ 15,118
Number of shares issued (in shares) | shares		289,468,159
Oxford Finance LLC | Vedanta
Disclosure of detailed information about borrowings [line items]
Long-term loan			$ 15,400
Final fee, percentage of original principal amount outstanding	0.07
Debt instrument, payment terms, final fee trigger amount	$ 1,050
Oxford Finance LLC | Vedanta | Preferred share warrants
Disclosure of detailed information about borrowings [line items]
Number of shares issued (in shares) | shares					12,886
Exercise price (in dollars per share) | $ / shares					$ 23.28
Oxford Finance LLC | Vedanta | Floating interest rate
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate	7.70%
Borrowings, adjustment to interest rate basis						0.17%
Oxford Finance LLC | Vedanta | Cost
Disclosure of detailed information about borrowings [line items]
Long-term loan	$ 15,000

Long-term loan - Schedule of Lo

Long-term loan - Schedule of Long-Term Loan Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of detailed information about borrowings [line items]
Beginning balance	$ 15,400	$ 15,118
Accrued interest	363	1,755
Interest paid	(300)	(1,436)
Other	(17)	(38)
Deconsolidation of subsidiary	(15,446)	0
Ending balance	$ 0	$ 15,400

Long-term loan - Schedule of De

Long-term loan - Schedule of Detailed Information about Borrowings (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Long-term loan [Abstract]
Current portion of long-term loan	$ 0	$ 5,156
Long-term loan	0	10,244
Total Long-term loan	$ 0	$ 15,400	$ 15,118

Leases and subleases - Schedule

Leases and subleases - Schedule of Quantitative Information About Right-of-use Assets and Lease Liability (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Presentation of leases for lessee [abstract]
Balance at beginning of period	$ 14,281	$ 17,166
Additions	0	163
Depreciation	(1,979)	(3,047)	$ (2,938)
Deconsolidated	(2,477)	0
Balance at end of period	$ 9,825	$ 14,281	$ 17,166

Leases and subleases - Schedu_2

Leases and subleases - Schedule of Lease Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Presentation of leases for lessee [abstract]
Balance at beginning of period	$ 29,128	$ 32,990
Additions	0	163
Cash paid for rent - principal - financing cash flow	(3,338)	(4,025)	$ (3,375)
Cash paid for rent - interest	(1,544)	(1,982)
Interest expense	1,544	1,982	2,181
Deconsolidated	(4,146)	0
Balance at end of period	$ 21,644	$ 29,128	$ 32,990

Leases and subleases - Narrativ

Leases and subleases - Narrative (Details)			12 Months Ended
	Jan. 23, 2023 USD ($) ft²	Apr. 26, 2019 ft² period	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jun. 26, 2019 ft²
Leases - Rental [Line Items]
Depreciation			$ 1,979,000	$ 3,047,000	$ 2,938,000
Rental income			781,000	$ 0
Gelesis
Leases - Rental [Line Items]
Lease liability, subleased area (in square feet) | ft²						9,446
Sublease, write off			$ 1,266,000
Allonia LLC
Leases - Rental [Line Items]
Lease liability, initial term	2 years
Lease liability, subleased area (in square feet) | ft²	11,000
Sublease annual fees	$ 1,111,000
Lease At 6 Tide Street
Leases - Rental [Line Items]
Rentable area (in square feet) | ft²		50,858
Lease liability, initial term		10 years 3 months
Lease liability, number of renewal options | period		2
Lease liability, renewal term		5 years

Leases and subleases - Schedu_3

Leases and subleases - Schedule of Short-term and Long-term Portion of Lease Liability (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Presentation of leases for lessee [abstract]
Short-term portion of lease liability	$ 3,394	$ 4,972
Long-term portion of lease liability	18,250	24,155
Total lease liability	$ 21,644	$ 29,128	$ 32,990

Leases and subleases - Schedu_4

Leases and subleases - Schedule of Maturity Analysis of Operating Lease Payments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of maturity analysis of operating lease payments [line items]
Total undiscounted lease maturities	$ 25,785
Interest	4,141
Total lease liability	21,644	$ 29,128	$ 32,990
Less than one year
Disclosure of maturity analysis of operating lease payments [line items]
Total undiscounted lease maturities	4,689
One to two years
Disclosure of maturity analysis of operating lease payments [line items]
Total undiscounted lease maturities	4,644
Two to three years
Disclosure of maturity analysis of operating lease payments [line items]
Total undiscounted lease maturities	4,419
Three to four years
Disclosure of maturity analysis of operating lease payments [line items]
Total undiscounted lease maturities	4,551
Four to five years
Disclosure of maturity analysis of operating lease payments [line items]
Total undiscounted lease maturities	4,687
More than five years
Disclosure of maturity analysis of operating lease payments [line items]
Total undiscounted lease maturities	$ 2,796

Capital and Financial Risk Ma_3

Capital and Financial Risk Management - Credit Risk (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Capital And Financial Risk Management [Abstract]
Cash and cash equivalents	$ 191,081	$ 149,866	$ 465,708	$ 403,881
Short-term investments	136,062	200,229
Trade and other receivables	2,376	11,867
Total	$ 329,518	$ 361,961

Capital and Financial Risk Ma_4

Capital and Financial Risk Management - Liquidity Risk (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Liquidity Risk [Line Items]
Long-term loan	$ 0	$ 15,400	$ 15,118
Current financial liabilities	3,699	2,345
Total	47,975	103,103
Long-term loan
Liquidity Risk [Line Items]
Long-term loan		18,531
Subsidiary notes payable
Liquidity Risk [Line Items]
Current financial liabilities	3,699	2,345
Trade and other payables
Liquidity Risk [Line Items]
Current financial liabilities	44,107	54,840
Warrants
Liquidity Risk [Line Items]
Current financial liabilities		47
Subsidiary preferred shares
Liquidity Risk [Line Items]
Current financial liabilities	169	27,339
Carrying Amount
Liquidity Risk [Line Items]
Total	47,975	99,971
Carrying Amount | Long-term loan
Liquidity Risk [Line Items]
Long-term loan		15,400
Carrying Amount | Subsidiary notes payable
Liquidity Risk [Line Items]
Current financial liabilities	3,699	2,345
Carrying Amount | Trade and other payables
Liquidity Risk [Line Items]
Current financial liabilities	44,107	54,840
Carrying Amount | Warrants
Liquidity Risk [Line Items]
Current financial liabilities		47
Carrying Amount | Subsidiary preferred shares
Liquidity Risk [Line Items]
Current financial liabilities	169	27,339
Within Three Months
Liquidity Risk [Line Items]
Total	47,975	86,409
Within Three Months | Long-term loan
Liquidity Risk [Line Items]
Long-term loan		1,838
Within Three Months | Subsidiary notes payable
Liquidity Risk [Line Items]
Current financial liabilities	3,699	2,345
Within Three Months | Trade and other payables
Liquidity Risk [Line Items]
Current financial liabilities	44,107	54,840
Within Three Months | Warrants
Liquidity Risk [Line Items]
Current financial liabilities		47
Within Three Months | Subsidiary preferred shares
Liquidity Risk [Line Items]
Current financial liabilities	169	27,339
Three to Twelve months
Liquidity Risk [Line Items]
Total	0	5,281
Three to Twelve months | Long-term loan
Liquidity Risk [Line Items]
Long-term loan		5,281
Three to Twelve months | Subsidiary notes payable
Liquidity Risk [Line Items]
Current financial liabilities	0	0
Three to Twelve months | Trade and other payables
Liquidity Risk [Line Items]
Current financial liabilities	0	0
Three to Twelve months | Warrants
Liquidity Risk [Line Items]
Current financial liabilities		0
Three to Twelve months | Subsidiary preferred shares
Liquidity Risk [Line Items]
Current financial liabilities	0	0
One year to Five Years
Liquidity Risk [Line Items]
Total	0	11,413
One year to Five Years | Long-term loan
Liquidity Risk [Line Items]
Long-term loan		11,413
One year to Five Years | Subsidiary notes payable
Liquidity Risk [Line Items]
Current financial liabilities	0	0
One year to Five Years | Trade and other payables
Liquidity Risk [Line Items]
Current financial liabilities	0	0
One year to Five Years | Warrants
Liquidity Risk [Line Items]
Current financial liabilities		0
One year to Five Years | Subsidiary preferred shares
Liquidity Risk [Line Items]
Current financial liabilities	$ 0	$ 0

Capital and Financial Risk Ma_5

Capital and Financial Risk Management - Narrative (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($)	Aug. 19, 2022 shares	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Capital And Financial Risk Management [Line Items]
Cash and cash equivalents	$ 191,081	$ 149,866		$ 465,708	$ 403,881
Short-term investments	136,062	200,229
Investments held at fair value	$ 317,841	$ 251,892		$ 493,888
Bristol Myers Squibb | Karuna
Capital And Financial Risk Management [Line Items]
Business combination, share price paid (in dollars per share) | $ / shares	$ 330
Karuna, Vor and Akili
Capital And Financial Risk Management [Line Items]
Investments held at fair value	$ 292,831
Karuna
Capital And Financial Risk Management [Line Items]
Number of associate's common stock held at fair value | shares	886,885
Investment percentage related to common share	96%
Vor
Capital And Financial Risk Management [Line Items]
Number of associate's common stock held at fair value | shares	2,671,800
Akili
Capital And Financial Risk Management [Line Items]
Number of shares held (in shares) | shares			12,527,477
Equity price risk | Karuna, Vor and Akili
Capital And Financial Risk Management [Line Items]
Sensitivity analysis for equity price risk, impact on pre-tax earnings, percentage	0.10
Sensitivity analysis for equity price risk, impact on pre-tax earnings	$ 29,283
Sonde
Capital And Financial Risk Management [Line Items]
Investments in associates accounted for using equity method	$ 3,185

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Commitments and Contingencies [Table]
Payments in respect of developmental milestones	$ 7,371	$ 8,666
Non-cancellable contractual commitments	$ 16,422	$ 11,288

Related Parties Transactions -

Related Parties Transactions - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Related party transactions [Line Items]
Key management personnel compensation	$ 10,772	$ 7,109	$ 8,711
General and administrative expenses	53,295	60,991	57,199
Associates
Related party transactions [Line Items]
Receivables due from related parties	1,569
Associates | Gelesis
Related party transactions [Line Items]
Sublease receivable	0	1,285
Interest income on sublease receivable		23	89	$ 113
Royalty income	0	509	231
Related parties
Related party transactions [Line Items]
Key management personnel compensation	4,732
General and administrative expenses	46	51
Directors and Senior Managers | Convertible notes
Related party transactions [Line Items]
Payables to related parties	$ 104	99
Directors and Senior Managers | Common
Related party transactions [Line Items]
Number of shares held (in shares)	23,547,554
Percent voting rights of the Company	11.50%
Additional number of shares authorized to purchase (in shares)	2,262,500
Nonexecutive Directors
Related party transactions [Line Items]
Remuneration expense	$ 475	655	605
Share-based payment expense	$ 373	$ 365	$ 161
Senior Managers | Common
Related party transactions [Line Items]
Number of shares issuable based on performance conditions (in shares)	7,301,547	7,301,547	7,301,547
Director | Common
Related party transactions [Line Items]
Number of shares issuable based on performance conditions (in shares)			102,732

Related Parties Transactions _2

Related Parties Transactions - Schedule of Key Management Personnel Compensation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Related party transactions [abstract]
Short-term employee benefits	$ 9,714	$ 4,162	$ 4,612
Post-employment benefits	41	55	54
Termination Benefits	417	152	0
Share-based payment expense	599	2,741	4,045
Total	$ 10,772	$ 7,109	$ 8,711

Related Parties Transactions _3

Related Parties Transactions - Schedule of Directors’ and Senior Managers’ Shareholdings and Share Incentive Awards (Details) $ in Thousands	Dec. 31, 2023 USD ($) shares
Dr Robert Langer | Entrega | Common
Directors and Senior Managers Shareholdings and Share Incentive awards [Line Items]
Number of shares held (in shares)	250,000
Number of options held (in shares)	82,500
Number of RSUs held (in shares)	0
Ownership interest	4.09%
Dr Raju Kucherlapati | Enlight | Class B common
Directors and Senior Managers Shareholdings and Share Incentive awards [Line Items]
Number of shares held (in shares)	0
Number of options held (in shares)	30,000
Number of RSUs held (in shares)	0
Ownership interest	3%
Dr John LaMattina | Akili | Common
Directors and Senior Managers Shareholdings and Share Incentive awards [Line Items]
Number of shares held (in shares)	56,554
Number of options held (in shares)	0
Number of RSUs held (in shares)	0
Ownership interest	0.07%
Dr John LaMattina | Vedanta | Common
Directors and Senior Managers Shareholdings and Share Incentive awards [Line Items]
Number of shares held (in shares)	25,000
Number of options held (in shares)	15,000
Number of RSUs held (in shares)	0
Ownership interest	0.24%
Dr Bharatt Chowrira | Karuna | Common
Directors and Senior Managers Shareholdings and Share Incentive awards [Line Items]
Number of shares held (in shares)	5,000
Number of options held (in shares)	0
Number of RSUs held (in shares)	0
Ownership interest	0.01%
Dr John LaMattina (individually) | Appeering | Convertible notes
Directors and Senior Managers Shareholdings and Share Incentive awards [Line Items]
Aggregate principal amount | $	$ 50

Taxation - Narrative (Details)

Taxation - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Taxation [Line Items]
Percentage vote and value of subsidiaries included in the Group consolidated federal tax return	80%	80%	80%
Percentage vote and value of subsidiaries in the Group consolidated state tax return	50%	50%	50%
Income tax expense/(benefit)	$ 30,525	$ (55,719)	$ 3,756
Deferred income tax expense (benefit)	32,817	(70,120)	(18,491)
Current tax expense	(2,292)	14,401	22,247
Federal - current
Taxation [Line Items]
Deferred income tax expense (benefit)	29,294	(48,240)	(15,416)
Current tax expense	(2,246)	13,065	22,138
Tax losses			215,400
Tax credits	1,396	4,500	3,900
Unused federal orphan drug tax credits	930	6,100
Federal - current | Operating loss carryforwards not subject to expiration
Taxation [Line Items]
Tax losses	2,305
Massachusetts
Taxation [Line Items]
Tax losses	111,446	71,700	27,900
Tax credits	98	600	$ 1,300
US
Taxation [Line Items]
Deferred tax assets (liabilities), net, not recognized	$ 88,058	$ 92,962

Taxation - Schedule of Income T

Taxation - Schedule of Income Taxes Recognized in Comprehensive Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Taxation [Abstract]
Income/(loss) for the year	$ (66,628)	$ (37,065)	$ (62,709)
Income tax expense/(benefit)	30,525	(55,719)	3,756
Income/(loss) before taxes	$ (36,103)	$ (92,783)	$ (58,953)

Taxation - Schedule of Recogniz

Taxation - Schedule of Recognized Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Recognised Income Tax Expense [Line Items]
Total current income tax expense/(benefit)	$ (2,292)	$ 14,401	$ 22,247
Total deferred income tax expense/(benefit)	32,817	(70,120)	(18,491)
Total income tax expense/(benefit), recognized	30,525	(55,719)	3,756
Federal - current
Recognised Income Tax Expense [Line Items]
Total current income tax expense/(benefit)	(2,246)	13,065	22,138
Total deferred income tax expense/(benefit)	29,294	(48,240)	(15,416)
State - current
Recognised Income Tax Expense [Line Items]
Total current income tax expense/(benefit)	(46)	1,336	109
Total deferred income tax expense/(benefit)	$ 3,523	$ (21,880)	$ (3,075)

Taxation - Schedule of Reconcil

Taxation - Schedule of Reconciliation of Effective Tax Rate (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Taxation [Abstract]
US federal statutory rate	$ (7,573)	$ (19,486)	$ (12,380)
US federal statutory rate	21%	21%	21%
State taxes, net of federal effect	$ (3,974)	$ (8,043)	$ (4,484)
State taxes, net of federal effect	11.01%	8.67%	7.61%
Tax credits	$ (9,167)	$ (6,876)	$ (5,056)
Tax credits	25.39%	7.41%	8.58%
Stock-based compensation	$ 589	$ 788	$ 555
Stock-based compensation	(1.63%)	(0.85%)	(0.94%)
Finance income/(costs) – fair value accounting	$ (556)	$ (28,783)	$ (2,017)
Finance income/(costs) – fair value accounting	1.54%	31.02%	3.42%
Loss with respect to associate for which no deferred tax asset is recognized	$ 249	$ 1,413	$ 11,542
Loss with respect to associate for which no deferred tax asset is recognized	(0.69%)	(1.52%)	(19.58%)
Revaluation of deferred due to rate change	$ 0	$ (8,856)	$ 0
Revaluation of deferred due to rate change	0%	9.54%	0%
Nondeductible compensation	$ 872	$ 300	$ 746
Nondeductible compensation	(2.42%)	(0.32%)	(1.27%)
Recognition of deferred tax assets and tax benefits not previously recognized	$ (433)	$ (184)	$ (414)
Recognition of deferred tax assets and tax benefits not previously recognized	1.20%	0.20%	0.70%
Unrecognized deferred tax asset	$ 83,984	$ 17,287	$ 14,375
Unrecognized deferred tax asset	(232.63%)	(18.63%)	(24.38%)
Deconsolidation of subsidiary	$ (17,506)	$ (3,572)	$ 0
Deconsolidation of subsidiary	48.49%	3.85%	0%
Other	$ 1,321	$ 293	$ 889
Other	(3.65%)	(0.32%)	(1.51%)
Worthless stock deduction	$ (17,281)	$ 0	$ 0
Worthless stock deduction	47.87%	0%	0%
Income tax expense/(benefit)	$ 30,525	$ (55,719)	$ 3,756
Average effective tax rate	(84.52%)	60.05%	(6.37%)

Taxation - Schedule of Deferred

Taxation - Schedule of Deferred Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Deferred Tax Assets and Liabilities [Line Items]
Deferred tax liabilities	$ (52,462)	$ (19,645)
US
Deferred Tax Assets and Liabilities [Line Items]
Deferred tax assets	93,729	127,061
Deferred tax liabilities	(58,133)	(53,744)
Deferred tax assets (liabilities), net	35,596	73,317
Deferred tax liabilities, net, recognized	(52,462)	(19,645)
Deferred tax assets (liabilities), net, not recognized	88,058	92,962
US | Operating tax losses
Deferred Tax Assets and Liabilities [Line Items]
Deferred tax assets	3,849	48,317
US | Tax credits
Deferred Tax Assets and Liabilities [Line Items]
Deferred tax assets	2,425	11,101
US | Share-based payments
Deferred Tax Assets and Liabilities [Line Items]
Deferred tax assets	5,210	8,423
US | Capitalized research & development expenditures
Deferred Tax Assets and Liabilities [Line Items]
Deferred tax assets	39,422	36,084
US | Investment in Associates
Deferred Tax Assets and Liabilities [Line Items]
Deferred tax assets	0	13,036
US | Lease liability
Deferred Tax Assets and Liabilities [Line Items]
Deferred tax assets	5,133	7,143
US | Sale of future royalties
Deferred Tax Assets and Liabilities [Line Items]
Deferred tax assets	35,920	0
US | Other temporary differences
Deferred Tax Assets and Liabilities [Line Items]
Deferred tax assets	1,770	2,957
US | Investments held at fair value
Deferred Tax Assets and Liabilities [Line Items]
Deferred tax liabilities	(53,411)	(47,877)
US | Right of use assets
Deferred Tax Assets and Liabilities [Line Items]
Deferred tax liabilities	(2,330)	(3,519)
US | Property and equipment, net
Deferred Tax Assets and Liabilities [Line Items]
Deferred tax liabilities	(1,637)	(2,348)
US | Investment in Associates
Deferred Tax Assets and Liabilities [Line Items]
Deferred tax liabilities	$ (755)	$ 0

Taxation - Schedule of Unrecogn

Taxation - Schedule of Unrecognized Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Gross Amount
Unrecognized deferred tax assets [Line Items]
Deductible temporary difference	$ 353,323	$ 132,145
Tax losses	13,681	219,466
Tax credits	468	11,101
Total	367,472	362,712
Tax Effected
Unrecognized deferred tax assets [Line Items]
Deductible temporary difference	83,741	33,544
Tax losses	3,849	48,317
Tax credits	468	11,101
Total	$ 88,058	$ 92,962

Taxation - Schedule of Unreco_2

Taxation - Schedule of Unrecognized Tax Losses and Tax Credits Carryforwards (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Gross Amount
Tax losses and tax credits carryforwards [Line Items]
Tax losses expiring	$ 13,681	$ 219,466
Tax credits expiring	468	11,101
Gross Amount | Within 10 years
Tax losses and tax credits carryforwards [Line Items]
Tax losses expiring	4,741	23,930
Tax credits expiring	43	43
Gross Amount | More than 10 years
Tax losses and tax credits carryforwards [Line Items]
Tax losses expiring	6,635	42,822
Tax credits expiring	425	11,058
Gross Amount | Available indefinitely
Tax losses and tax credits carryforwards [Line Items]
Tax losses expiring	2,305	152,714
Tax credits expiring	0	0
Tax Effected
Tax losses and tax credits carryforwards [Line Items]
Tax losses expiring	3,849	48,317
Tax credits expiring	468	11,101
Tax Effected | Within 10 years
Tax losses and tax credits carryforwards [Line Items]
Tax losses expiring	1,284	5,387
Tax credits expiring	43	43
Tax Effected | More than 10 years
Tax losses and tax credits carryforwards [Line Items]
Tax losses expiring	1,455	10,509
Tax credits expiring	425	11,058
Tax Effected | Available indefinitely
Tax losses and tax credits carryforwards [Line Items]
Tax losses expiring	1,110	32,421
Tax credits expiring	$ 0	$ 0

Taxation - Schedule of Tax Bala

Taxation - Schedule of Tax Balances as Presented in Statement of Financial Position (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Taxation [Line Items]
Income tax receivable – current	$ 11,746	$ 10,040
Trade and other payables	$ 0	$ (57)

Subsequent Events (Details)

Subsequent Events (Details) $ in Thousands

1 Months Ended

2 Months Ended

12 Months Ended

Nov. 09, 2021 USD ($) shares

Feb. 09, 2021 USD ($) shares

Apr. 30, 2024 USD ($)

Mar. 31, 2024 USD ($) shares

Sep. 30, 2022 USD ($)

Dec. 31, 2023 USD ($) shares

Dec. 31, 2022 USD ($)

Dec. 31, 2021 USD ($)

Feb. 29, 2024 shares

Jan. 31, 2024 entity

Aug. 08, 2022 shares

May 09, 2022 USD ($) pence

Disclosure of non-adjusting events after reporting period [line items]

Sale of investments held at fair value

$ 33,309

$ 118,710

$ 218,125

Karuna

Disclosure of non-adjusting events after reporting period [line items]

Sale of investments held at fair value

$ 100,125

$ 118,000

$ 115,457

$ 33,309

Common

Disclosure of non-adjusting events after reporting period [line items]

Value of shares authorized to be repurchased

$ 50,000

Stock repurchase program, purchase price per share | pence

1

Aggregated number of shares repurchased under share repurchase program (in shares) | shares

18,278,873

Common | Karuna

Disclosure of non-adjusting events after reporting period [line items]

Sale of equity instruments in other entities (in shares) | shares

750,000

1,000,000

167,579

125,000

Establishment of new entities

Disclosure of non-adjusting events after reporting period [line items]

Number of entities established | entity

2

Major ordinary share transactions

Disclosure of non-adjusting events after reporting period [line items]

Proposed capital return amount

$ 100,000

Major ordinary share transactions | Common

Disclosure of non-adjusting events after reporting period [line items]

Aggregated number of shares repurchased under share repurchase program (in shares) | shares

20,182,863

Sale of investment held at fair value | Karuna

Disclosure of non-adjusting events after reporting period [line items]

Sale of investments held at fair value

$ 292,672

Sale of investment held at fair value | Common | Karuna

Disclosure of non-adjusting events after reporting period [line items]

Sale of equity instruments in other entities (in shares) | shares

886,885,000

Major Financing Activity | Seaport Therapeutics

Disclosure of non-adjusting events after reporting period [line items]

Series A financing, amount

$ 100,000

Major Equity Investment | Seaport Therapeutics

Disclosure of non-adjusting events after reporting period [line items]

Purchase of equity investment

$ 32,000

Ownership interest

61.50%